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The role of phospholipase D1 in trafficking and processing 
of amyloid precursor protein 
Kimberly S. Point du Jour 
Growing evidence indicates that intracellular signaling lipids control the trafficking and 
processing of amyloid precursor protein (APP) with major implications for pathological 
and behavioral manifestations associated with Alzheimer's disease (AD). One such lipid 
is phosphatidic acid (PA), which mediates membrane trafficking and is produced by a 
variety of enzymes, including phospholipase D (PLD). We previously demonstrated that 
a PLD isoform, PLD2, is required for the synaptotoxic and memory-impairing actions of 
Aβ in AD mouse models. The role that the other PLD isoform, PLD1, plays in AD is 
unclear, although cell culture studies from other groups have suggested it modulates 
the trafficking of APP and presenilin 1, the catalytic subunit of -secretase. Here, we 
investigate the role of PLD1 in the biology of APP as well as in an AD mouse model. We 
report that silencing Pld1, unlike Pld2, causes a dramatic decrease in brain levels of PA, 
indicating that PLD1 is a major source of PA in the brain.  Additionally, Pld1 ablation in 
primary neurons causes a redistribution of APP from endosomes, a primary station for 
amyloidogenesis, to the Golgi complex, while PLD1 overexpression produces the 
converse phenotype. Pld1 null mice harboring familial AD-linked (FAD) APP mutations 
exhibited decreased brain amyloid and an accumulation of APP COOH-terminal 
fragments. This finding was particularly evident in Pld1 null membrane rafts, whose 
lipidome was profoundly altered. Consistent with a regulatory role of the lipid raft 
environment on γ-secretase, a complex highly active in membrane rafts, acute inhibition 




cognitive deficits in the transgenic model. Thus PLD1 and its product PA control the 
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Chapter 1 General Introduction 
Opening remark: 
This thesis encompasses a number of traditional scientific disciplines such as 
phospholipid metabolism, comparative neuroscience, and cell biology as well as the 
emerging field of lipidomics. Introductory comments will cover these broad fields as they 
relate to this work. First, I will describe Alzheimer’s disease and the mental, molecular 
and gross pathology associated with its presentation. Following this I will focus on 
providing background for lipid metabolism pathways related to this work. Then I will 
present the findings of this thesis on exploiting a murine genetic ablation model to study 
both the physiology of the central nervous system and the pathological state with the 
goal of contributing knowledge towards understanding the mechanisms of Alzheimer’s 
disease. 
 
1.1 Alzheimer’s Disease 
Alzheimer’s disease (AD), a fatal, insidious, neurodegenerative disorder, is the most 
common cause of dementia in the elderly (Querfurth and LaFerla, 2010; Tanzi and 
Bertram, 2005). It may occur as a sporadic disease for which there is currently no 
precise cause or, in less than 3% of cases, it may present as an autosomal dominant 
disease caused by nearly 200 mutations in amyloid precursor protein (APP) or 
presenilin 1 (PSEN1) and presenilin 2 (PSEN2), the catalytic components of the γ-
secretase complex (Tanzi and Bertram, 2005). In both manifestations, patients exhibit 






leading cause of death in the US, and over 5 million Americans, or 1 in 8 elderly 
individuals, has the disease. The number of patients is projected to increase 
exponentially as the population ages. The psychological and financial costs of AD are 
staggering; over $200 billion of services was rendered for AD patients in 2011. 
(Alzheimer's, 2012) (Fig 1).   
 
Clinical characteristics of AD 
In 1984 the National Institute of Neurological and Communicative Disorders and Stroke 
and the Alzheimer’s disease and Related Disorders Association established criteria for 
the clinical diagnosis of AD (McKhann, 2011). These criteria were updated in 2011 to 
reflect advances in several fields of AD research over the past 27 years (Alzheimer's, 
2012; McKhann, 2011)).  The new guidelines propose an early, or prodromal, phase of 
the disease during which pathology develop without symptoms. During the second 
phase, termed mild cognitive impairment (MCI), patients recognize minor deficiencies in 
cognition, but symptoms do not significantly impair activities of daily living. Clinically, the 
third stage of AD is characterized by progressively worsening dementia with onset over 
months or years. Cognitive decline must be observed by a caretaker or confirmed by 
mental status examination, and there may be amnestic or non-amnestic symptoms. The 
most common presentation of the disease includes amnestic symptoms such as 
declining ability to learn and retain information. Presenting non-amnestic symptoms 
include word-finding difficulty, impaired face and object recognition, and diminished 
reasoning, planning, and problem solving skills. At the latest stages of AD, patients are 






groom, and in some cases walk or control bladder and bowel function. Importantly, 
these symptoms must present in the absence of other potential causes of dementia, 
such as history of stroke, brain tumor, or depression (Alzheimer's, 2012; Holtzman et 
al., 2011; McKhann, 2011). The consensus is that therapies to slow or stop progression 
of AD must be administered in prodromal or MCI phases of the disease to have the 
most potential for success. 
In addition to eliciting clinical signs and symptoms of AD from history given by the 
patient or caregiver, clinicians at research centers may now also increase certainty of 
diagnosis earlier and even track the progression of the disease in patients by using 
biomarkers. The chief AD biomarkers measure brain amyloid beta (Aβ) and correlate 
pathology with low Aβ42 measured in cerebrospinal fluid (CSF) from patients or positive 
amyoid imaging within the brain using Pittsburg compound B - positron emission 
tomography (PiB-PET) scan. Other biomarkers of AD measure neuronal injury and 
include elevation of both total and phosphorylated tau in CSF and disproportionate 
atrophy of all brain regions observed by structural magnetic resonance imaging 
(Alzheimer's, 2012; McKhann, 2011).  These tools may be used in presymptomatic or 
MCI phases of the disease to identify patients who may benefit from investigational 
treatments (Holtzman et al., 2011). 
 
AD management in the clinic 
Decades of research devoted to uncovering the basic mechanisms of AD point to Aβ 
aggregation as the initiation factor of AD pathology (Musiek and Holtzman, 2012), 






therapies directly targeting the pathogenesis of AD. Symptomatic treatments curtail 
untoward behavioral changes and may delay loss of cognitive symptoms by months. 
The U.S Food and Drug Administration has approved two classes of drugs for use for 
patients with AD. Acetylcholinesterase inhibitors such as Aricept (donepezil), Exelon 
(rivastigmine), Razadyne (galantamine), and Cognex (tacrine) act by preventing the 
breakdown of the neurotransmitter acetylcholine in the synapse. This enhances neural 
networks, particularly in a setting of neuronal loss, by prolonging and increasing the 
intensity of the endogenously produced signal at the individual synapse. The single 
NMDA receptor agonist, Namenda (memantine) also works at synapses, but it stabilizes 
cognitive symptoms by mimicking and thus increasing signaling via the endogenous 
neurotransmitter (Alzheimer's, 2012). 
 Clinical trials have been designed based on the understanding of fundamental 
mechanisms of neuronal dysfunction elucidated in the past 30 years. These all target 
Aβ either by diminishing the function of relevant cleavage enzymes or enhancing the 
disposal of this peptide. Unfortunately inhibitors of both BACE1 and γ-secretase have 
been administered to large cohorts of AD patients and have failed to slow progression 
of disease; in some cases they have paradoxically led to worsening of symptoms. Most 
of the mutations in PSEN1 and PSEN2 do not result in increased γ-secretase activity; 
many mutations simply alter APP processing through the γ-secretase complex to shift 
the ratio of Aβ42:Aβ40. Thus, inhibiting γ-secretase, while it may robustly diminish Aβ 
levels in the brain, may not be a sufficiently targeted strategy to alter the course of this 






interacts with and cleaves substrates, have shown more promise despite being less 
studied in humans (Wagner et al., 2012). 
 
Pathological characteristics of AD 
Patients with AD display senile plaques, neurofibrillary tangles and frank neuronal loss 
(Haass and Selkoe, 2007). Extracellular senile plaques consist of Aβ, a peptide derived 
from sequential cleavage of amyoid precursor protein (APP) by β- site APP cleavage 
enzyme 1 (BACE1) and the γ-secretase complex. In a non-amyloidogenic route, APP 
may first be cleaved by α-secretase. This cleavage precludes the formation of Aβ as it 
lies within the sequence of the peptide. The initial cleavage step by either BACE1 or α-
secretase releases the secreted NH3-terminal fragments sAPPβ or sAPPα, respectively. 
The remaining COOH-terminal fragments of APP, CTFβ or CTFα, are cleared from the 
membrane by γ-secretase. Cleavage of both CTFs releases the APP intracellular 
domain (AICD), a small peptide which translocates into the nucleus. The cleavage of 
CTFα releases an innocuous P3 fragment, while the product of CTFβ cleavage is Aβ.  
As the γ-secretase complex cleaves the CTFβ in several steps it produces a variation of 
Aβ isoforms; Aβ species from 36 to 49 amino acids in length have been identified 
(Querfurth and LaFerla, 2010; Wagner et al., 2012). The most common peptides are 
Aβ40 and Aβ42. The latter contains two additional amino acids within the 
transmembrane region at the COOH-terminus; this isoform is more hydrophobic and 
aggregate-prone (Duyckaerts et al., 2009). APP and peptide fragments produced from 






In the brain, Aβ may be further degraded by neprilysin and/or insulin degrading 
enzyme.  When Aβ accumulates, either through increased production or reduced 
clearance, it may form structures with variable characteristics. Non-fibrillary deposits of 
Aβ form diffuse plaques (Fig. 1.2a), while fibrils of Aβ with beta-sheet conformation 
make stellate deposits that are more compact and may be stained by Congo red or 
Thioflavin-S. These deposits are often surrounded by reactive glial cells which 
proliferate in AD probably contribute to disease (Duyckaerts et al., 2009; Holtzman et 
al., 2011). 
The “amyloid cascade hypothesis” that Aβ is the initiating factor of AD is based 
on the toxicity of this peptide as well as genetic links to APP metabolism (Hardy and 
Selkoe, 2002). While the physiologic function of Aβ is unknown, one study suggests a 
role as a neuromodulator at picomolar concentrations (Puzzo et al., 2008). Nonetheless, 
the peptide is known to be toxic at higher concentrations via direct effects on cellular 
membranes as well as induction of inflammation and exacerbation of tau aggregation 
(Holtzman et al., 2011). Aβ poisons synapses in a many ways. At the plasma 
membrane the peptide drives the endocytosis of N-methyl-D-aspartate (NMDA) and (α-
amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors. Aβ binds to 
and suppresses receptors for p75 neurotrophin and the nicotinic acetylcholine (ACh) 
receptor, decreasing ACh release from the presynaptic terminal. These effects weaken 
synaptic transmission and contribute to the dysfunctional neuronal network seen in AD 
(Querfurth and LaFerla, 2010). Within the neuron, Aβ disrupts mitochondrial 
membranes by inhibiting electron transport and ATP production and causing oxidative 






1987, AD researchers questioned whether Aβ had a potential relationship with other 
amyloidogenic proteins, such as prion protein (Tanzi et al., 1987). More recently, a 
relationship between these peptides has been revealed in studies showing that Aβ 
binds with high affinity to cellular prion protein (PrP) and that preventing this interaction 
via anti-PRP antibodies protects against impairments in synaptic function in brain slices 
treated with Aβ (Lauren et al., 2009). In addition, signaling through PrP was shown to 
stimulate Fyn kinase with resultant phosphorylation of NMDA receptors and 
synaptotoxicity (Um et al., 2012). Though  one strain of mice harboring human APP with 
FAD mutations (J20 line) that lack PrP were not protected against neurodegeneration 
(Cisse et al., 2011), PrP has been accepted as one Aβ receptor that may be important 
in pathogenesis (Palop and Mucke, 2010). 
While Aβ has received the most attention as the neurotoxic species in AD, other 
metabolites of APP, such as CTFβ (Grbovic et al., 2003; Jiang et al., 2010) or the AICD 
(Xu et al., 2011) may also contribute to toxicity. CTFβ is composed of the entire Aβ 
sequence, the APP transmembrane domain, and the cytodomain, and thus it may retain 
some of the toxic signaling properties of Aβ or cause independent pathology. In 
addition, overexpression of APP or mutants that cause increased processing through 
BACE1 also increase cellular levels of CTFβ as well as Aβ. An example of this was 
reported when Jiang et al. overexpressed CTFβ as well as a CTFβ mutant that could 
not be cleaved to form Aβ and observed functional and morphological defects in 
endosomes that phenocopied dysfunction seen in AD (Jiang et al., 2010). The AICD 
has been linked to regulation of genes in the nucleus, but very little is known about the 






interactions and the nature of its targets may uncover novel contributors to AD 
pathogenesis (Xu et al., 2011). 
 The second prominent pathological feature of AD is neurofibrillary tangles 
(NFTs). These structures form when aggregates of hyperphosphorylated tau protein 
accumulate within neurons. Tau is created in neurons as well as glia and functions to 
bind and stabilize microtubules; in the hyperphosphorylated state the protein dissociates 
from microtubules and NFTs form in cell bodies as well as axon and dendrites (Fig.1 
d,g). Neuritic dystrophy and neuropil threads of paired helical filament of tau are 
commonly observed near Aβ plaques in AD brain (Fig1.2 e,f). Tau pathology has 
traditionally focused on neuronal loss, but tau transgenic mice also have synaptic 
dysfunction.  Like Aβ, aggregates of tau are synaptotoxic and impair cognition 
(Holtzman et al., 2011; Querfurth and LaFerla, 2010). While several lines of evidence 
ascribe a central role to Aβ in AD pathogenesis, emerging studies link tau-related 
pathology to transsynaptic propagation of neurodegeneration from the entorhinal cortex 
throughout the hippocampus and distant sites in the brain (de Calignon et al., 2012; 
Holtzman et al., 2011; Liu et al., 2012).  In one study, Liu and colleagues restricted 
human tau (4R0NtauP301L) expression to the entorhinal cortex in mice. They 
documented spread of tauopathy from this brain region to the hilus and dentate gyrus 
regions within the hippocampus and synaptically connected areas of the neocortex (Liu 
et al., 2012). Another study also reported progressive spread of tauopathy in the same 
pattern as early AD neurodegeneration (de Calignon et al., 2012)  Indeed, Aβ may 
initiate the disease process, but tau could possibly mediate progressive cognitive 






a molecular signature at early stages of AD that may be targeted to prevent the 
pathological sequence from advancing. 
The third gross pathological anomaly of AD is neuronal loss. Historically, memory 
loss in AD was attributed to disruption of neuronal connectivity, viability, and overall 
architecture due to accumulation of senile plaques and NFTs. While molecular insight 
into the pathology of AD has been gained from several mouse models of the disease, 
these models are largely incomplete due the lack of gross neuronal loss seen in human 
patients (Ashe and Zahs, 2010). A precursor of neuronal loss, decreased number of 
synapses in AD has been described ultrastructurally and via immunohistochemistry. 
Synaptophysin, a marker of the preynapse, is decreased in early stages of the disease 
(Duyckaerts et al., 2009). More grossly, the atrophy observed in patients with AD 
correlates with areas of tau and Aβ pathology, namely the entorhinal cortex, the 
hippocampus, and the amygdala Progressive decrease in volume is related with the 
thickness of the cortical ribbon, and with decreased cortical volume there is a converse 
increase in the volume of the lateral ventricles (Duyckaerts et al., 2009). 
 
1.2 AD: the lipid and membrane trafficking connection 
On a molecular level, several lines of evidence support the notion that lipid metabolism 
may be disrupted in AD or at the very least contribute to AD pathogenesis (Di Paolo and 
Kim, 2011; Grosgen et al., 2010). To begin, genetic studies have identified an ApoE 
variant, ApoE4, as a risk factor for AD (Lane et al., 2010; Rajendran and Annaert, 2012; 
Tanzi, 2012). Second, APP, -secretase, BACE1, and γ-secretase are either 






particularly lipid raft association, has been shown to modulate the activity and sub-
cellular localization of these molecules with resultant effects on their ability to generate 
Aβ (Fig 1.3). Additionally, Aβ disrupts physiologic lipid signaling pathways by altering 
the activity of lipid-cleaving enzymes at the plasma membrane such as phospholipase 
A2(PLA2) (Sanchez-Mejia and Mucke, 2010), phospholipase C (PLC) (Berman et al., 
2008), or phospholipase D2 (PLD2) (Oliveira et al., 2010). In a similar vein, Aβ 
aberrantly associates with numerous proteins in lipid rafts within the cellular membrane, 
and these interactions may be synaptotoxic. (Ehehalt et al., 2003; Matsuzaki et al., 
2010).  Finally, neurons metabolize accumulations of Aβ and hyperphosphorylated tau 
by autophagy, a lipid regulated pathway that involves mobilization, specialization, and 
regulated traffic of cellular membranes. (Dall'Armi et al., 2010; Nixon et al., 2005; 
Pickford et al., 2008).  
 
Lipid associated genetic risk factors in AD 
Recent genome-wide association studies have provided population level analysis of 
genes that may predispose individuals to developing AD as they age. Intriguingly, 
seminal studies on the major cholesterol transporter apolipoprotein E (ApoE) as well as 
more recent genome wide association studies point to lipid metabolism as well as 
membrane trafficking as critical factors modulating the risks of developing LOAD 
(Rajendran and Annaert, 2012; St George-Hyslop and Fraser, 2012; Tanzi, 2012). The 
ApoE4 allele is associated with as many as 30% of LOAD AD cases (Small and Gandy, 
2006). While the function of ApoE in peripheral cholesterol transport is known, how it 






reductase and reduce cholesterol production, decrease Aβ levels in murine brain; 
however, genetic mutations to lower circulating cholesterol levels do not decrease Aβ 
brain levels (Fagan et al., 2004), suggesting that statins may exert effects in a yet 
undetermined manner. In humans, statin therapy for AD has remained controversial due 
to conflicting results in large trials ((Arvanitakis et al., 2008; Martins et al., 2009). 
Though cholesterol clearly modulates amyloidogenesis, statin therapy may be less 
effective because cholesterol in the periphery does not exist in equilibrium with brain 
cholesterol and statins do not efficiently cross the blood brain barrier (Di Paolo and Kim, 
2011). Importantly, cholesterol distribution in neurons, rather than cholesterol levels 
overall, may be more relevant to amyloidogenesis in the central nervous system (Burns 
et al., 2006). 
 
APP trafficking and processing 
Genetic studies in the past 3 decades have elucidated innumerous molecular insights to 
the disease, particularly with respect to the trafficking and processing of APP. In non-
autosomal dominant, late onset AD (LOAD), the cause of inappropriate amyloidogenic 
cleavage of APP remains unknown. However, the observation that Aβ plaques were 
found in patients with AD and Down’s syndrome (Trisomy 21- the chromosome 
harboring APP) as well as the identification of the first mutations in APP responsible for 
autosomal dominant AD underscore the fact that metabolism of this protein is key to AD 
pathogenesis (Holtzman et al., 2011). 
Genome-wide association studies have identified polymorphisms in 






case, how these proteins may contribute to AD is better defined (Rogaeva et al., 2007; 
Small, 2008). APP interacts with members of this family, which includes SorCS1 and 
SorL1/SorLA. SorL1 colocalizes with APP and directs its traffic from the endosome via 
interaction with the retromer complex (Rogaeva et al., 2007; Small and Gandy, 2006). In 
addition, rodents deficient in SorL1 phenocopy aspects of AD (Muhammad et al., 2008).  
Another Vps10 family member, SorCs1 exists in complex with APP, SorL1, and 
retromer component Vps35; overexpression of this protein reduced Aβ generation, likely 
via redirecting the traffic of APP (Lane et al., 2010).  
Variation of lipid composition among cellular organelles affects APP processing 
which is tightly linked to its intracellular traffic in neurons.  Growing evidence indicates 
that proteins directing the traffic of APP, whether by direct interaction or by modulating 
lipid signaling in cellular membranes can significantly shift the processing of APP with 
notable effects on the generation of Aβ and other APP metabolites. APP produced in 
the ER follows the biosynthetic pathway through the Golgi complex to reach the plasma 
membrane where it is endocytosed and may be recycled back to the Golgi or follow 
other routes, such as the lysosomal pathway (Fig. 1.4) (Rajendran and Annaert, 2012; 
Small and Gandy, 2006). While the non-amyloidogenic processing of APP initiated by 
-secretase is believed to predominate at the plasma membrane, amyloidogenic 
processing initiated by BACE1 primarily occurs in the endosomal pathway, although 
other studies suggest it may also occur in the Golgi (Burgos et al., 2010). Consistent 
with a critical role of the endocytic pathway in controlling the amyloidogenic pathway, 
endosomal anomalies have been reported in the brain and cells of patients with 






and/or diminishing the residence time of APP in endosomes may prove beneficial in the 
treatment or prevention of AD (Rajendran and Annaert, 2012; Small and Gandy, 2006).  
 APP may interact with proteins that direct its trafficking through cells, and it has 
several domains that facilitate this traffic. Mutating these domains or modulating 
accessory trafficking proteins can have significant effects on amyloidogenesis.  The 
YENPTY endocytosis motif mediates APP internalization; mutations within this 
sequence, or in clathrin binding adaptor proteins such as autosomal-recessive 
hypercholesterolemia (ARH) protein, members of the Fe65 family, or members of the 
X11 family,  inhibit traffic of APP from the plasma membrane to endosomes and 
decreases Aβ production (Small and Gandy, 2006; Thinakaran and Koo, 2008); TGN to 
endosome traffic of APP may be mediated by the µ4 subunit of adaptor protein 4 (AP-4) 
via a distinct interaction with the YKFFE sequence in the APP COOH-terminus; 
disrupting the interaction of these proteins enhances production of Aβ and decreases 
APP residence in endosomes (Burgos et al., 2010).  Recent studies identified an ER 
retention factor (RER1) that when overexpressed causes a shift in the translational 
modification of APP and its levels at the plasma membrane. This, along with modulation 
in the trafficking of γ-secretase caused a decrease in generation of Aβ (Park et al., 
2012). These all demonstrate how redirecting the trafficking of the APP substrate as 
well as its secretases has the potential to reverse pathological accumulation of Aβ. 
In addition, clear evidence links membrane lipid composition to processes 
controlling APP metabolism, largely through the modulation of both BACE1 and γ-
secretase activity (Fig.1.3) (Di Paolo and Kim, 2011)). The activity of у-secretase, a four 






phosphoinositide-4, 5-bisphosphate (PtdIns(4,5)P2), cholesterol, and sphingolipids, and 
the complex is particularly active in lipid rafts, ordered cholesterol- and sphingolipid 
enriched domains that serve as platforms for a plethora of signaling pathways (Fig. 
1.6a) (Di Paolo and Kim, 2011; Hartmann et al., 2007). Specifically, the γ- secretase 
complex is enriched in membrane rafts containing post-Golgi and endosome, but not 
plasma membrane or endoplasmic reticulum (ER), markers (Vetrivel et al., 2004), and 
purified γ-secretase cleaves CTFβ with most efficiency within a reconstituted raft-like 
lipid milieu (Osenkowski et al., 2008). Taken together with data indicating that BACE1 
activity also increases within rafts (Kalvodova et al., 2005), this suggests that the 
majority of amyloidogenic APP processing likely occurs in lipid rafts. 
Overall, biochemical, clinical, and genetic evidence gathered so far underscores 
the importance of delineating the mechanisms that regulate trafficking of APP from the 
TGN to the plasma membrane and endosomes in order to fully understand AD 
pathogenesis (Haass and Selkoe, 2007). 
 
Aβ and lipid signaling 
Phosphoinositides signal ubiquitously within cellular membranes. Importantly, 
this class of lipids was found to be reduced in brains of individuals with AD, prompting 
researchers to investigate how its metabolism is affected by the disease. Though seven 
members of this family of lipids have been identified PtdIns(4,5)P2 and 
phosphoinositide-3,4,5-triphosphate (PtdIns (3,4,5)P3) are concentrated on the 
cytoplasmic side of the plasma membrane and regulate signal transduction, cytoskeletal 






demonstrated that Aβ activates the PLC pathway at the plasma membrane. The lab 
observed that PtdIns(4,5)P2 was decreased in primary cortical neurons treated with 
synthetic or naturally secreted Aβ oligomers. Our lab also reported a trend for increased 
phosphatidic acid (PA) in these neurons. Of note, PtdIns(4,5)P2 hydrolysis at the cell 
membrane after Aβ application was blocked by inhibiting PLC, the phospholipase that 
cleaves PtdIns (4,5)P2 to produce diacylglycerol (DAG). In addition, removing one copy 
of synaptojanin, a phosphatase that catabolizes PtdIns(4,5)P2, attenuated the effects of 
treatment with Aβ in culture as well as neurobehavioral deficits exhibited by mice with 
elevated levels of Aβ in the brain (McIntire et al., 2012). Taken together these results 
establish strong evidence that Aβ affects phosphoinositide metabolism and that this 
effect may be abrogated by targeting of lipid modifying enzymes that rectify the 
perturbation. 
 PtdIns(4,5)P2 dysregulation in AD has also been identified and characterized in 
FAD PSEN1/PSEN2 mutants. As discussed previously, PSEN1 or PSEN2 form the 
catalytic component of the ү-secretase complex whose activity releases Aβ and other 
signal peptides from cellular membranes. In addition to this function, other cleavage-
independent roles for these proteins have been associated with AD(Gandy et al., 2007; 
Rajendran and Annaert, 2012). Landman and colleagues investigated the cause of 
transient receptor potential melastatin 7-associated Mg2+-inhibited cation channel 
dysfunction in cells expressing FAD PS mutations. They reported a specific, ү-secretase 
independent decrease in PtdIns(4,5)P2 in HEK293 cells stably expressing the L286V or 
∆E9 mutants of PS1 and that exogenous application of this lipid restores normal current 






PLC. Inhibiting the phospholipase decreased secretion of Aβ and stimulating PLC 
increased secretion of the peptide (Landman et al., 2006). Thus, PtdIns(4,5)P2 
metabolism may be implicated in several mechanisms of neuronal dysfunction in AD 
including APP processing intracellularly as well as signal transduction at the plasma 
membrane downstream of extracellular Aβ. 
Aβ exerts diverse effects on cellular membranes. In addition to activating PLC 
with downstream effects mediated by PtdIns(4,5)P2, Aβ also enhances cytosolic levels 
of arachidonic acid through activation of cytosolic PLA2. An increase in arachidonic acid 
was observed in brains from patients who died with AD, and genetic reduction or 
ablation of cPLA2 ameliores deficits in learning and memory a murine FAD model. 
(Sanchez-Mejia and Mucke, 2010). 
 Like Ptdns(4,5)P2, PA is a pleiotropic second messenger within cellular 
membranes. PLD production of the PA has been linked to control of APP traffic and Aβ 
production in-vitro and Aβ signaling in a mouse model of AD. Cai and colleagues have 
shown that overexpressing PLD1 increases APP traffic from the TGN and inhibition of 
PA formation by 1-butanol treatment results in decreased APP trafficking from TGN in 
WT fibroblasts (Cai et al., 2006b). They also published work showing that 
overexpression of PLD1 in neurons increases the production of Aβ. On the other hand, 
Oliveira et al. demonstrated that mice from the FAD model Tg2576 that lacked one or 
two copies of PLD2 had comparable levels of Aβ to wild type animals but were 
protected from deficits in hippocampus- and amygdala -dependent memory tests. Slices 
from these animals were also resistant to depressed long term potentiation upon 






While overall levels of PA were unchanged, our lab used lipidomic analysis to uncover 
changes in species of PA that have been shown to be important regulators of neuronal 
function (Oliveira et al., 2010). Thus, APP metabolites, and Aβ specifically, may cause 
shifts in the cellular lipidome that contribute to disease pathogenesis. 
 
Lipidomics in AD 
Metabalomics is an important tool used in analytical chemistry to provide a 
comprehensive assessment of chemical species with the goal of better understanding 
processes in living cells (Myers et al., 2011; Wenk, 2010). Lipidomics is one field within 
the greater arena of metabolic profiling; it provides unbiased information on the lipid 
composition of cells and tissues to uncover potential interconnected metabolic pathways 
and generate hypothesis about initiating factors and responses in disease states. Lipids, 
unlike proteins, are not specified in the genetic code. Indeed, the diversity of lipid 
species far surpasses that of proteins, yet tools to study these integral components of 
biology have been sorely lacking (Wenk, 2010).  Modern lipidomic analysis may rely 
upon the coupling of two analytical modalities: high performance liquid chromatography 
(HPLC) and mass spectrometry (MS). HPLC provides the initial separation step as polar 
lipids pass through a positively charged column and elute at different times according to 
their own charge. This instrument is coupled to a mass spectrometer that receives and 
vaporizes the lipids, ionizes them, further separates the ionized fragments by mass to 
charge ratio, and then quantitatively detects the lipid fragments via their interaction with 
electromagnetic field (Wenk, 2010). This technique is highly sensitive and specific; 






modulations (for example the generation of stable products such as phosphatidylalcohol 
by phospholipase D) or give information on lipid flux (Myers et al., 2011). 
Chan et al. harnessed the power of this approach and performed lipidomic 
analysis on three brain regions (prefrontal cortex (PFC), entorhinal cortex (ERC), and 
cerebellum) from AD patients. We also examine aged (9-11.5 month old) mice from 
transgenic FAD mouse models (PS1, APP, and PS1-APP). We analyzed 26 high and 
low abundance lipid subclasses including lysophospholipids, glycerophospholipids, 
sphingolipids, and sterols. This study covered over 300 lipid species and led to the 
identification of subclasses of lipids that are dysregulated in both human AD tissue and 
AD mouse models (Chan et al., 2012a).  
 In both PFC and ERC from patients who lived with AD had significant changes 
compared to unaffected controls, and different lipid alterations were observed in the 
PFC compared to the ERC. The most striking observation was a 1.8-fold increase in 
DAG in the prefrontral cortex. This included a pool of DAG (38:4) that derives from PLC-
mediated cleavage of Ptdns(4,5)P2 and thus is involved in signaling. In contrast, in the 
ERC, we observed notable increases in sphingomyelin, GM3, and specific pools of 
cholesterol esters. 
 While the individual FAD mouse models exhibited variations in lipid changes 
compared to control mice, PS1-APP mice were the most severely altered, perhaps 
reflecting the intensified pathology conferred by the two trasngenes. Our lab reported 
trends for decreases in phospholipids (LBPA, PS, PG for example) and dysregulation in 
specific species of PA emerged. Importantly, APP and PS1-APP mice phenocopied 






also examined PA metabolism in older (14-15 month old) APP mice and found that 
several species of PA were indeed elevated above the levels seen in 9-11 month old 
APP mice. Interestingly, APP mice lacking PLD2 (an enzyme that produces PA, 
discussed in the next section) exhibited normalization of GM3 levels (Chan et al., 
2012a). Our data suggest that there may be a variety of ways to influence detrimental 
lipid metabolism that may contribute to AD pathogenesis. 
 
1.3 Phospholipase D  
Phospholipase D (PLD) activity was first described in plants and has been characterized 
in bacteria, yeast, and worms as well as several mammalian systems (Klein, 2005). 
Early papers identified differing PLD activities that favored diverse requirements in pH 
and activation. In 1987, optimal PLD activity was described in rat synaptosomes at a 
slightly acidic pH 6.5. The same study reported that at neutral pH optimal PLD activity 
was observed in plasma membrane preparations from rat synaptosome (Gustavsson, 
1995). It is now understood that these two activities correspond to mammalian isoforms, 
PLD1 and PLD2 (Fig1.5a), that are being characterized and have been localized in 
internal compartments such as endosomes, Golgi, and autophagosomes and the 
plasma membrane, respectively (Colley et al., 1997; Dall'Armi et al., 2010; Du et al., 
2004; Hammond et al., 1997). 
PLD catalyzes a transphosphatidylation reaction that hydrolyzes 
phosphatidylcholine to choline and PA. PA is also produced by phosphorylation of 
diacylglycerol (DAG) by DAG kinase, modulation of lysophosphatidic acid by 






and CoA-linked fatty acids through other acyltransferases (Oliveira and Di Paolo, 
2010)(Figure 1.5b). PLD isoforms undergo differential regulation; PLD1 is controlled in 
vivo and in vitro by lipids such as PtdIns(4,5)P2 and oleate, protein signaling molecules 
such as protein kinase C and small GTPases of the ARF and RhoA families (Brown et 
al., 2007; Exton, 1999).  
 
PLD1 in Physiology 
PLD1 and PLD2 are distinctly localized and regulated isoforms that have been 
implicated in diverse cellular functions through the production of PA.  With its small 
head group, PA is a cone shaped lipid that prefers or induces negative curvature, 
lowering the energy barrier for membrane budding and fusion (Fig. 1.6) (Cazzolli et al., 
2006; Vitale, 2010). PLD1 mediates signaling and membrane dynamics in intracellular 
stations such as the Golgi where it has been shown to stimulate the release of nascent 
secretory vesicles (Jenkins and Frohman, 2005; Riebeling et al., 2009). In vitro studies 
demonstrated that PLD1 associates with lipid rafts and binds to membranes via 
plekstrin homology (PH) and phox (PX) domains (Du et al., 2003);  in addition, two 
cysteines within the PH domain have been shown to be essential for proper function, 
internalization, and subcellular localization of the enzyme (Diaz et al., 2002; Han et al., 
2002; Hitomi et al., 2004; Sugars et al., 1999).  
 Through production of PA, PLD1 mediates a lipid signaling cascade that 
integrates mitogenic signals upstream of mTORC1. These signals may proceed through 
CDC43, Vps34, or other molecules dispatched upon stimulation of G-protein coupled 






interacts with the FKBP12-rapamycin-binding (FRB) domain of mTOR and is a critical 
regulator of mTOR signaling, although not all activators of PLD result in mTORC1 
activation (Sun and Chen, 2008). In particular, PLD1 was shown to bind Rheb, a small 
GTPase of the Ras superfamily. This association facilitated activation of mTORC1 via 
the mitogenic TSC-Rheb pathway (Sun et al., 2008). Thus PLD1 emerges as an 
intracellular integrator of rapamycin sensitive mTOR signaling. 
 Our group published a paper linking PLD1 to autophagy in vivo. 
Macroautophagy, generally referred to as autophagy, is a major pathway for breakdown 
of organelles and proteins. This process that relies upon the generation of double 
membrane structures, termed autophagosomes (De Duve and Wattiaux, 1966). Basal 
or constitutive autophagy eliminates old or defective organelles and rids cells of 
aggregate prone proteins that are too large to be degraded by the proteasome. On the 
other hand, autophagy may be activated by cellular stress such as nutrient deprivation 
and oxidative damage (Boland et al., 2008). While the process of autophagy has been 
described in cells for decades, it has only recently been identified and characterized in 
neurons. Of note, autophagy has been increasingly linked to neurodegenerative 
disease, especially AD (Boland et al., 2008; Harris and Rubinsztein, 2012; Johnson et 
al., 2012; Wong and Cuervo, 2010). (Harris and Rubinsztein, 2012) 
We established that upon nutrient starvation PLD1 partially relocalized from the 
endosomal system to autophagosomes (Dall'Armi et al., 2010). We observed an 
increase in PLD activity induced by starvation and we reported that genetic ablation or 
pharmacologic inhibition of PLD1 impaired the expansion of LC3 positive structures, 






quantified aggregated tau in brains from mice overexpressing human tau in a murine 
Tau KO background. Intriguingly, brain slices treated with a PLD inhibitor accumulated 
more tau(Dall'Armi et al., 2010). Taken together with our observation of an accumulation 
of p62 aggregates upon PLD inhibition this suggests a role for PLD in autophagy. 
Physiological roles for PLD1 have been examined less in neurons. One early 
study ascribed a role for PLD1 in neurotransmitter release via its effects to prime 
synaptic vesicles. Humeau et al. confirmed the presence of PLD1 in rat synaptosomes, 
specifically in plasma membrane zones specialized for neurotransmitter release. They 
microinjected PLD1 or a catalytically dead mutant in neurons from Aplysia and they 
noted inhibition of acetylcholine release in the case of the mutant but not WT PLD1. The 
authors postulated that PLD1 may control the fusogenic status of presynaptic vesicles 
and thus affect synaptic transmission (Humeau et al., 2001). 
 
PLD1 in Pathology 
PLD1 has been increasingly studied for its role in cancer pathogenesis (Chen et al., 
2012; Su et al., 2009). This enzyme is activated by oncogenic factors  at the membrane 
that directly activate the Ras-Ral signaling pathway or it may be stimulated by growth 
factor signaling through receptor tyrosine kinase transphosphorylation that converge on 
the same pathway (Foster and Xu, 2003). PLD1 is overexpressed human breast cancer 
(Noh et al., 2000) and its activity is upregulated in gastric cancer (Uchida et al., 1999). 
This year, Chen et al reported that PLD1 activity supports both angiogenesis and 
metastasis through facilitation of integrin binding.  The group observed that tumors 






in Pld2 null or WT mice. They linked this to reduced integrin binding to several ligands in 
PLD1 deficient endothelial cells. Tumor cells injected into Pld1 null mice had reduced 
incidence of lung metastasis, consistent with decreased integrin binding in endothelial 
cells in that organ as well (Chen et al., 2012). Thus via intracellular signaling to promote 
oncogenesis or mediating the interaction of cancerous cells with their 
microenvironment, PLD1 plays a detrimental role in tumor growth. 
In a similar vein, PLD1 has been identified as a potential target in treatment 
and/or prevention of ischemic stroke. Damaged endothelium within blood vessels 
inappropriately display components of the extracellular matrix; this may eventually  
causes platelet aggregation, reduced blood flow distal to the site of blockage, and 
subsequent stroke. Genetic ablation of PLD1 caused impaired activation of the major 
adhesion receptor α11bβ3 in platelets. Decreased signaling through this receptor 
weakened platelet aggregation and provided protection against thrombosis and cerebral 
ischemia in vivo. This finding has even greater potential clinical application because 
blocking PLD1-mediated signaling did not impair normal coagulation after tail wounding 
(Elvers et al., 2010). This finding confirms a role for PLD1 in integrin signaling and 
highlights the therapeutic potential of this enzyme. 
Importantly, cell culture and in vitro studies from others revealed a link between 
PLD1 and the trafficking of APP and PSEN1. Cai et al. found that overexpression of 
PLD1 in N2a cells increases the delivery of APP to the cell surface (Cai et al., 2006b). 
Another study from the same group reported that PLD1 overexpression in N2a cells 
expressing FAD mutant PS1∆E9 reduces Aβ secretion, while knocking down PLD1 in 






of PLD1 on -secretase complex stability via the association of PLD1 with PSEN1 (Cai 
et al., 2006a). In addition, PLD1 overexpression has also been shown to increase 
trafficking of PSEN1 to the cell surface in an APP-independent fashion (Liu et al., 2009). 
Further connecting the PLD family to AD, we have previously reported that PLD2 is 
required for the synaptotoxic and memory-impairing actions of A oligomers, although it 
does not modulate the processing of APP (Oliveira et al., 2010). Altogether, data from 
our group and others suggest that PLD1, unlike PLD2, may modulate the amyloidogenic 
processing of APP.  
 Many studies on PLD activity rely upon the unique product of PLD, 
phosphatidylethanol (PEtOH) which is preferentially formed from during the  
transphosphatidylation reaction catalyzed by these enzymes in the presence of primary 
alcohols PLD  (Yang et al., 1967). For example, in the presence of ethanol, PLD will 
produce phosphatidylethanol (PEtOH) at a much greater rate than PA (Fig1.5c). While 
this effectively inhibits the generation of the physiologic product of the enzyme, this 
method is imperfect because (1) it may cause non-specific effects due to the presence 
of the alcohol, (2) it causes the generation of a novel lipid with could produce its own 
effects, and (3) the enzyme is still present and able to perform possible non-catalytic 
functions.  Recently isoform specific as well as pan PLD inhibitors have been 
engineered (Scott et al., 2009). Of even greater benefit, PLD1 and PLD2 isoform 
specific knock out animals are being studied to address old conclusions as well as 
elucidate new roles for these enzymes. (Dall'Armi et al., 2010; Elvers et al., 2010; 
Oliveira et al., 2010). Thus, it is now possible to examine the contribution of PLD to 






In this work, we investigate the role of PLD1 in APP trafficking and processing 
using a mouse genetic model. We show that PLD1 is the main source of PA in the 
forebrain.  We report that ablation of PLD1 modulates traffic of APP in cultured neurons, 
and, unexpectedly, leads to decreased Aβ and altered APP processing in lipid rafts in 
vivo. This results in diminished plaque load in FAD hAPP mice with resolution of 
neurobehavioral dysfunction. Overall, our results suggest blocking PLD1 or PLD2 may 
be beneficial in AD, although these related lipases affect fundamentally distinct aspects 









Chapter 1 FIGURES 
Figure 1.1 Projected numbers of people age 65 and over in the U.S. population 
with Alzheimer’s disease using the U.S. Census Bureau Estimates of Population 











Figure 1.2 Hallmark Lesions of Alzheimer’s disease.  Various types of Aβ deposits 
and aspects of tau pathology. a) Diffuse deposits in the striatum. b) Stellate deposits 
(arrows). c) Accumulation of Aβ peptide in the cell body of an astrocyte (arrows) in 
contact with a diffuse deposit (brown, lower left part of the picture, 6F/3D antibody). 
Scale bar 10µm.  d) A typical flame shaped neurofibrillary tangle (arrow). Tau also 
accumulates in the dendritic shaft (arrowheads). Extracellular ghost tangles (small 
arrows) are visible. AT8 antibody. e) Globose neurofibrillary tangles (arrows) in the 
nucleus basalis of Meynert. Tau polyclonal antibody (Dako). f) The crown of the senile 
plaque contains tau positive (mainly axonal processes) while the amyloid core is not 
immunostained. Tau polyclonal antibody (Dako). g) A neuropil thread. The dendritic 
nature of the process is apparent. It is thicker than an axon. Its contour (arrowheads) 
appears fuzzy, probably in relation with dendritic spines. Tau polyclonal antibody 












Figure 1.3 APP trafficking. APP, shown in green, is trafficked through the biosynthetic 
pathway and the Golgi complex. It exits the trans-Golgi network (TGN) and reaches the 
plasma membrane by the secretory pathway. APP is internalized to early endosomes 
via the endocytic pathway where it has a number of fates. It may be recycled back to 
the plasma membrane via recycling endosomes, progress through multivesicular bodies 
to late endosomes and lysosomes, or re-enter the TGN via retrograde, retromer-guided 
traffic. At any point in the itinerary APP may undergo proteolysis, provided it interacts 






Figure 1.4 Lipids and APP processing. Several lipids (shown in blue boxes) and lipid 
metabolizing proteins (shown in yellow boxes) influence APP processing through a 
variety of mechanisms. (a)APP undergoes amyloidogenic processing mediated either 
by β- and γ-secretases to yield amyloid-β (Aβ) peptide (shown by purple rectangles). 
Amyloidogenic processing of APP largely occurs in lipid rafts. Cholesterol and low-
density lipoprotein (LDL) receptor-related protein (LRP), an apolipoprotein E (APOE) 
receptor, promote the localization of BACE1 to lipid rafts. GGPP (geranylgeranyl 
pyrophosphate, a short chain isoprenoid) has been shown to promote the association of 
the γ-secretase complex with lipid rafts. (b) APP is also subjected in neurons to a non-
amyloidogenic pathway mediated by α-secretase. Localization of APP to non-lipid raft 
compartments favors processing by α-secretase. Isoprenoids, diacylglycerol and 
phospholipase C (PLC) have been shown to promote the non-amyloidogenic pathway. 
(c)The relative abundance or absence of the lipids listed (shown in the blue boxes) 
directly influences the activity of BACE1 or γ-secretase. Increased levels of cholesterol 
or ceramide enhance the activity of BACE1. Cholesterol and sphingolipids are positive 
modulators of γ-secretase activity, whereas sphingomyelinase (SMase) and 
phospholipase D1 (PLD1) have been identified as negative modulators of γ-secretase 






stimulating γ-secretase activity and PtdIns(4,5)P2 has been shown to directly inhibit γ-









Figure 1.5 PLD structure, PA metabolism, and reactions catalyzed by PLD. (a) 
Structure of PLD isozymes. Structurally, the two isozymes differ by the presence of a 
loop domain in the PLD1 isozyme. (b) PA metabolism. Besides the PLD source, PA can 
be generated from other sources and further metabolized as represented in the figure. 
The dashed arrow represents the biosynthetic pathway. The enzymes catalyzing the 
respective reactions are shown in red. (c) PLD activity. In the presence of water, PLD 
produces PA. In the presence of primary alcohols, such as ethanol, PLD has a 1000-
fold higher affinity for primary alcohols as nucleophiles, leading to a preferential 
generation of phosphatidylethanol (PEtOH). PLD, Phospholipase D; PC, 
phosphatidylcholine; PA, phosphatidic acid; LPA, lyso-PA; DAG, diacylglycerol; CDP-
DAG, cytidine diphosphate-DAG; PLA2, phospholipase A2; LPAAT, LPA 
acyltransferase; PAP, PA phosphatase; DGK, DAG kinase; CDS, CDP-DAG synthase; 







Figure 1.6 Cartoon showing membrane fusion. a) Lipid rafts are ordered 
microdomains enriched in cholesterol, sphingolipids such as sphingomyelin (SM), and 
saturated fatty acids. b) PLD derived phosphatidic acid (PA) induces negative curvature 
on the inner, cytoplasmic, membrane leaflet. Ceramide (Cer) and convex lipids such as 
lysophosphatidylcholine (LPC) and facilitate vesicle budding from the membrane leaflet 







Chapter 2 Characterization of PLD activity in the Pld1 KO mouse 
PLD mediates its functions in the cell through production of PA; however, whether the 
two isoforms contribute substantially to the pool of PA within neurons was unclear. Thus 
we generated mice lacking PLD1, PLD2 and both isoforms to study address this 
question. The protocol for generating the Pld1 knock out (KO) mouse (Fig. 2.1) was also 
employed to create the Pld2 KO mouse; the mice were then subsequently crossed to 
produce the Pld1/2 double KO. 
 
 2.1 PLD1 contributes the majority of PA in murine forebrain 
We examined PLD activity in forebrain from Pld1 KO, Pld2 KO, and Pld1/2 double 
knockout mice. As reported previously, mice lacking PLD1 or PLD2 appeared healthy 
and exhibited no overt anomalies up to at least 18 months of age (Chen et al., 2012; 
Dall'Armi et al., 2010; Elvers et al., 2010; Oliveira et al., 2010). Similarly, mice lacking 
both PLD1 and PLD2 exhibited no obvious differences from WT mice, surprisingly 
suggesting that under basal conditions PLD1 and PLD2 are not essential for survival. 
Upon evaluation of relative PLD protein levels in the four genotypes, we observed that 
mice lacking PLD1 do not display compensatory overexpression of PLD2 and vice versa 
(Fig. 2.2a); In the presence of primary alcohols, such as ethanol, PLD enzymes 
preferentially catalyze the production of phosphatidylalcohols instead of PA. We took 
advantage of this finding and performed an in vivo PLD activity by quantifying PEtOH 
production in the forebrain of mice acutely injected with ethanol.  While mice lacking 
PLD2 had a 25% decrease in forebrain PLD activity, mice lacking PLD1 exhibited a 






contained virtually no PEtOH, similar to non-injected mice, suggesting that PLD1 and 
PLD2 contribute the totality of PLD activity in this tissue (Fig. 2.2b). We observed only 
partial overlap in the 42 molecular species of PEtOH recovered from Pld1 KO and Pld2 
KO forebrain. Membrane forming lipids vary in certain characteristics such as fatty acyl 
carbon chain length, number of hydrogen saturated carbon bonds, and polar headgroup 
type; the generated pool of PEtOH reflects characteristics of the parent PC molecules. 
Higher abundance species PEtOH 36:1/18:1 and PEtOH 38:4/20:4 were significantly 
reduced in Pld1 KO brains, unlike in Pld2 KO animals. In contrast, several lower 
abundance species containing shorter fatty acyl chains declined in Pld2 animals that 
were unaffected by PLD1 ablation (Fig. 2.3). This indicates that each isoform of PLD 
cleaves distinct, yet overlapping, pools of PC, consistent with the differential subcellular 
localization of each enzyme reported in various cell types (Jenkins and Frohman, 2005; 
McDermott et al., 2004). 
 Though PLD produces the bioactive lipid PA, this lipid may be derived from a 
variety of pathways in the cell, including through the phosphorylation of diacylglycerol 
(DAG) by DAG kinase or the acylation of lysophosphatidic acid (LPA) by LPA acyl 
transferase (Oliveira and Di Paolo, 2010). Remarkably, mice lacking PLD1 showed a 
60% decrease in the levels of PA relative to WT mice. While mice lacking PLD2 exhibit 
a trend for a slight decrease in PA, consistent with our previous study (Oliveira et al., 
2010), mice lacking both PLD isoforms showed a further reduction in PA relative to Pld1 
KO forebrain, with 30% of WT levels. Other phospholipids, including cardiolipin, 
phosphatidylserine, and phosphatidylinositol 4-phosphate (PI4P) were unchanged in the 






5- kinase to stimulate the synthesis of PtdIns(4,5)P2, (Jenkins and Frohman, 2005), we 
observed a slight increase in PtdIns(4,5)P2, levels in forebrain lacking only PLD1 (Fig. 
2.2c). Together, these data show that PLD1 contributes a significant fraction of brain PA 
levels, allowing us to test for the physiological role of this lipid in APP trafficking and 
processing.  
 
2.2 Effect of PLD1 ablation on murine forebrain lipidome 
Lipid dyshomeostasis figures prominently in proposed mechanisms of AD pathogenesis 
(Di Paolo and Kim, 2011). We surmised that the aforementioned effects of PLD1 
ablation on APP trafficking and processing result from its effects on cellular membranes, 
so we extracted total lipids from whole forebrain Pld1 KO and WT animals. Eighteen 
sub-classes of lipids from total murine forebrain were analyzed by LC-MS. The detailed 
molecular distribution of the individual lipid species measured can be found in Fig. 2.4 
and Dataset 1. PLD1 ablation caused a very specific decrease in overall PA levels in 
total forebrain (Fig. 2.4a), as seen in the more general analysis in Fig.2.2.  No 
differences were observed in the number of unsaturated bonds or carbon chain length 
within total phospholipid (PL) (Fig. 2.4 b, c) or sphingolipids (Fig. 2.4d, e). Among all 
other lipid subclasses only PI was significantly decreased by lack of PLD1, although 
several deficiencies were observed in molecular species of PA metabolite DAG such as 
DAG 28:0/14:0, 36:1/18:0, and 38:3/18:1 (Fig. 2.4f). 
 We generated primary neurons and mouse embryonic fibroblasts (MEFs) from 
Pld1 null mice to analyze the contribution of this isoform to total PLD activity in vitro. 






activity compared to control in unstimulated neurons (Fig. 2.5a). This would suggest a 
compensatory increase in PLD2 activity. It is known that PLD1 is less constitutively 
active compared to PLD2 and that the isoform increases activity in response to signals 
from protein kinase C (PKC), Rho GTPases, and ARF GTPases, among other 
molecules  (Jenkins and Frohman, 2005). Thus, we also treated neurons with phorbol 
myristate acetate (PMA), a compound that stimulates PLD1 via the PKC pathway. 
Unlike WT neurons, PLD1 deficient neurons did not respond with a significant increase 
in activity upon stimulation (Fig. 2.5b). In contrast to the previous findings, we observed 
no difference in basal activity among WT and Pld1 null MEF. On the other hand, as in 
neurons, we observed that MEFs lacking PLD1 had significantly less increase in activity 
upon stimulation with PMA (Fig. 2.5c, d). Taken together, the data in both neuron and 
MEF culture suggests that in basal conditions PLD2 activity is sufficient to maintain total 
PLD activity in cells. However, both culture models indicate that cells are unable to 
effectively increase PLD activity in response to stimulation without PLD1. Thus, PLD1 
plays a critical role in the physiologic increase in overall PLD activity in cells 
downstream of diverse signaling pathways.  















Chapter 2 FIGURES 
Figure 2.1 Generation of Pld1 KO mice. (a) Gene targeting strategy showing the Cre-
mediated ablation of exon 13-14 from the Pld1 gene. (b) Southern blot analysis of tail 
DNA from an F1 litter derived from Pld1Flox-Neo/+ and Rosa26-Cre/Cre breedings. The 
autoradiogram shows several wild type (WT) and heterozygous (Het) genotypes. The 
size of the WT and mutant (Mut) allele is indicated. The probe used lies in the 5’ region, 









Figure 2.2 Genetic ablation of PLD1 reduces PLD activity and PA levels in murine 
forebrain.  (a) Western blot of forebrain lysate from null mutants of each PLD isoform 
and double knockout (DKO) are shown with loading control. (b) Bar diagram showing 
the in vivo PLD activity of WT, Pld1 KO, Pld2 KO and Pld1/2 DKO forebrains as 
measured by phosphatidylethanol (PEtOH) quantification via LC-MS (n=6 per 
genotype). Non-injected WT animals were used to assess background levels. 
Phosphatidylethanolamine (PE) levels are shown as a control. (c) Analysis of anionic 
phospholipids in the four genotypes using HPLC combined with suppressed conductivity 
(n=4-6 per genotype). For (b) and (c), values denote mean ± S.E.M. Statistical analyses 
were performed using two-tailed Student’s t-test. P-values < 0.05, < 0.01, and <0.001 






Figure 2.3 PLD isoforms have only partially overlapping substrates. (a) 
Phosphatidylethanol (PEtOH) species displayed as mol % of total lipids grouped by 
number of carbons (n=6 per genotype). (b) Table of % of PEtOH produced in indicated 
Pld KO compared to Pld1 WT. Highlighting indicates significance. Red (P<0.05), yellow, 
(P<0.01), green (P<0.001). Values denote mean ± S.E.M. Statistical analyses were 








Figure 2.4 Effect of PLD1 ablation on the murine forebrain lipidome. (a) Bar graph 
showing selected lipid sub-classes assayed from total murine forebrain as mol % of total 
lipids. Bar graphs showing total phospholipid unsaturated bonds(b) or  total 
phospholipid chain length (c) as % total phospholipids. Bar graphs showing total 
sphingolipid unsaturated bonds (d), or total sphingolipid chain length (e) as % total 
sphingolipids. (f) Heat map of complete lipidomic analysis of forebrain. Data is ratio of 
lipids from Pld1 KO/Pld1 WT animals.  Log 2 increase is shown in red, decrease in lipid 
species is shown in blue. (n=6) Values denote mean ± S.E.M. Statistical analyses were 








Figure 2.5 In vitro PLD activity varies with PLD1 ablation. (a) Bar graphs showing 
PLD activity in Pld1 WT, HET, or KO neurons treated with DMSO or 100nM phorbol 
myristate acetate (PMA). (b) Bar graph showing effect of PMA stimulation on primary 
neurons of indicated genotypes. n=8. Values denote mean ± SEM (c) Bar graph 
showing PLD activity in Pld1 WT or KO mouse embryonic fibroblasts (MEFs). (d) Bar 
graph showing effect of PMA stimulation on MEFS.  n=3 independent cultures, done in 
duplicate. Values denote mean ± SEM; Statistical analyses were performed using two-















Chapter 3 The interaction and subcellular distribution of PLD1 and APP 
As we set out to investigate whether PLD1 impacts the trafficking of APP, we first 
identified whether the enzyme spatially interacts with APP.  Our laboratory has tested 
and attempted to generate several antibodies to PLD1; to date there are no sufficient 
antibodies for immunocytochemistry. We used HA-PLD1 to perform a limited 
assessment of the colocalization of the enzyme with APP-mRFP in HeLa cells. Upon 
overexpressing the two enzymes we observed substantial colocalization of both HA-
PLD1 and APP-mRFP with early endosome marker EEA1 and late endosome/lysosome 
marker Lamp1. ~20% of PLD1 was colocalized with APP in these cells, while a greater 
share ~50% of APP was localized with PLD1 (Fig. 3.1) Encouraged by these results we 
embarked on a more thorough analysis of APP and PLD1 interaction in neurons. 
 
3.1 PLD1 localization in neurons 
A variety of studies have suggested that PLD1 traffics in cells with patterns reminiscent 
of transmembrane proteins, although its membrane association is mediated by several 
lipid-binding regions, including its NH2-terminal PX and PH domains as well as its 
COOH-terminal polybasic region. Depending on cell types and states, PLD1 has been 
found in the Golgi complex, secretory vesicles, the plasma membrane as well as the 
endolysosomal and autophagic compartments, all of which have also been reported to 
carry APP (Dall'Armi et al., 2010; Donaldson, 2009; Roth, 2008; Small and Gandy, 
2006). To test whether PLD1 and APP reside in specific intracellular compartments, we 
expressed GFP-PLD1 in primary hippocampal neurons at DIV 8 and stained them 24 h 






various endogenous organelle markers, including Vps35, EEA1, Lamp1, Giantin, 
GM130, and LC3 (Fig. 2a). Importantly, GFP-PLD1 greatly colocalizes with APP, though 
this localization is greater for antibodies to the NH2- terminus (~55% colocalization) than 
to the COOH-terminus (~40% colocalization) (Fig. 2b). Confocal analysis of GFP-PLD1 
showed that a significant pool of this enzyme resides in sorting endosomes, indicated 
by 50% colocalization with EEA1 and ~60% colocalization with retromer component 
Vps35. GFP-PLD1 colocalized to a lesser extent with late endosome marker LAMP1 
(~25% colocalization) or Golgi markers giantin (~20% colocalization) and GM130 (~15% 
colocalization).  We previously described a role for PLD1 in autophagy (Dall'Armi et al., 
2010). Upon nutrient deprivation, HA-PLD1 is localized with LC3 on autophagic 
membranes in non-neuronal cells. However, in neurons at steady-state, GFP-PLD1 
exhibits very little colocalization with LC3 (Fig. 2b). Taken together, these results 
position PLD1 primarily in the endosomal compartment in neurons and indicate that a 
large pool of PLD1 colocalizes with APP where it may direct the traffic of this protein 
through production of PA. 
 
3.2 PLD1 controls the subcellular localization of endogenous APP in neurons  
Previous PLD1 overexpression studies suggested a role for the lipase in promoting the 
cell surface delivery of APP in fibroblasts or N2a cells expressing an FAD-linked mutant 
of PSEN1(Cai et al., 2006b). However, this study had not addressed the impact of PLD1 
overexpression on the endosomal localization of APP. Here, we found that expression 
of GFP-PLD1 in primary neurons caused a shift in the subcellular localization of APP-






giantin, and a significant 3-fold accumulation in EEA1-positive early endosomes when 
compared to GFP expression alone (Fig. 3b). Additionally, expression of GFP-PLD1 
decreased the association of APP-CT with GM130 by ~50% relative to GFP expression 
(Fig. 3b). Importantly, the converse phenotype was observed upon ablation of PLD1 in 
mutant neurons. Indeed, lack of PLD1 reduced the colocalization of APP-CT with EEA1- 
and Vps35-positive endosomes by 40% and 50%, respectively (Fig 4). APP stained 
by an NT antibody was also 40% less associated with Vps35. In contrast, 30% more 
APP-NT was localized in the Golgi in PLD1-deficient neurons compared to WT neurons. 
Association of APP with late-endosomal/lysosomal marker LAMP1 was unaffected by 
PLD1 ablation (Fig. 4). Altogether, these results suggest that, consistent with a role of 
PLD-derived PA in driving the exit of protein cargoes from the Golgi, a significant 
fraction of APP is retained in the Golgi and depleted from endosomes in neurons 
lacking PLD1. Whether by overexpression or genetic ablation, these results establish 
that PLD1 controls the localization of pools of APP, and can shift this protein among 







Chapter 3 FIGURES 
 
 
Figure 3.1 HA-PLD1 and APP-mRFP colocalize in HeLa cells. Confocal analysis of 
the subcellular localization of HA-PLD1, APP-mRFP, and endogenous organelle 
markers in HeLa cells. (a) HA-PLD1 is shown in blue; APP-mRFP is shown in red. 
Markers used were: Lamp1 (late endosome/lysosome) in green and EEA1 (early 
endosome) in orange.  High magnification inset, 150x. (b) Bar diagram showing the 
quantification of % colocalization calculated from total fluorescence of HA-PLD1 and 







 Figure 3.2 PLD1-GFP and APP colocalize in neuronal endosomes. Confocal 
analysis of the subcellular localization of GFP-PLD1 and endogenous organelle markers 
in 9 day-old primary hippocampal neurons. (a) Blue markers used were (from top): 
EEA1 (early endosome), Vps35 (retromer-positive endosome), Lamp1 (late 
endosome/lysosome), Giantin and GM130 (Golgi complex), LC3 (autophagosomes).  
APP (N-terminal) and APP (C-terminal) stainings are shown in red.  High magnification 
inset, 300x. Arrows indicate areas of colocalization. (b) Bar diagram showing the 
quantification of % colocalization calculated from total fluorescence of indicated 
organelle marker with GFP-PLD1 (n=12-41 neurons per staining). Values denote mean 






.Figure 3.3 PLD1 overexpression drives APP traffic.  Confocal analysis of the 
subcellular localization of APP and endogenous organelle markers in 9 day-old primary 
hippocampal neurons transfected with GFP-PLD1 or GFP alone. (a) Markers used, 
shown in blue, were (from top): EEA1, Giantin, LAMP1, GM130, LC3. APP is shown in 
red. High magnification inset, 300x. Arrows highlight areas of colocalization. (b) Bar 
diagram showing the quantification of % colocalization calculated from total 
fluorescence of indicated organelle marker with APP (n=10-12 neurons per staining). 
Values denote mean ± S.E.M. Scale bar: 5 µm. Statistical analyses were performed 











Figure 3.4  PLD1 ablation redistributes APP from endosomes to the Golgi in 
neurons.  Confocal analysis of the subcellular localization of APP and endogenous 
organelle markers in 14-day old primary neurons from WT or Pld1 KO pups. (a) 
Organelle markers in red (from top going left): EEA1, Vps35, Lamp1, Giantin. High 
magnification inset, 250x. Arrows highlight areas of colocalization. (b) Bar diagram 
showing the quantification of % colocalization calculated from total fluorescence of 
indicated marker with APP (n=10-14 neurons per condition). Values denote mean ± 
S.E.M. Scale bar: 5 µm. Statistical analyses were performed using two-tailed Student’s 








Chapter 4 The role of phospholipase D1 in AD pathology in an FAD model 
 Since PLD1 directs the traffic of murine APP, we were emboldened to test if targeting 
Pld1 could modify APP processing in the brain. We assayed full length APP (FL APP), 
secreted APPα and β fragments (sAPPα, sAPPβ), and APP COOH-terminal fragments 
(CTFα, CTFβ) in 4-6 month old control and PLD1-deficient mice via Western blot (Fig. 
4.1). Because PLD1 has been previously linked to γ-secretase function (Cai et al., 
2006a), we also assayed for the Notch1 intracellular domain, another product of γ-
secretase cleavage. In mice lacking PLD1 we observed an increase in APP CTFα and a 
trend for increased CTFβ, but we did not appreciate increases in sAPPα, sAPPβ, or 
Notch1 ICD (Fig.4.1b, d). An increase in APP CTFs could be due to increased cleavage 
through either α- and β-secretase or decreased processing of the CTFs by γ-secretase. 
In the same animals, we observed trends for a decrease in both Aβ40 and Aβ42, but 
these did not reach significance (Fig4.1c). Thus, while lack of PLD1 increased APP CTF 
in murine brain, it did significantly reduce amyloidogenesis. These studies were 
informative but limited because murine APP may be processed differently than human 
APP; APP metabolites were shown to have shorter half-lives than hAPP metabolites in 
murine brain (Morales-Corraliza et al., 2009). Interestingly, these results indicate that if 
PLD1 modulates γ-secretase activity, it does so without affecting cleavage of other γ-
secretase substrates.   
 
4.1 Effect of hAPP gene expression in murine forebrain lipidome 
To investigate whether PLD1 could modulate processing of hAPP, we crossed Pld1 null 






(KM670/671/N) and Indiana (V717F) mutations, in an isogenic, C57BL/6 background. 
This model is well characterized and exhibits mild to moderate amyloid plaque burdan 
as well as cognitive dysfunction at the age of 4-6 months (Mucke et al., 2000; Sanchez-
Mejia et al., 2008). We analyzed lipids from total forebrain extracts of mice 
overexpressing the hAPP transgene and compared them to the lipid profile of wild type 
mice (Figs. 4.2, 4.3 and Dataset 1). Comparing total forebrain extracts from hAPP mice 
to non-transgenic mice we observed no changes in abundant lipid subclasses (Fig. 
4.2a), and only one significant change in lipid sub-class, an increase in 
monohexosylceramide (Fig. 4.2f). There were no changes in unsaturated bonds or 
abundance of lipids with a particular carbon chain length in either total phospholipids 
sphingolipids (Fig. 4.2 b, c) or total sphingolipids (Fig. 4.2 d, e). Several molecular 
species of DAG were increased above WT levels (Fig. 4.2f). Of note, levels of PA were 
not enhanced in hAPP mice (Fig. 4.2a), as we had previously observed in an different  
hAPP model, the Tg2576 (which expresses the Swedish mutant of APP), though those 
mice were 6 months older than the current cohort (Chan et al., 2012a).  
 
4.2 Effect PLD1 ablation on hAPP murine forebrain lipidome 
Silencing Pld1 in the hAPP resulted in a significant reduction of PA (Fig. 4.3a) in the 
forebrain compared to hAPP mice expressing PLD1. There were no changes in 
unsaturated bonds or abundance of lipids with a particular carbon chain length in either 
total phospholipids sphingolipids (Fig. 4.3 b, c) or total sphingolipids (Fig. 4.3 d, e). 
Interestingly, removing this protein reduced specific lipid species (DAG 38:1/18:0 and 







4.3 PLD1 ablation decreases the amyloidogenic processing of APP 
Next, we tested whether the change in APP localization caused by the absence of 
PLD1, influences the production of human APP (hAPP) transgene fragments in vivo. 
Using Western blotting we measured human full length APP (FL APP), secreted APPα 
and β fragments (sAPPα, sAPPβ), and APP COOH-terminal fragments (CTFα, CTFβ) in 
4-6 month old control and PLD1-deficient mouse forebrains expressing hAPP (Fig 4.4. 
a, b). No change in FL-APP expression was observed in either genotype; levels of 
secreted sAPPα and sAPPβ in Pld1 null brain were comparable to hAPP animals 
expressing PLD1, consistent with no change in processing through α-secretase or 
BACE1 (Fig. 4.4b). However, levels of CTFα were increased by ~50% in transgenic 
forebrain lacking PLD1 compared to controls (Fig. 4.4b). Remarkably, soluble Aβ40 
measured by ELISA significantly decreased, and this resulted in an increased soluble 
Aβ42/40 ratio in Pld1 KO mice. The increased ratio, a result of decreased soluble Aβ40 
and no change in soluble Aβ42, could reflect subtle changes in γ-secretase activity or 
processivity, which is pattern of activity or the release of varied lengths of Aβ species 
(Selkoe and Wolfe, 2007). Both insoluble Aβ40 and Aβ42 also declined in the absence 
of PLD1; no change in ratio of insoluble Aβ42/40 was observed, although a trend for a 
decrease was observed (Fig. 4.4c). Consistent with decreased Aβ levels, 
immunostainings performed on forebrain coronal sections of these animals with human 
Aβ-specific antibody showed a dramatic reduction in the number of senile plaques in 
PLD1-deficient hAPP mice relative to controls (Fig. 4.4d). Overall, these data 






Chapter 4 FIGURES  
Figure 4.1 Effect of the hAPP transgene on murine forebrain lipidome. (a) Bar 
graph showing selected lipid sub-classes assayed from total murine forebrain as mol % 
of total lipids. Bar graphs showing total phospholipid unsaturated bonds(b) or  total 
phospholipid chain length(c) as % total phospholipids. Bar graphs showing total 
sphingolipid unsaturated bonds (d), or total sphingolipid chain length (e) as % total 






lipids from hAPP/ WT animals.  Log 2 increase is shown in red, decrease in lipid 
species is shown in blue. (n=6) Values denote mean ± S.E.M. 
 
 
Figure 4.2 PLD1 ablation specifically modulates murine APP processing in vivo. 
(a)Representative Western blots of forebrain homogenates from 4-6 month old Pld1 WT 
and KO mice probed for full length APP, APP C-terminal fragments (CTF) α; and β; 
secreted soluble fragments sAPPα; and sAPPβ; Notch1, and loading control. See 
Methods for antibody details. (b) Bar diagram showing the quantitative analysis of the 
APP blots and the significant increase in APP CTFα; (n= 3-6 animals per genotype). (c) 






murine Aβ40 and Aβ42 measured by ELISA in Pld1 WT and KO mice (n=9 mice per 
genotype). The Aβ42/40 ratio is also shown. (d) Bar graph quantifying Notch1 
intracellular domain (ICD) (n=4 mice) Values denote mean ± S.E.M. Statistical analyses 









 Figure 4.3 Lipidomic analysis of hAPP mice lacking PLD1. (a) Bar graph showing 
selected lipid sub-classes assayed from total murine forebrain as mol % of total lipids. 
Bar graphs showing total phospholipid unsaturated bonds (b) or total phospholipid chain 
length(c) as % total phospholipids. Bar graphs showing total sphingolipid unsaturated 
bonds (d), or total sphingolipid chain length (e) as % total sphingolipids. (f) Heat map of 
complete lipidomic analysis of forebrain. Data is ratio of lipids from hAPP Pld1 KO/hAPP 
Pld1 WT animals.  Log 2 increase is shown in red, decrease in lipid species is shown in 
blue. (n=6). Values denote mean ± S.E.M. Statistical analyses were performed using 








Figure 4.4 PLD1 ablation decreases amyloidogenesis in an FAD mouse model. (a) 
Representative Western blots of forebrain homogenates from hAPP-expressing Pld1 
WT and KO mice probed for full length APP, APP C-terminal fragments (CTF) α and β, 
secreted soluble fragments sAPPα and sAPPβ, and loading control. See Methods for 
antibody details. (b) Bar diagram showing the quantitative analysis of the blots and the 
significant increase in APP CTFα (n= 9-10 animals). (c) Bar diagram showing the levels 
of soluble and insoluble human Aβ40 and 42 measured by ELISA in hAPP-expressing 
Pld1 WT and KO mice (n =6 hAPP/Pld1 WT, 8 hAPP/Pld1 KO animals). The Aβ42/40 
ratio is also shown. (d) Forebrain slices from Pld1 WT and KO animals stained for 
human Aβ deposition in the hippocampus. Green arrows highlight representative senile 
plaques in tissue expressing Pld1 and fewer in Pld1 KO (n=6 hAPP/Pld1 WT, n= 4 
hAPP/Pld1 KO. For (b) and (c), values denote mean ± S.E.M. Statistical analyses were 
performed using two-tailed Student’s t-test. P-values < 0.05, and < 0.01 were indicated 







Chapter 5 Molecular characterization of phospholipase D1 activity in lipid rafts in 
an FAD model 
 5.1 Lack of PLD1 disrupts APP processing and the lipidome in membrane rafts  
BACE1 and γ-secretase, the two critical factors responsible for amyloidogenic 
processing of APP, both reside and have elevated proteolytic activity in lipid rafts. In 
addition, a significant pool of PLD1 also concentrates in membrane rafts and may 
mediate physiological roles in these specialized locales (Jenkins and Frohman, 2005). 
With these insights we probed purified murine forebrain for relevant cleavage products 
and APP-cleaving enzymes in lipid rafts (Fig. 5.1a). FL-APP and BACE1 were not 
enriched in the rafts, as identified by enrichment in flotillin-1; however, we observed a 
~80% increase in CTFα, comparable to the increase observed in total forebrain 
homogenates (Fig. 5.1b) as well as trends for increased CTFβ and PSEN1 in lipid rafts 
from mouse forebrains lacking PLD1 (Fig. 5.1b). 
  In contrast to the few lipid variations observed in total forebrain of hAPP mice 
lacking PLD1, extensive changes in several lipid sub-classes were appreciated in 
purified rafts when comparing hAPP Pld1 null mice to controls (Fig 5.1f). Lack of PLD1 
in mice expressing hAPP caused a significant increase in sphingolipids such as 
sphingomyelin and ceramide (Fig. 5.1c). A slight, but significant, increase in cholesterol 
was also observed in brain lipid rafts from mice lacking PLD1 (Fig. 5.1c). This suggests 
that PLD1 activity contributes to the composition of lipid rafts, and loss of PLD1 activity 








5.2  Pharmacological inhibition of PLD1 decreases γ-secretase cleavage of APP 
In the brain, we observed decreased Aβ production in Pld1 null animals and an 
accumulation of APP CTFα in lipid rafts. To investigate the mechanism of these 
observations, we focused specifically on the effects of PLD1 ablation on γ-secretase 
activity. Because Pld1 null brain extracts contain higher levels of substrate CTFs, we 
could not utilize them for these experiments. Instead, we turned to an in vitro system 
and quantified γ-secretase cleavage of APP CTFs by measuring APP intracellular 
domain (AICD) production over time. We set out to use a specific pharmacological 
inhibitor of PLD1 to assay for APP processing. We first tested the PLD1 inhibitor on 
MEFs expressing WT (Fig. 5.2a) and Swedish (Fig 5.2b) hAPP. After incubating cells 
with the PLD1 inhibitor or γ-secretase inhibitor Compound E (CompE) for 24 hours we 
observed decreases in Aβ 42 produced from WT hAPP (Fig. 5.2a). We also tested the 
PLD1 inhibitor on neurons from theTg2576 mouse which expresses hAPP with the 
Swedish mutation. Incubation with either the PLD1 inhibitor or CompE reduced secreted 
Aβ42 in these neurons. Thus, we have evidence that pharmacologic inhibition of PLD1 
reduces Aβ production from WT hAPP and Swedish hAPP in vitro. 
We applied the PLD1 inhibitor to purified membranes from primary neuronal 
cultures expressing hAPP (and thus hAPP CTFs) to examine whether acute inhibition of 
PLD1 catalytic activity decreases amyloidogenic processing of APP.  These membrane 
extracts were incubated with the PLD1 inhibitor for 10, 20, 30, or 45 minutes; these 
neurons produced less AICD compared to vehicle treated control, consistent with 
decreased γ-secretase cleavage of APP CTFs (Fig. 5.3 a, b). Control membranes 






with the knockout data and the ability of the PLD1 inhibitor to reduce γ-secretase 
activity, treatment of neurons with the PLD1 inhibitor for 24 hours decreased secretion 
of Aβ40 and Aβ42 relative to vehicle-treated neurons (Fig. 5.3c). Comparable effects 
were obtained with Compound E (Fig. 5.3c). Thus, in addition to PLD1 shifting APP 
away from sites of amyloidogenic cleavage, these data suggest that PLD1-derived PA 
also regulates APP processing by decreasing γ-secretase cleavage of CTFs. Together, 








Chapter 5 FIGURES 
 
 Figure 5.1 Lack of PLD disrupts APP processing and the lipidome in membrane 
rafts. (a) Western blot analysis of equal fractions from forebrain detergent homogenates 






separation of lipid rafts. Membranes were probed for APP (6E10), APP-CTF, BACE1, 
PSEN1 CTF, and Flotillin-1. Flotillin-1 enrichment denotes the lipid raft-containing 
fractions. (c) Bar diagram showing the quantification of selected proteins in pooled lipid 
raft fractions. (n= 4 mice, Pld1 KO and hAPP/Pld1 WT, n=3 mice Pld1 WT and 
hAPP/Pld1 KO). Values denote mean ± S.E.M. (c) Heat map of lipidomic analysis of raft 
fractions. Data is ratio of Pld1 KO vs. Pld1 WT in the left column or hAPP Pld1 KO/ vs. 
hAPP/Pld1 WT expressing mice in the right column. (n= 4 mice, Pld1 KO and 
hAPP/Pld1 WT, n=3 mice Pld1 WT and hAPP/Pld1 KO).  Log 2 increases are shown in 
red, decreases in lipid species are shown in blue. Statistical analyses were performed 







Figure 5.2 Pharmacologic PLD1 inhibition reduces amyloidogenic processing of 
WT hAPP and the Swedish hAPP mutant. (a) Bar graph expressing Aβ42 secreted 
from mouse embryonic fibroblasts expressing WT hAPP. (n=3 per condition) Values 
denote mean ± S.E.M. (b) Bar graph expressing Aβ42 secreted from mouse embryonic 
fibroblasts expressing the Swedish hAPP mutant. For PLD1 inhibitor p=0.0562. (n=3 per 
condition) Values denote mean ± S.E.M.    (c) Bar graph of Aβ42, secreted from primary 
neurons from the Tg2576 FAD model, which expresses the Swedish hAPP mutant. 
(n=4) 100nM PLD1 inhibitor (CAY10593) or 2µM γ-secretase inhibitor (CompE) was 
added for 24 hours in all cases. Values denote mean ± S.E.M. Statistical analyses were 
performed using two-tailed Student’s t-test. P-values < 0.05 and < 0.01 were indicated 




















Figure 5.3 Pharmacologic PLD1 inhibition reduces APP processing by γ-
secretase. (a) Western blot showing the time course of AICD-GFP production by 
gamma-secretase activity in extracts derived from hAPP-GFP expressing primary 
neurons incubated for the indicated durations at 37˚C (n=4). 100nM PLD1 inhibitor 
(CAY10593) or 2µM γ-secretase inhibitor (CompE) was added. (b) Diagram showing the 
quantification of AICD-GFP released at 0, 10, 20, 30, and 45 minutes.(n=4) Values 
denote mean ± S.E.M. (c) hAPP-expressing cortical neurons were cultured for 13 days, 
then treated for 24 hours with the indicated inhibitor. Media was assayed for secreted 
Aβ40 and by ELISA (n = 4). Values denote mean ± S.E.M. Statistical analyses were 
performed using two-tailed Student’s t-test. P-values < 0.05 and < 0.01 were indicated 













Chapter 6 Neurobehavioral and synaptic effects of phospholipase D1 
 Four to 6 month-old hAPP animals have been previously shown to exhibit significant 
age-dependent deficits in learning and memory. Transgenic animals perform poorly in 
the Fear Conditioning (FC) test, which evaluates hippocampus and amygdala-
dependent associative memory via contextual and cued tests, respectively (LeDoux, 
1992; Maren, 2008; Sanchez-Mejia et al., 2008).  These learning deficits correlate with 
a robust Aβ load (particularly, in the form of soluble oligomers) as well as functional and 
morphological defects at hippocampal synapses (Palop and Mucke, 2010). We tested 
whether the decrease in amyloidogenic processing in Pld1 KO mice could mitigate FAD 
hAPP-associated cognitive deficits in this test using the same mice in which we studied 
APP metabolism. While both sets of mice displayed little freezing during the training 
portion of the FC task, hAPP mice lacking PLD1 exhibited increased freezing compared 
to transgenic littermates upon exposure to the contextual environment 24 hours later 
(Fig. 6.1a). Pld1 null mice perform indistinguishably from wild type mice during training 
and contextual portions of this test (Fig. 6.2a). No differences in freezing times were 
observed in the cued portion of the FC task (Fig. 6.2b).   
 We exploited a second test, the Two-Day Radial Arm Water Maze, to efficiently 
discriminate between mice with deficits in hippocampus-dependent spatial reference 
memory (Alamed et al., 2006; Lassalle et al., 2000). hAPP expressing mice failed to 
consistently locate a submerged platform over the two day test period. In contrast, 
hAPP mice without PLD1 learned the location of the hidden platform over the same 10 






differences in vision, motivation to find the platform, or physical activity as all mice 
performed with similar acuity when probed with a visible platform (Fig. 6.2d). These 
independent behavioral tests indicate that mice lacking PLD1 are protected from 
hippocampus-associated deficits in mnemonic capacity caused by the hAPP transgene, 
as would be expected from concomitant decrease in Aβ load.  
To ascertain whether PLD1 affects other aspects of cognition, we also performed 
the Elevated Plus Maze test. This test, which is unrelated to learning or memory, 
measures anxiety and is more correlated to amygdala function(Silveira et al., 1993). 
hAPP mice lacking PLD1 performed indistinguishably from hAPP mice expressing PLD1 
(Fig. 6.2c). Thus, PLD1 ablation restores hippocampus associated deficits while 
behaviors related to amygdale function are unaffected. 
 Deficits in learning and memory are correlated with synaptic pathology and 
parallel extent of cognitive decline. While not exhibiting gross neuronal loss seen in 
patients with AD, the hAPP mouse also displays loss of synaptic terminals typified by a 
deficiency of synaptophysin labeled presynaptic terminals (Mucke et al., 2000). In mice 
lacking the human transgene, we noted that ablation of Pld1 did not affect the levels of 
this protein or PSD95, a postsynaptic marker whose levels are also depleted in a FAD 
murine model (Oliveira et al., 2010). PLD ablation in hAPP mice increases the amount 
of these proteins in the brain over levels seen in mice expressing the lipase (Fig. 8c), 
consistent with maintained synaptic health in these animals. Taken together, these data 
indicate that hAPP mice lacking PLD1 have restored cognition as well as protection 







Chapter 6 FIGURES 
Figure 6.1. PLD1 ablation improves neurobehavioral deficits in the FAD hAPP 
model. (a) Bar graphs showing freezing behavior of hAPP mice in the fear conditioning 
test during training and contextual periods. (n=16 hAPP/Pld1 WT mice, 14 hAPP/Pld1 
KO mice) Values denote mean ± S.E.M. (b) Diagram showing performance of mice by 
latency to platform and errors in the two-day radial arm water maze. (n=10 mice per 
genotype) (c) Representative 60s trace of mice after 10 training sessions in pool lacking 
platform. (d) Western blot analysis comparing synaptic proteins synaptophysin and 
PSD95  in Pld1 WT and KO mice with and without the hAPP transgene. (e) 
Quantification of Western blots (n=6 mice). Values denote mean ± S.E.M. Statistical 
analyses were performed using two-tailed Student’s t-test. P-values < 0.05, < 0.01, and 










Figure 6.2. Supplementary behavioral tests. (a) Bar graphs showing freezing of Pld1 
WT and Pld1 KO animals in training, contextual, and cued portions fear conditioning 
test. (n=11 mice for both genotypes) (b) Bar graph showing in freezing during the cued 
portion of the fear conditioning test in hAPP mice. (n=16 hAPP/Pld1 WT mice, 14 
hAPP/Pld1 KO mice)  (c) Bar graph showing % time spent in open arms and number of 
open arm entries of hAPP mice in the elevated plus maze. (n=6 per genotype) (d) 
Diagram of visible platform assessment of the two-day radial arm water maze. (n=10 
mice) Values denote mean ± S.E.M. Statistical analyses were performed using two-







Chapter 7 Discussion 
In sum, the results from this study establish that PLD1 and its product PA regulate the 
neuronal traffic of APP along the Golgi and endosomes in a manner that influences 
amyloidogenesis in mammalian brain. In addition to the previously proposed role for 
PLD1 regulating intracellular vesicular traffic along these organelles through PA 
(Donaldson, 2009; Jenkins and Frohman, 2005; Roth, 2008), this study also 
demonstrates that PLD1 regulates intramembranous proteolysis of APP within lipid rafts 
and that it functions as a γ-secretase modulator (Fig. 7.1). Using genetic approaches, 
we show that targeting PLD1 may be a preventative or therapeutic option against AD 
pathogenesis. 
 We previously investigated the role of PLD2 in AD and found that this enzyme 
lies in the signaling pathway of Aβ. While PLD1 and PLD2 share significant sequence 
homology, these isoforms are differentially localized and regulated within cells. We and 
others have shown that PLD2 is primarily located at the plasma membrane, while PLD1 
cycles mostly between intracellular vesicles (Oliveira and Di Paolo, 2010; Roth, 2008). 
Interestingly, while lack of PLD2 disrupts the toxic effects of Aβ with no discernible 
impact on APP trafficking and processing (Oliveira et al., 2010), PLD1 ablation impacts 
both the trafficking and metabolism of APP. PLD1 deletion or inhibition causes a striking 
reduction in Aβ levels, the result of decreased APP cleavage by у-secretase based on 
the accumulation of APP CTFs and the lack of effects on sAPP or . These different 
effects of the two PLD isoforms are consistent with the fact that these enzymes are 
differentially localized in cells and use distinct, yet partially overlapping, PC substrates, 






species in forebrain of Pld1 and Pld2 KO mice.  Importantly, while striking differences 
are observed in the context of neurodegenerative disease, unperturbed PLD1- or PLD2-
deficient mice are indistinguishable from wild type littermates. Taken together, our 
results indicate inhibiting either PLD1 or PLD2 may be beneficial in AD although these 
two related lipases appear to affect distinct aspects of APP biology. This is consistent 
with a growing number of studies showing isoform-specific functions for these two 
enzymes (Chen et al., 2012; Peng and Frohman, 2012; Rudge and Wakelam, 2009).   
 
7.1 PLD activity and APP trafficking 
PLD1 contributes more than half of the PA found in murine forebrain, yet this 
pool is surprisingly dispensable for life in light of the plethora of functions assigned to 
PA (Jenkins and Frohman, 2005) (Kooijman, BBA 2009). One of the proposed functions 
of PLD1-derived PA is to facilitate vesicular trafficking, particularly as the enzyme cycles 
within the secretory pathway from the trans-Golgi network (TGN) to the plasma 
membrane (Cazzolli et al., 2006; Roth, 2008; Vitale, 2010). Relevant to our work, a 
previous study showed that overexpressing PLD1 enhances budding of APP-laden 
vesicles from the TGN; the same report used primary alcohols to inhibit PLD activity and 
reported decreased liberation of these vesicles from the TGN (Cai et al., 2006b).  While 
our study provides genetic evidence in support of the idea that PLD1 physiologically 
controls the trafficking of APP in neurons, it further expands upon this notion by showing 
that PLD1 controls a pool of APP in endosomes, a key site of Aβ generation. The 
pathological relevance of this role, and of PA production specifically, is uncovered in a 






Another study described how silencing Pld1 increased amyloidogenesis in vitro and 
suggested a role for the lipase in physically disrupting γ-secretase components (Cai et 
al., 2006a), which may also disrupt APP localization as PSEN1 mutations affect APP 
trafficking. We report that whether by genetic ablation in vivo or acute inhibition of 
cultured neurons, removing PA decreases Aβ levels by suppressing, rather than 
increasing, γ-secretase activity. Furthermore, this decrease in amyloidogenesis is 
accompanied by a resolution of Aβ- associated neurobehavioral and synaptic sequelae. 
Thus, our in vivo experiments demonstrate that PLD1- derived PA promotes the 
amyloidogenic processing of APP by directing the traffic of this molecule into 
endosomes in addition to enhancing its processing through γ-secretase. 
 
7.2 PLD activity and lipid rafts 
Additional evidence from our study suggests that a central aspect of PLD1-mediated 
regulation of APP metabolism lies in lipid rafts. These cholesterol- and sphingolipid- 
enriched lipid microdomains facilitate compartmentalization of enzymatic reactions, and 
thus have long been investigated as prime locales of amyloidogenic processing of APP, 
particularly by γ-secretase (Grimm et al., 2005; Lingwood and Simons, 2010; Rajendran 
and Simons, 2005). Previous studies have shown that in addition to the physical 
association of amyloid producing proteins within rafts, the activity of the amyloidogenic 
enzymes themselves are influenced by their lipid environment (Di Paolo and Kim, 2011; 
Vetrivel et al., 2004). For example, purified γ-secretase cleaves CTFβ most efficiently 
within a raft-like lipid milieu (Osenkowski et al., 2008). This principle is further 






(i.e., the release of varied lengths of Aβ species) of the complex is sensitive to 
differences in bilayer composition such as fatty acyl carbon chain length, degree and 
isomerization of acyl chain saturated carbon-carbon bonds, and polar head group type 
(Holmes et al., 2012). Moreover, this and a previous study (Osenkowski et al., 2008) 
explicitly ascribe a modulatory role for γ-secretase activity to PA; specifically, increasing 
PA levels elevates Aβ40 production and decreases the Aβ42/Aβ40 ratio (Holmes et al., 
2012). In agreement with these studies, our work provides genetic and pharmacological 
evidence showing that decreasing PA levels by knocking out PLD1 or inhibiting its 
catalytic activity reduces γ-secretase-mediated cleavage of APP. Because the 
membrane raft lipidome of Pld1 KO mice expressing the hAPP transgene is profoundly 
altered, we hypothesize that PLD1-derived PA, which is decreased in KO membrane 
rafts, plays an important role in the stability of membrane microdomains, consistent with 
studies showing that PLD1 co-fractionates with these membrane microdomains Indeed, 
in addition to the PA deficiency, sphingolipids, particularly certain species of ceramides, 
were increased in lipid rafts from FAD model mice lacking PLD1. Another report also 
demonstrated that increases in membrane ceramide levels, via inhibition of 
glycosylceramide synthase, leads to decreases of Aβ levels with concomitant increase 
in APP CTF fragments, consistent with a role for ceramide as another γ-secretase 
modulator(Li et al., 2010).  We also observed increased levels of cholesterol in these 
rafts. Increasing plasma and CNS cholesterol levels exacerbates AD pathology in FAD 
models (Refolo et al., 2000), and depleting cholesterol from membranes abrogates Aβ 
production in hippocampal neurons, consistent with deleterious effects on γ-secretase 






cholesterol levels modulates the enzymatic processing of APP within rafts. Indeed, 
conflicting experimental outcomes with cholesterol modulation have been observed 
(George et al., 2004; Howland et al., 1998), underscoring the need for closer 
investigation of raft dysfunction in AD. Overall, our data suggest that perturbation of the 
raft lipidome in Pld1 null mice renders the lipid environment suboptimal for γ-secretase-
mediated cleavage of APP CTFs.  
  
7.3 Future Directions 
The results of this work generate questions as to how PLD1-derived PA disrupts APP 
cleavage by γ-secretase and drives the traffic of APP through neurons.  We speculate 
that PA may directly modulate γ-secretase activity, perhaps by binding to PSEN1 or 
another member of the γ-secretase complex and/or stabilizing this complex. This can be 
investigated by using PA binding assays to quantify the association of  each γ-secretase 
component (Fang et al., 2001; Lehman et al., 2007). If one protein is identified, it may 
be truncated and mutagenized until a putative PA binding site is specified. In addition, it 
would also be important to assay the localization of  other relevant proteins, such as 
BACE1 and γ-secretase in the Pld1 KO neurons to ascertain if mislocalization of these 
enzymes contributes to our observed phenotypes. It would also be useful to rule out any 
functions of PLD1 that are unrelated to PA production  by overexpressing catalytically 
dead and truncated constructs of PLD1 in a Pld1 null background to see if these also 
direct the traffic of APP or other substrates, such as γ-secretase, in neurons. As PSEN1 
influences the traffic of APP (Cai et al., 2006b; Gandy et al., 2007), it may be that PLD1 






These studies naturally lead to greater questions on the role of PLD1 in 
membrane trafficking and γ-secretase activity in vivo.  Using the Pld1 KO mouse we 
have established that PLD1 is an important modulator of APP processing, and we have 
demonstrated that acute inhibition of this lipase can also reduce amyloidogenesis. 
Because we have shown in the past the Pld2 ablation is also protective in an FAD 
model (Oliveira et al., 2010), it would be useful to test whether existing dual- isoform or 
isoform-specific PLD inhibitors can cross the blood brain barrier and decrease Aβ 
production, attenuate synaptotoxic Aβ signaling, or have other effects within the brain of 
mammals. We have used the dual-isoform inhibitor 5-fluoro-2indolyl des-
chlorohalopemide (FIPI) in vitro, but it is unclear if this compound enters the brain with 
any efficacy.  Other dual-isoform and PLD1 specific inhibitors have been generated 
using a targeted diversity approach to vary a halopemide backbone for the purpose of 
identifying strong inhibitors (Scott et al., 2009). First, compounds that passed in-vitro 
screening would need to be injected intraperitoneally into WT mice and brain levels 
could be measured to see if the compounds cross the blood-brain barrier. If existing 
compounds are insufficient, medicinal chemistry could be used to generate more 
compounds based on the halopemide structure or other validated PLD inhibitors such 
as presqualene diphosphate or selective estrogen receptor modulators such as 
raloxifene (Scott et al., 2009). Newly generated compounds could be screened for 
inhibitory activity in vitro by measuring a transphosphatidylation product (such as 
PEtOH) via mass spectrometry (Scott et al., 2009) before being used in vivo.  
Efficacious compounds could then be applied to both young and old FAD model mice. 






immunohistochemistry as in this study to determine whether PLD inhibition could 
prevent and/or reverse amyloidogenesis. Behavioral experiments and 
electroencephalography (Sanchez et al., 2012), can be performed on FAD mice that 
exhibit known deficits with and without PLD inhibitor treatment. This would provide 
insight as to whether neural circuitry is preserved or restored after PLD inhibition. 
 
Closing statement  
Our findings reveal a novel role for PLD1 as a modulator of trafficking of APP and 
as a factor promoting the amyloidogenic processing of APP through γ-secretase. Our 
work and that of others has implicated various phospholipid signaling pathways in 
relevant aspects of AD pathology including APP metabolism (Cai et al., 2006a; Cai et 
al., 2006b), Aβ signaling (Berman et al., 2008; McIntire et al., 2012; Oliveira et al., 2010; 
Sanchez-Mejia et al., 2008), and tau clearance through autophagy (Dall'Armi et al., 
2010). These studies converge on phospholipid metabolism as a promising therapeutic 
avenue in AD, consistent with the numerous alterations of phospholipids observed in 







Chapter 7 Summary Diagram 
 
Diagram 7.1 Model for roles of PLD1 in trafficking and processing of APP. PLD1 
facilitates APP traffic through the secretory pathway by promoting exit from the TGN via 
its lipid product PA. PLD1 is also responsible for a pool of APP in early and retromer- 
positive endosomes. Without PLD1, less APP is processed by γ-secretase, perhaps 
through interaction with PS1, the catalytic component of this complex. PA may also 









Chapter 8 Materials and Methods 
Animals. 
Pld1 and Pld2 null mice were generated as previously described (Dall'Armi et al., 2010; 
Oliveira et al., 2010). Pld double knockout animals were generated by first 
crossbreeding Pld1 and Pld2 null mice and subsequently breeding mice heterozygous 
for both genes in the F1 generation.  Pld1 mice were then backcrossed for 6 
generations into the C57BL background, prior to breedings with hAPP mice expressing 
human APP under the PDGF promoter two FAD mutations, also referred to as J20 
(Mucke et al., 2000). Pld1 WT and Pld1 KO mice were used to isolate MEFS  from 13.5 
day embryos. Cell were plated in a 100mm dish and labeled passage 0. Each culture 
was derived from a single embryo and 1.2 × 106 cells per dish were subsequently plated 
and passaged every 3–4 days. MEFs were used after immortalization (around passage 
25). All experiments involving animals were performed in accordance with protocols 
approved by the Institutional Animal Care and Use Committee of Columbia University. 
In vivo  PLD activity assay. 
Mice were injected intraperitoneally with 3 g/kg ethanol and killed 1 h post-injection, as 
previously described (Oliveira et al., 2010). Forebrains were then removed from the 
mice and levels of phosphatidylethanol (PEtOH) produced via a PLD-specific 
transphosphatidylation reaction were measured in lipid extracts via liquid 
chromatography-mass spectrometry (Oliveira et al., 2010). 
 In vitro PLD activity. 
Ten day-old neurons  or immortalized MEFs were incubated with [3H] palmitic acid (2 






thepresence of 0.3% butanol for 30 min, which leads to the production and 
accumulation of [3H]phosphatidylbutanol via a PLD-specific transphosphatidylation 
reaction. Radiolabeled lipids, including phosphatidylbutanol, were isolated by solvent 
extraction and separated by thin layer chromatography. The total amount of 
[3H]phosphatidylbutanolis expressed as a percentage of total[3H]-labeled lipids (Morris 
et al., 1997). 
Western blotting. 
Brain extracts were separated by SDS-PAGE according to the manufacturer's protocols 
(Invitrogen).  Samples were prepared with NuPAGE LDS sample buffer and loaded onto 
4–12% Bis-Tris NuPage gels in NuPAGE MES running buffer. Electroblotting to 
nitrocellulose membranes was accomplished using the iblot system according to 
manufacturer’s instructions (Invitrogen). Membranes were probed using the following 
antibodies and concentrations: rabbit antiserum to PLD1 and PLD2 (1:200) (kind gift 
from Dr. Sung Ho Ryu, Pohang University of Science and Technology, Pohang, South 
Korea), mouse monoclonal to α-tubulin (1:1,000) (Sigma), GFP (1:1000)(Roche), 
murine and human APP-NT (1:500)(clone 3E9- Calbiochem), human APP (1:500)(6e10- 
Covance), human sAPPα (1:500)(clone 2B3- ARP), Flotillin-1 (1:1,000)(BD 
transduction), PSD95 (1,2,000) (Abcam) synaptophysin (1:1000)(Millipore); rabbit 
polyclonal to murine and human APP-CT (1:500)(Calbiochem), murine and human 
sAPPβ (Covance), BACE1 (1:1,000) (Thermo), PS1 CTF (1:1,000)(Cell Signaling). 
HRP-conjugated anti-rabbit and mouse secondary antibodies (Biorad) were used at 






Chemiluminescent HRP Substrate per manufacturer’s instructions.  Quantification was 
performed using ImageJ software. 
Anionic phospholipid analysis. 
Anionic phospholipid-enriched lipid fractions were extracted from frozen brain tissue 
samples and deacylated according to previously described methods (Berman et al., 
2008; Voronov et al., 2008). The deacylated lipid samples were dissolved in the 
appropriate volume of water for further analysis by anion-exchange high performance 
liquid chromatography with suppressed conductivity detection as described (Berman et 
al., 2008; Nasuhoglu et al., 2002) but with slight modification to the KOH gradient 
profile. Specifically, the elution was carried out in five stages; (1) a gradient change of 
1.5 to 4 mM KOH from injection time to 7 min postinjection, (2) 4 to 16 mM from 7 to 
12min post injection, (3) 16 to 25.75 mM from 12 to 35min postinjection, (4) 25.75 to 86 
mM from 35 to 60min postinjection and finally (5) 5 min isoelectric elution with 86mM 
KOH followed by re-equilibration of the column. 
Lipidomic analysis. 
Lipid extracts from frozen brain tissue and lipid raft fractions were subjected to 
comprehensive lipidomic analysis as described previously (Chan et al., 2012b; Dumont 
et al., 2012). The analyses were conducted with an Agilent Technologies 6490 Ion 
Funnel liquid chromatography/mass spectrometry (LC/MS) Triple Quadrupole system 
with front end 1260 Infinity high-performance liquid chromatography (HPLC). 
Phospholipids and sphingolipids were analyzed by a normal-phase HPLC using a 
Phenomenex Luna silica column (i.d. 2.0 × 150 mm) using a gradient consisting of A: 






(55:39:5.5:0.5), starting at 5% B and changing to 70% B over a 40 min period at a flow 
rate of 0.3 ml/min. Neutral lipids were separated by reverse phase HPLC on an Agilent 
Zorbax XDB-C18 column (i.d. 4.6 × 100 mm) using an isocratic mobile-phase 
CHCl3/CH3OH/0.1 M CH3COONH4 (100:100:4) at a flow rate of 0.25 ml/min. 
Quantitative analysis of different lipid subclasses was carried out by referencing to 
spiked internal standards using multiple reaction monitoring transitions as described 
previously(Chan et al., 2012b; Dumont et al., 2012) 
Lipid data analysis and presentation. 
Lipid levels for each sample were calculated by summing up the total number of moles 
of all lipid species measured by all three LC-MS methodologies, and then normalizing 
that total to mol %. The final data are presented as mean mol % as indicated. 
Immunofluorescence on cultured cells. 
Primary cultures of hippocampal neurons were obtained from P0 mice hippocampi. 
Neurons were plated on poly-L-lysine coated coverslips, and incubated with Neurobasal 
media with 10% FBS. After 5 h, neurons were transferred into serum-free medium 
supplemented with B27 (Invitrogen) and cultured for 8-9 days in vitro (DIV). 7-8DIV 
neurons were transfected for 60 min with 2-3 μl of Lipofectamine 2000 (Invitrogen) 
combined with 1 μg of DNA, washed, and incubated for 24 h prior to 
immnuofluorescence analysis. Neurons were washed three times with ice-cold PBS, 
fixed with 4% paraformaldehyde for 20 min at room temperature (RT) and washed three 
times with PBS. They were then permeabilized with 200 μg ml − 1 digitonin (Invitrogen) 
for 15 min and incubated for 1 h at RT with indicated primary antibodies diluted in 






secondary antibodies for 1 h at RT, washed three times in PBS and coverslips were 
mounted in Vectashield with DAPI (Vector). Images were acquired by confocal laser 
scanning microscopy (Zeiss LSM 700) at 63X magnification. Antibodies used, with 
dilutions, were: mouse monoclonal to murine and human APP-NT (1:100)(clone 
3E9)(Calbiochem), GM130 (1:200) (BDbiosciences); rabbit polyclonal to murine and 
human APP-CT (1:200)(Calbiochem), giantin (1:1,000)(Covance), LAMP1 (1:500) 
(Abcam), and LC3 (1:100)(MBL); goat polyclonal to Vps35 (1:200)(Abcam) and EEA1 
(1:200) (Santa Cruz). Anti-mouse Cy5 (1:100)(Jackson Immunoresearch), anti-rabbit 
and anti-goat Alexa Fluor secondary antibodies (1:200)(Invitrogen) were used. 
Quantification was performed using ImageJ software. 
Inhibitors and у-secretase assay 
Primary neurons were incubated with 2uM у-secretase inhibitor (Compound E, EMD 
chemicals) or 100 nM PLD1 isoform specific inhibitor (CAY 10593, Cayman Chemicals) 
(Lavieri et al., 2009). WT neurons were infected with APP-GFP and expression 
proceeded for 6 days. On the seventh day inhibitor was applied for 24 hours. Neurons 
were scraped into hypotonic buffer (10mM Tris, pH 7.4, 1mM EDTA, 1mM EGTA, 
protease inhibitor (Roche) and lysate was maintained at 4˚C. Cells were homogenized 
and centrifuged for 45 min at 16000xg. Pelleted membrane was resuspended in 
hypotonic buffer and incubated for indicated times in 37˚C oven. Samples were again 
spun for 45 min at 16000xg and supernatant was assessed for APP intracellular domain 







Brains were homogenized and mouse Aβ was extracted for ELISA analysis as 
described previously (Schmidt et al., 2005). In short, brain hemispheres were 
homogenized by 5 ml glass tissue grinder (20 strokes) at 10% w/v (wet brain weight) in 
ice-cold tissue homogenization buffer (THB) [250 mm sucrose, 20 mm Tris-HCl, pH 7.4, 
1 mm EDTA, 1 mm EGTA,  and EDTA-free Mini-Complete protease inhibitor mixture 
tablet (Roche)]. Soluble mouse Aβ was extracted by adding diethylamine (DEA) buffer 
(0.4% DEA in 100 mm NaCl) to form a 10% solution. The samples were then 
rehomogenized by six strokes using a 5 ml glass grinder and were centrifuged at 
100,000 × g for 1 h at 4°C. The resulting supernatant was neutralized with 0.5 m Tris-
HCl, pH 6.8, and divided into three to four aliquots. Insoluble Aβ was extracted from the 
pellet as described previously(Schmidt et al., 2005). The pellet was resuspended at 
10% w/v of initial wet weight in ice-cold RIPA buffer (10 mm Tris-HCl, pH 8, 150 mm 
NaCl, 0.5% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 5 mm EDTA, 1 mm EGTA, 
1 mm PMSF, and EDTA-free Mini-Complete protease inhibitor mixture tablet) and 
sonicated  on ice. The samples were cleared from debris by centrifugation at 10,000 × g 
for 10 min at 4°C, and the supernatant was saved for further analysis. The levels of 
soluble and insoluble Aβ40 and 42 were measured from these samples or diluted media 
of hAPP expressing cells using ELISA kits (Invitrogen). 
Immunohistochemistry. 
Mouse brains were harvested after transcardial perfusion and drop-fixed in 4% 
paraformaldehyde overnight, followed by cryoprotection treatment in 30% sucrose in 
PBS for 48 hours. Brains were embedded in O.T.C compound and frozen in a 






glass slides and immunostained with H&E and overnight with 6E10 antibody (Covance 
Inc) which recognizes only human APP. Sections were examined blind to genotype 
under a light microscope. 
Lipid raft isolation. 
Brains were subject to dounce homogenization in Tris buffer (25 mM Tris-HCl pH 7.5, 
150 mM NaCl, 5 mM EDTA, 1 mM 4-(2-Aminoethyl) benzenesulfonyl fluoride 
hydrochloride and 50 mM NaF). After normalizing protein concentration to 4mg/ml (BCA 
protein assay, Thermo Scientific), homogenate was incubated with 1% Brij-98 (Sigma) 
for 30 mins at 4˚C. This sample was  mixed with an equal volume of 80% (wt/vol) 
sucrose in Tris buffer, transferred to an ultracentrifuge tube, and then layered with 35% 
(wt/vol) sucrose in Tris buffer and 5% (wt/vol) sucrose in Tris buffer. Tubes were 
centrifuged at 39,000rpm for 18h at 4˚C in a Beckman SW41 rotor and equavolume 
fractions were taken from the top of the gradient (Schuck et al., 2003). 
Behavioral testing.  
All behavioral analyses were performed blind to genotype. Two-day radial arm water-
maze experiments were carried out according to a published procedure (Alamed et al., 
2006).  Mouse swim traces were recorded over 60s by using a ceiling-mounted camera 
and analyzed with an HVS-2020 video tracking system.  Fear conditioning was 
performed as previously described (Oliveira et al., 2010). The elevated plus maze 
(EPM) was also chosen for this work to test anxiety of hAPP Pld1 KO animals 
compared to controls with the Pld1 gene. Briefly, animals were placed in the center of a 
black 60-cm by 60cm plus maze located 30-cm above a table. Two arms were open and 







At least three independent experiments were performed, unless indicated otherwise in 
the figure legends. Statistical analyses were performed using two-tailed equal variance 
Student’s t-test or ANOVA as appropriate. P-values < 0.05, < 0.01, and <0.001 were 



















































































































































































































































































































































































Dataset 1: Molecular and lipid composition of murine WT and hAPP model 
forebrain 
Dataset 2: Molecular and lipid composition of murine WT and hAPP forebrain lipid 
rafts 
91
Color code for t-test
A Mean SEM Mean SEM t-test p≥ 0.05
LBPA 0.013 ± 0.003 0.010 ± 0.001 0.430 p≥ 0.01
Plasmalogen PE (PEp) 12.986 ± 1.401 13.423 ± 1.296 0.823 p≥ 0.001
PG 0.080 ± 0.013 0.073 ± 0.005 0.642
Sulfatide 0.916 ± 0.100 0.830 ± 0.041 0.448
GM3 0.078 ± 0.016 0.055 ± 0.011 0.258
PA 1.771 ± 0.324 0.638 ± 0.210 0.015
PI 2.602 ± 0.296 1.770 ± 0.071 0.021
PS 8.201 ± 1.015 7.435 ± 0.807 0.568
Ceramide 0.297 ± 0.014 0.268 ± 0.019 0.247
Monhexosylceramide 3.752 ± 0.553 2.714 ± 0.500 0.194
Ether PC (ePC) 0.975 ± 0.035 0.953 ± 0.067 0.779
PC 25.851 ± 3.925 27.049 ± 4.016 0.835
PE 6.944 ± 0.726 6.940 ± 0.913 0.997
Sphingomyelin 3.000 ± 0.072 2.999 ± 0.179 0.997
Diacylglycerol 0.067 ± 0.006 0.050 ± 0.005 0.059
Cholesterol ester 1.450 ± 0.287 1.324 ± 0.217 0.733
Triacylglycerol 0.033 ± 0.002 0.031 ± 0.002 0.468
Free cholesterol 30.986 ± 3.822 33.438 ± 5.444 0.720
A Ave SEM Ave SEM t-test
LBPA 32:0 0.000 ± 0.000 0.000 ± 0.000 0.995
LBPA 32:1 0.000 ± 0.000 0.000 ± 0.000 0.747
LBPA 34:0 0.000 ± 0.000 0.000 ± 0.000 0.764
LBPA 34:1 0.001 ± 0.000 0.000 ± 0.000 0.644
LBPA 34:2 0.000 ± 0.000 0.000 ± 0.000 0.825
LBPA 36:0 0.000 ± 0.000 0.000 ± 0.000 0.153
LBPA 36:1 0.001 ± 0.000 0.001 ± 0.000 0.526
LBPA 36:2 0.010 ± 0.002 0.008 ± 0.001 0.409
LBPA 36:3 0.000 ± 0.000 0.000 ± 0.000 0.812
LBPA 38:3 0.000 ± 0.000 0.000 ± 0.000 0.228
LBPA 38:4 0.000 ± 0.000 0.000 ± 0.000 0.294
LBPA 38:5 0.000 ± 0.000 0.000 ± 0.000 0.615
PE 32:0p 0.090 ± 0.044 0.052 ± 0.008 0.417
PE 32:1p 0.043 ± 0.018 0.031 ± 0.007 0.567
PE 34:0p 0.238 ± 0.071 0.223 ± 0.045 0.862
PE 34:1p 1.191 ± 0.217 1.094 ± 0.209 0.754
PE 34:2p 0.133 ± 0.024 0.120 ± 0.025 0.709
PE 36:0p 0.131 ± 0.014 0.134 ± 0.026 0.907
PE 36:1p 1.568 ± 0.204 1.511 ± 0.192 0.843
PE 36:2p 1.691 ± 0.216 1.676 ± 0.167 0.957
PE 36:3p 0.162 ± 0.014 0.175 ± 0.014 0.511
PE 36:4p 0.447 ± 0.052 0.463 ± 0.037 0.810
PE 38:2p 0.393 ± 0.037 0.394 ± 0.040 0.975
PE 38:3p 0.203 ± 0.019 0.224 ± 0.014 0.402
PE 38:4p 1.144 ± 0.094 1.260 ± 0.102 0.420
PE 38:5p 0.676 ± 0.033 0.732 ± 0.041 0.315
PE 38:6p 1.299 ± 0.121 1.380 ± 0.123 0.649
PE 40:3p 0.069 ± 0.005 0.065 ± 0.009 0.760
PE 40:4p 0.448 ± 0.034 0.573 ± 0.050 0.067
Pld1  KOPld1 WT
Pld1 WT Pld1  KO
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PE 40:5p 0.592 ± 0.035 0.721 ± 0.074 0.144
PE 40:6p 2.341 ± 0.288 2.474 ± 0.298 0.754
PE 42:5p 0.045 ± 0.014 0.043 ± 0.006 0.886
PE 42:6p 0.083 ± 0.031 0.077 ± 0.010 0.854
PG 32:0 0.017 ± 0.002 0.015 ± 0.001 0.402
PG 32:1 0.001 ± 0.000 0.001 ± 0.000 0.360
PG 34:0 0.004 ± 0.001 0.003 ± 0.000 0.641
PG 34:1 0.029 ± 0.005 0.026 ± 0.001 0.637
PG 34:2 0.000 ± 0.000 0.000 ± 0.000 0.326
PG 36:0 0.001 ± 0.000 0.000 ± 0.000 0.719
PG 36:1 0.004 ± 0.001 0.003 ± 0.000 0.592
PG 36:2 0.012 ± 0.002 0.012 ± 0.001 0.985
PG 36:3 0.001 ± 0.000 0.001 ± 0.000 0.470
PG 38:3 0.000 ± 0.000 0.000 ± 0.000 0.972
PG 38:4 0.011 ± 0.002 0.011 ± 0.001 0.715
PG 38:5 0.000 ± 0.000 0.000 ± 0.000 0.451
Sulf d18:1/16:0 0.004 ± 0.001 0.003 ± 0.000 0.173
Sulf d18:1/18:0 0.068 ± 0.016 0.053 ± 0.004 0.376
Sulf d18:1/18:0h 0.014 ± 0.002 0.012 ± 0.001 0.340
Sulf d18:1/18:1 0.003 ± 0.001 0.002 ± 0.000 0.371
Sulf d18:1/20:0 0.014 ± 0.002 0.011 ± 0.001 0.253
Sulf d18:1/20:0h 0.014 ± 0.002 0.012 ± 0.001 0.535
Sulf d18:1/22:0 0.051 ± 0.009 0.049 ± 0.004 0.800
Sulf d18:1/22:0h 0.058 ± 0.008 0.053 ± 0.004 0.667
Sulf d18:1/22:1h 0.029 ± 0.002 0.024 ± 0.001 0.035
Sulf d18:1/24:0 0.188 ± 0.018 0.161 ± 0.011 0.228
Sulf d18:1/24:0h 0.057 ± 0.007 0.047 ± 0.005 0.263
Sulf d18:1/24:1 0.369 ± 0.059 0.363 ± 0.017 0.921
Sulf d18:1/24:1h 0.046 ± 0.005 0.040 ± 0.005 0.404
GM3 18:1/16:0 0.004 ± 0.001 0.002 ± 0.000 0.098
GM3 18:1/18:0 0.050 ± 0.010 0.039 ± 0.008 0.408
GM3 18:1/20:0 0.010 ± 0.002 0.006 ± 0.001 0.119
GM3 18:1/22:0 0.006 ± 0.001 0.003 ± 0.001 0.115
GM3 18:1/24:0 0.003 ± 0.001 0.002 ± 0.000 0.104
GM3 18:1/24:1 0.005 ± 0.001 0.003 ± 0.001 0.162
PA 32:0 0.050 ± 0.006 0.038 ± 0.011 0.319
PA 32:1 0.028 ± 0.005 0.008 ± 0.003 0.007
PA 34:0 0.048 ± 0.010 0.016 ± 0.005 0.016
PA 34:1 0.408 ± 0.073 0.103 ± 0.043 0.005
PA 34:2 0.022 ± 0.004 0.007 ± 0.003 0.008
PA 36:0 0.036 ± 0.007 0.012 ± 0.004 0.015
PA 36:1 0.360 ± 0.065 0.097 ± 0.043 0.007
PA 36:2 0.132 ± 0.023 0.027 ± 0.013 0.003
PA 38:1 0.048 ± 0.010 0.014 ± 0.004 0.010
PA 38:2 0.060 ± 0.013 0.015 ± 0.007 0.014
PA 38:3 0.071 ± 0.015 0.029 ± 0.011 0.052
PA 38:4 0.386 ± 0.087 0.199 ± 0.061 0.110
PA 40:5 0.037 ± 0.010 0.014 ± 0.006 0.069
PA 40:6 0.085 ± 0.020 0.059 ± 0.014 0.304
PI 34:0 0.044 ± 0.007 0.030 ± 0.004 0.116
PI 34:1 0.072 ± 0.017 0.044 ± 0.005 0.137
PI 36:1 0.074 ± 0.016 0.027 ± 0.004 0.016
PI 36:2 0.023 ± 0.005 0.012 ± 0.001 0.035
PI 36:3 0.048 ± 0.008 0.033 ± 0.002 0.099
PI 36:4 0.387 ± 0.058 0.265 ± 0.018 0.073
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PI 38:3 0.172 ± 0.021 0.117 ± 0.007 0.030
PI 38:4 1.369 ± 0.136 0.972 ± 0.071 0.027
PI 38:5 0.285 ± 0.030 0.186 ± 0.011 0.011
PI 38:6 0.059 ± 0.010 0.038 ± 0.002 0.063
PI 40:6 0.069 ± 0.011 0.046 ± 0.004 0.083
PS 34:0 0.029 ± 0.004 0.027 ± 0.005 0.838
PS 34:1 0.159 ± 0.013 0.145 ± 0.031 0.678
PS 36:0 0.197 ± 0.039 0.180 ± 0.026 0.727
PS 36:1 1.772 ± 0.349 1.728 ± 0.246 0.920
PS 36:2 0.519 ± 0.100 0.443 ± 0.064 0.537
PS 38:1 0.189 ± 0.043 0.172 ± 0.031 0.753
PS 38:2 0.099 ± 0.022 0.094 ± 0.017 0.862
PS 38:3 0.142 ± 0.024 0.139 ± 0.023 0.924
PS 38:4 0.403 ± 0.066 0.409 ± 0.067 0.953
PS 40:3 0.055 ± 0.007 0.057 ± 0.007 0.801
PS 40:4 0.352 ± 0.033 0.369 ± 0.041 0.757
PS 40:5 0.563 ± 0.044 0.485 ± 0.056 0.300
PS 40:6 3.700 ± 0.286 3.165 ± 0.336 0.253
PS 42:4 0.011 ± 0.001 0.012 ± 0.001 0.778
PS 42:5 0.010 ± 0.001 0.010 ± 0.001 0.997
Cer d18:0/16:0 0.000 ± 0.000 0.000 ± 0.000 0.968
Cer d18:0/18:0 0.023 ± 0.002 0.024 ± 0.003 0.889
Cer d18:0/20:0 0.001 ± 0.000 0.001 ± 0.000 0.317
Cer d18:0/22:0 0.001 ± 0.000 0.001 ± 0.000 0.147
Cer d18:0/24:0 0.001 ± 0.000 0.000 ± 0.000 0.214
Cer d18:0/24:1 0.001 ± 0.000 0.000 ± 0.000 0.281
Cer d18:1/18:0 0.230 ± 0.010 0.211 ± 0.016 0.350
Cer d18:1/18:1 0.000 ± 0.000 0.000 ± 0.000 0.472
Cer d18:1/20:0 0.006 ± 0.001 0.006 ± 0.001 0.983
Cer d18:1/22:0 0.003 ± 0.000 0.003 ± 0.000 0.236
Cer d18:1/24:0 0.003 ± 0.000 0.002 ± 0.000 0.215
Cer d18:1/24:1 0.027 ± 0.004 0.018 ± 0.003 0.103
Cer d18:1/26:0 0.001 ± 0.000 0.000 ± 0.000 0.640
Cer d18:1/26:1 0.001 ± 0.000 0.000 ± 0.000 0.024
GluCer d18:0/18:0 0.008 ± 0.002 0.006 ± 0.001 0.155
GluCer d18:0/20:0 0.002 ± 0.000 0.001 ± 0.000 0.084
GluCer d18:0/22:0 0.019 ± 0.004 0.013 ± 0.002 0.184
GluCer d18:0/24:0 0.030 ± 0.007 0.021 ± 0.003 0.258
GluCer d18:0/24:1 0.050 ± 0.012 0.037 ± 0.004 0.329
GluCer d18:0/26:0 0.001 ± 0.000 0.001 ± 0.000 0.152
GluCer d18:0/26:1 0.001 ± 0.000 0.000 ± 0.000 0.396
GluCer d18:1/18:0 0.681 ± 0.115 0.423 ± 0.053 0.069
GluCer d18:1/20:0 0.133 ± 0.030 0.088 ± 0.010 0.181
GluCer d18:1/22:0 0.403 ± 0.143 0.235 ± 0.029 0.277
GluCer d18:1/24:0 0.507 ± 0.087 0.377 ± 0.035 0.197
GluCer d18:1/24:1 1.900 ± 0.279 1.501 ± 0.408 0.439
GluCer d18:1/26:0 0.004 ± 0.001 0.003 ± 0.000 0.125
GluCer d18:1/26:1 0.013 ± 0.002 0.009 ± 0.001 0.183
ePC 32:0 0.127 ± 0.004 0.116 ± 0.008 0.266
ePC 32:1 0.037 ± 0.009 0.041 ± 0.008 0.771
ePC 34:0 0.039 ± 0.007 0.042 ± 0.009 0.782
ePC 34:1 0.122 ± 0.023 0.130 ± 0.022 0.791
ePC 34:2 0.017 ± 0.003 0.016 ± 0.003 0.895
ePC 36:0 0.010 ± 0.002 0.010 ± 0.002 0.995
ePC 36:1 0.054 ± 0.008 0.052 ± 0.008 0.921
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ePC 36:2 0.036 ± 0.004 0.035 ± 0.004 0.888
ePC 36:3 0.024 ± 0.001 0.025 ± 0.002 0.797
ePC 38:2 0.054 ± 0.005 0.059 ± 0.009 0.601
ePC 38:3 0.011 ± 0.001 0.011 ± 0.001 0.762
ePC 38:4 0.038 ± 0.004 0.039 ± 0.004 0.867
ePC 38:5 0.042 ± 0.001 0.045 ± 0.003 0.507
ePC 40:4 0.047 ± 0.002 0.047 ± 0.004 0.968
ePC 40:5 0.017 ± 0.001 0.017 ± 0.001 0.939
ePC 40:6 0.042 ± 0.003 0.041 ± 0.003 0.727
ePC 42:5 0.008 ± 0.001 0.008 ± 0.001 0.609
ePC 42:6 0.008 ± 0.001 0.007 ± 0.001 0.335
ePC 44:3 0.032 ± 0.004 0.029 ± 0.004 0.602
ePC 44:4 0.032 ± 0.005 0.028 ± 0.004 0.619
ePC 44:5 0.171 ± 0.030 0.148 ± 0.023 0.550
ePC 44:6 0.006 ± 0.001 0.005 ± 0.001 0.416
PC 30:0 0.910 ± 0.037 0.844 ± 0.049 0.308
PC 32:0 5.233 ± 0.874 4.864 ± 0.558 0.729
PC 32:1 0.582 ± 0.109 0.642 ± 0.132 0.733
PC 34:0 1.119 ± 0.261 1.288 ± 0.284 0.670
PC 34:1 2.783 ± 0.873 3.130 ± 0.948 0.793
PC 34:2 0.212 ± 0.060 0.242 ± 0.069 0.753
PC 36:0 0.195 ± 0.042 0.218 ± 0.046 0.731
PC 36:1 2.036 ± 0.404 2.322 ± 0.487 0.662
PC 36:2 1.177 ± 0.162 1.240 ± 0.180 0.798
PC 36:3 0.596 ± 0.071 0.562 ± 0.062 0.728
PC 36:4 2.697 ± 0.339 2.957 ± 0.397 0.630
PC 38:1 0.158 ± 0.012 0.176 ± 0.018 0.423
PC 38:2 0.187 ± 0.014 0.187 ± 0.019 0.999
PC 38:3 0.264 ± 0.043 0.281 ± 0.053 0.807
PC 38:4 1.608 ± 0.319 1.751 ± 0.314 0.756
PC 38:5 0.886 ± 0.124 0.948 ± 0.144 0.751
PC 38:6 1.430 ± 0.177 1.548 ± 0.277 0.728
PC 40:4 0.152 ± 0.022 0.171 ± 0.026 0.590
PC 40:5 0.340 ± 0.024 0.353 ± 0.035 0.775
PC 40:6 1.799 ± 0.088 1.873 ± 0.174 0.709
PC 40:7 1.249 ± 0.047 1.241 ± 0.066 0.917
PC 42:5 0.033 ± 0.002 0.032 ± 0.001 0.825
PC 42:6 0.048 ± 0.004 0.043 ± 0.003 0.317
PC 42:7 0.157 ± 0.017 0.137 ± 0.009 0.327
PE 32:0 0.190 ± 0.013 0.182 ± 0.020 0.750
PE 32:1 0.104 ± 0.008 0.087 ± 0.006 0.117
PE 34:0 0.520 ± 0.018 0.504 ± 0.035 0.692
PE 34:1 2.063 ± 0.050 2.002 ± 0.138 0.685
PE 34:2 0.144 ± 0.008 0.146 ± 0.015 0.914
PE 36:0 0.111 ± 0.016 0.113 ± 0.019 0.934
PE 36:1 0.995 ± 0.114 0.987 ± 0.127 0.964
PE 36:2 0.700 ± 0.102 0.715 ± 0.117 0.924
PE 36:3 0.081 ± 0.015 0.080 ± 0.018 0.978
PE 36:4 0.172 ± 0.039 0.179 ± 0.038 0.899
PE 38:0 0.089 ± 0.008 0.086 ± 0.009 0.816
PE 38:1 0.039 ± 0.004 0.046 ± 0.006 0.415
PE 38:2 0.046 ± 0.007 0.050 ± 0.007 0.632
PE 38:3 0.091 ± 0.022 0.095 ± 0.024 0.906
PE 38:4 0.500 ± 0.141 0.514 ± 0.116 0.940
PE 38:5 0.102 ± 0.023 0.101 ± 0.022 0.984
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PE 38:6 0.270 ± 0.057 0.296 ± 0.081 0.796
PE 40:3 0.008 ± 0.002 0.009 ± 0.002 0.609
PE 40:4 0.065 ± 0.018 0.073 ± 0.018 0.778
PE 40:5 0.077 ± 0.018 0.084 ± 0.021 0.801
PE 40:6 0.533 ± 0.124 0.548 ± 0.128 0.935
PE 42:5 0.001 ± 0.000 0.002 ± 0.000 0.749
PE 42:6 0.003 ± 0.000 0.002 ± 0.000 0.747
pPC 40:6 0.042 ± 0.004 0.039 ± 0.004 0.589
SM d18:0/16:0 0.010 ± 0.001 0.009 ± 0.001 0.065
SM d18:0/18:0 0.112 ± 0.011 0.108 ± 0.012 0.815
SM d18:1/16:0 0.290 ± 0.021 0.259 ± 0.018 0.286
SM d18:1/18:0 1.293 ± 0.073 1.309 ± 0.105 0.907
SM d18:1/18:1 0.286 ± 0.010 0.292 ± 0.023 0.830
SM d18:1/20:0 0.269 ± 0.014 0.266 ± 0.015 0.878
SM d18:1/22:0 0.178 ± 0.014 0.173 ± 0.011 0.777
SM d18:1/24:0 0.116 ± 0.005 0.120 ± 0.008 0.685
SM d18:1/24:1 0.436 ± 0.019 0.456 ± 0.026 0.554
SM d18:1/26:0 0.002 ± 0.000 0.002 ± 0.000 0.905
SM d18:1/26:1 0.006 ± 0.001 0.006 ± 0.001 0.885
DG 28:0/14:0 0.002 ± 0.001 0.000 ± 0.000 0.026
DG 30:0/14:0 0.000 ± 0.000 0.000 ± 0.000 0.179
DG 32:0/16:0 0.007 ± 0.001 0.007 ± 0.001 0.664
DG 32:1/16:0 0.001 ± 0.000 0.001 ± 0.000 0.497
DG 32:2/16:1 0.001 ± 0.001 0.000 ± 0.000 0.215
DG 34:0/16:0 0.006 ± 0.001 0.005 ± 0.001 0.327
DG 34:1/16:0 0.009 ± 0.001 0.008 ± 0.001 0.319
DG 34:2/16:0 0.001 ± 0.000 0.001 ± 0.000 0.621
DG 34:2/16:1 0.001 ± 0.000 0.001 ± 0.000 0.570
DG 36:0/18:0 0.004 ± 0.001 0.002 ± 0.000 0.054
DG 36:1/18:0 0.007 ± 0.001 0.003 ± 0.001 0.032
DG 36:2/18:0 0.000 ± 0.000 0.000 ± 0.000 0.027
DG 36:2/18:1 0.005 ± 0.001 0.003 ± 0.000 0.087
DG 36:3/18:1 0.001 ± 0.000 0.000 ± 0.000 0.110
DG 38:1/18:0 0.001 ± 0.000 0.000 ± 0.000 0.020
DG 38:2/18:0 0.000 ± 0.000 0.000 ± 0.000 0.816
DG 38:2/18:1 0.001 ± 0.000 0.000 ± 0.000 0.052
DG 38:3/18:0 0.002 ± 0.000 0.001 ± 0.000 0.096
DG 38:3/18:1 0.000 ± 0.000 0.000 ± 0.000 0.023
DG 38:4/18:0 0.015 ± 0.002 0.012 ± 0.001 0.181
DG 38:4/18:1 0.001 ± 0.000 0.000 ± 0.000 0.131
DG 40:4/18:0 0.001 ± 0.000 0.001 ± 0.000 0.078
DG 40:5/18:0 0.000 ± 0.000 0.000 ± 0.000 0.513
DG 40:5/18:1 0.000 ± 0.000 0.000 ± 0.000 0.255
DG 40:6/18:0 0.001 ± 0.000 0.001 ± 0.000 0.913
DG 40:6/18:1 0.000 ± 0.000 0.000 ± 0.000 0.405
CE 16:0 0.015 ± 0.003 0.014 ± 0.001 0.782
CE 16:1 0.007 ± 0.001 0.007 ± 0.001 0.958
CE 18:0 0.017 ± 0.002 0.015 ± 0.003 0.490
CE 18:1 0.018 ± 0.004 0.017 ± 0.002 0.775
CE 18:2 0.177 ± 0.031 0.131 ± 0.013 0.196
CE 20:0 0.032 ± 0.007 0.038 ± 0.010 0.640
CE 20:2 0.010 ± 0.001 0.007 ± 0.001 0.197
CE 20:3 0.038 ± 0.009 0.031 ± 0.005 0.484
CE 20:4 0.290 ± 0.040 0.273 ± 0.036 0.761
CE 22:4 0.046 ± 0.014 0.038 ± 0.007 0.658
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CE 22:5 0.093 ± 0.023 0.076 ± 0.010 0.509
CE 22:6 0.708 ± 0.183 0.678 ± 0.147 0.902
TG 48:0/16:0 0.010 ± 0.001 0.010 ± 0.001 0.715
TG 48:1/16:0 0.001 ± 0.000 0.001 ± 0.000 0.216
TG 50:0/16:0 0.005 ± 0.000 0.004 ± 0.000 0.389
TG 50:1/16:1 0.001 ± 0.000 0.001 ± 0.000 0.749
TG 50:2/16:1 0.001 ± 0.000 0.001 ± 0.000 0.568
TG 52:0/18:0 0.004 ± 0.000 0.004 ± 0.000 0.685
TG 52:1/18:0 0.002 ± 0.000 0.002 ± 0.000 0.793
TG 52:2/18:0 0.000 ± 0.000 0.000 ± 0.000 0.852
TG 52:3/18:1 0.001 ± 0.000 0.001 ± 0.000 0.725
TG 52:4/18:1 0.000 ± 0.000 0.000 ± 0.000 0.982
TG 52:5/18:1 0.000 ± 0.000 0.000 ± 0.000 0.818
TG 52:5/20:4 0.000 ± 0.000 0.000 ± 0.000 0.865
TG 54:0/18:0 0.001 ± 0.000 0.001 ± 0.000 0.150
TG 54:1/18:0 0.001 ± 0.000 0.001 ± 0.000 0.418
TG 54:2/18:0 0.000 ± 0.000 0.000 ± 0.000 0.317
TG 54:3/18:0 0.000 ± 0.000 0.000 ± 0.000 0.752
TG 54:4/18:1 0.001 ± 0.000 0.001 ± 0.000 0.891
TG 54:4/20:4 0.001 ± 0.000 0.001 ± 0.000 0.459
TG 54:5/18:1 0.000 ± 0.000 0.000 ± 0.000 0.732
TG 54:5/20:4 0.001 ± 0.000 0.000 ± 0.000 0.559
TG 54:6/18:1 0.000 ± 0.000 0.000 ± 0.000 0.716
TG 54:6/20:4 0.000 ± 0.000 0.000 ± 0.000 0.378
TG 54:7/18:1 0.000 ± 0.000 0.000 ± 0.000 0.453
TG 56:3/18:1 0.000 ± 0.000 0.000 ± 0.000 0.176
TG 56:4/18:1 0.000 ± 0.000 0.000 ± 0.000 0.491
TG 56:4/20:4 0.000 ± 0.000 0.000 ± 0.000 0.464
TG 56:5/18:1 0.000 ± 0.000 0.000 ± 0.000 0.337
TG 56:5/20:4 0.000 ± 0.000 0.000 ± 0.000 0.526
TG 56:6/20:4 0.000 ± 0.000 0.000 ± 0.000 0.533
TG 56:7/20:4 0.000 ± 0.000 0.000 ± 0.000 0.376
TG 56:8/20:4 0.000 ± 0.000 0.000 ± 0.000 0.786
TG 56:9/20:4 0.000 ± 0.000 0.000 ± 0.000 0.540
TG 58:5/20:4 0.000 ± 0.000 0.000 ± 0.000 0.369
TG 58:6/20:4 0.000 ± 0.000 0.000 ± 0.000 0.052
TG 58:7/20:4 0.000 ± 0.000 0.000 ± 0.000 0.758
TG 58:8/22:6 0.000 ± 0.000 0.000 ± 0.000 0.315
TG 58:9/22:6 0.000 ± 0.000 0.000 ± 0.000 0.186
TG 60:7/22:6 0.000 ± 0.000 0.000 ± 0.000 0.526
TG 60:8/22:6 0.000 ± 0.000 0.000 ± 0.000 0.314
TG 60:9/22:6 0.000 ± 0.000 0.000 ± 0.000 0.068
TG 50:3/16:1 0.000 ± 0.000 0.000 ± 0.000 0.861
FC 30.986 ± 3.822 33.438 ± 5.444 0.720
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Pld1 WT hAPP Color code for t-test
B Ave SEM Ave SEM t-test p≥ 0.05
LBPA 0.013 ± 0.003 0.038 ± 0.027 0.375 p≥ 0.01
Plasmalogen PE (PEp) 12.986 ± 1.401 12.745 ± 0.529 0.876 p≥ 0.001
PG 0.080 ± 0.013 0.074 ± 0.005 0.706
Sulfatide 0.916 ± 0.100 0.773 ± 0.091 0.316
GM3 0.078 ± 0.016 0.065 ± 0.013 0.543
PA 1.771 ± 0.324 1.381 ± 0.231 0.351
PI 2.602 ± 0.296 2.470 ± 0.268 0.748
PS 8.201 ± 1.015 8.059 ± 0.873 0.917
Ceramide 0.297 ± 0.014 0.283 ± 0.009 0.409
Monhexosylceramide 3.752 ± 0.553 2.260 ± 0.220 0.031
Ether PC (ePC) 0.975 ± 0.035 0.923 ± 0.019 0.225
PC 25.851 ± 3.925 26.261 ± 2.015 0.928
PE 6.944 ± 0.726 7.536 ± 0.453 0.505
Sphingomyelin 3.000 ± 0.072 2.950 ± 0.100 0.694
Diacylglycerol 0.067 ± 0.006 0.070 ± 0.012 0.796
Cholesterol ester 1.450 ± 0.287 1.263 ± 0.417 0.720
Triacylglycerol 0.033 ± 0.002 0.028 ± 0.003 0.144
Free cholesterol 30.986 ± 3.822 32.822 ± 2.518 0.697
Pld1 WT hAPP
B Ave SEM Ave SEM t-test
LBPA 32:0 0.000 ± 0.000 0.000 ± 0.000 0.634
LBPA 32:1 0.000 ± 0.000 0.000 ± 0.000 0.279
LBPA 34:0 0.000 ± 0.000 0.001 ± 0.000 0.292
LBPA 34:1 0.001 ± 0.000 0.002 ± 0.001 0.347
LBPA 34:2 0.000 ± 0.000 0.001 ± 0.001 0.303
LBPA 36:0 0.000 ± 0.000 0.001 ± 0.001 0.330
LBPA 36:1 0.001 ± 0.000 0.001 ± 0.000 0.601
LBPA 36:2 0.010 ± 0.002 0.029 ± 0.021 0.390
LBPA 36:3 0.000 ± 0.000 0.000 ± 0.000 0.300
LBPA 38:3 0.000 ± 0.000 0.001 ± 0.001 0.338
LBPA 38:4 0.000 ± 0.000 0.002 ± 0.001 0.341
LBPA 38:5 0.000 ± 0.000 0.000 ± 0.000 0.294
PE 32:0p 0.090 ± 0.044 0.076 ± 0.014 0.763
PE 32:1p 0.043 ± 0.018 0.037 ± 0.003 0.758
PE 34:0p 0.238 ± 0.071 0.207 ± 0.018 0.676
PE 34:1p 1.191 ± 0.217 1.020 ± 0.085 0.479
PE 34:2p 0.133 ± 0.024 0.118 ± 0.012 0.589
PE 36:0p 0.131 ± 0.014 0.117 ± 0.011 0.463
PE 36:1p 1.568 ± 0.204 1.314 ± 0.099 0.288
PE 36:2p 1.691 ± 0.216 1.456 ± 0.096 0.343
PE 36:3p 0.162 ± 0.014 0.196 ± 0.015 0.128
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PE 36:4p 0.447 ± 0.052 0.513 ± 0.031 0.301
PE 38:2p 0.393 ± 0.037 0.339 ± 0.025 0.260
PE 38:3p 0.203 ± 0.019 0.226 ± 0.024 0.475
PE 38:4p 1.144 ± 0.094 1.206 ± 0.054 0.579
PE 38:5p 0.676 ± 0.033 0.719 ± 0.037 0.405
PE 38:6p 1.299 ± 0.121 1.571 ± 0.059 0.070
PE 40:3p 0.069 ± 0.005 0.057 ± 0.007 0.216
PE 40:4p 0.448 ± 0.034 0.440 ± 0.011 0.817
PE 40:5p 0.592 ± 0.035 0.554 ± 0.034 0.449
PE 40:6p 2.341 ± 0.288 2.467 ± 0.172 0.714
PE 42:5p 0.045 ± 0.014 0.049 ± 0.008 0.819
PE 42:6p 0.083 ± 0.031 0.064 ± 0.005 0.565
PG 32:0 0.017 ± 0.002 0.016 ± 0.002 0.802
PG 32:1 0.001 ± 0.000 0.001 ± 0.000 0.863
PG 34:0 0.004 ± 0.001 0.003 ± 0.000 0.453
PG 34:1 0.029 ± 0.005 0.025 ± 0.002 0.485
PG 34:2 0.000 ± 0.000 0.000 ± 0.000 0.709
PG 36:0 0.001 ± 0.000 0.000 ± 0.000 0.331
PG 36:1 0.004 ± 0.001 0.003 ± 0.000 0.497
PG 36:2 0.012 ± 0.002 0.011 ± 0.001 0.817
PG 36:3 0.001 ± 0.000 0.001 ± 0.000 0.448
PG 38:3 0.000 ± 0.000 0.000 ± 0.000 0.327
PG 38:4 0.011 ± 0.002 0.012 ± 0.001 0.831
PG 38:5 0.000 ± 0.000 0.000 ± 0.000 0.853
Sulf d18:1/16:0 0.004 ± 0.001 0.003 ± 0.000 0.359
Sulf d18:1/18:0 0.068 ± 0.016 0.044 ± 0.004 0.182
Sulf d18:1/18:0h 0.014 ± 0.002 0.012 ± 0.002 0.308
Sulf d18:1/18:1 0.003 ± 0.001 0.002 ± 0.000 0.317
Sulf d18:1/20:0 0.014 ± 0.002 0.011 ± 0.001 0.177
Sulf d18:1/20:0h 0.014 ± 0.002 0.013 ± 0.002 0.729
Sulf d18:1/22:0 0.051 ± 0.009 0.047 ± 0.004 0.657
Sulf d18:1/22:0h 0.058 ± 0.008 0.052 ± 0.005 0.591
Sulf d18:1/22:1h 0.029 ± 0.002 0.025 ± 0.002 0.204
Sulf d18:1/24:0 0.188 ± 0.018 0.156 ± 0.017 0.221
Sulf d18:1/24:0h 0.057 ± 0.007 0.046 ± 0.004 0.223
Sulf d18:1/24:1 0.369 ± 0.059 0.324 ± 0.059 0.604
Sulf d18:1/24:1h 0.046 ± 0.005 0.037 ± 0.004 0.173
GM3 18:1/16:0 0.004 ± 0.001 0.003 ± 0.001 0.463
GM3 18:1/18:0 0.050 ± 0.010 0.043 ± 0.009 0.618
GM3 18:1/20:0 0.010 ± 0.002 0.007 ± 0.001 0.325
GM3 18:1/22:0 0.006 ± 0.001 0.005 ± 0.001 0.603
GM3 18:1/24:0 0.003 ± 0.001 0.002 ± 0.000 0.403
GM3 18:1/24:1 0.005 ± 0.001 0.004 ± 0.001 0.556
PA 32:0 0.050 ± 0.006 0.051 ± 0.013 0.965
PA 32:1 0.028 ± 0.005 0.025 ± 0.006 0.652
PA 34:0 0.048 ± 0.010 0.046 ± 0.007 0.885
PA 34:1 0.408 ± 0.073 0.327 ± 0.054 0.386
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PA 34:2 0.022 ± 0.004 0.018 ± 0.003 0.377
PA 36:0 0.036 ± 0.007 0.033 ± 0.006 0.813
PA 36:1 0.360 ± 0.065 0.306 ± 0.054 0.539
PA 36:2 0.132 ± 0.023 0.088 ± 0.013 0.124
PA 38:1 0.048 ± 0.010 0.033 ± 0.005 0.208
PA 38:2 0.060 ± 0.013 0.040 ± 0.007 0.203
PA 38:3 0.071 ± 0.015 0.057 ± 0.010 0.464
PA 38:4 0.386 ± 0.087 0.251 ± 0.045 0.200
PA 40:5 0.037 ± 0.010 0.027 ± 0.006 0.374
PA 40:6 0.085 ± 0.020 0.080 ± 0.013 0.834
PI 34:0 0.044 ± 0.007 0.031 ± 0.003 0.123
PI 34:1 0.072 ± 0.017 0.058 ± 0.008 0.470
PI 36:1 0.074 ± 0.016 0.058 ± 0.009 0.410
PI 36:2 0.023 ± 0.005 0.019 ± 0.002 0.461
PI 36:3 0.048 ± 0.008 0.053 ± 0.008 0.684
PI 36:4 0.387 ± 0.058 0.398 ± 0.054 0.886
PI 38:3 0.172 ± 0.021 0.171 ± 0.020 0.966
PI 38:4 1.369 ± 0.136 1.315 ± 0.145 0.792
PI 38:5 0.285 ± 0.030 0.270 ± 0.026 0.713
PI 38:6 0.059 ± 0.010 0.049 ± 0.004 0.365
PI 40:6 0.069 ± 0.011 0.048 ± 0.005 0.116
PS 34:0 0.029 ± 0.004 0.029 ± 0.003 0.998
PS 34:1 0.159 ± 0.013 0.146 ± 0.009 0.421
PS 36:0 0.197 ± 0.039 0.164 ± 0.023 0.478
PS 36:1 1.772 ± 0.349 1.511 ± 0.213 0.538
PS 36:2 0.519 ± 0.100 0.445 ± 0.045 0.513
PS 38:1 0.189 ± 0.043 0.137 ± 0.024 0.316
PS 38:2 0.099 ± 0.022 0.079 ± 0.011 0.449
PS 38:3 0.142 ± 0.024 0.162 ± 0.023 0.568
PS 38:4 0.403 ± 0.066 0.368 ± 0.054 0.693
PS 40:3 0.055 ± 0.007 0.048 ± 0.006 0.453
PS 40:4 0.352 ± 0.033 0.336 ± 0.043 0.777
PS 40:5 0.563 ± 0.044 0.598 ± 0.073 0.690
PS 40:6 3.700 ± 0.286 4.017 ± 0.492 0.590
PS 42:4 0.011 ± 0.001 0.009 ± 0.002 0.409
PS 42:5 0.010 ± 0.001 0.010 ± 0.001 0.699
Cer d18:0/16:0 0.000 ± 0.000 0.000 ± 0.000 0.828
Cer d18:0/18:0 0.023 ± 0.002 0.022 ± 0.001 0.675
Cer d18:0/20:0 0.001 ± 0.000 0.001 ± 0.000 0.447
Cer d18:0/22:0 0.001 ± 0.000 0.001 ± 0.000 0.680
Cer d18:0/24:0 0.001 ± 0.000 0.000 ± 0.000 0.058
Cer d18:0/24:1 0.001 ± 0.000 0.001 ± 0.000 0.922
Cer d18:1/18:0 0.230 ± 0.010 0.223 ± 0.010 0.663
Cer d18:1/18:1 0.000 ± 0.000 0.000 ± 0.000 0.444
Cer d18:1/20:0 0.006 ± 0.001 0.007 ± 0.001 0.499
Cer d18:1/22:0 0.003 ± 0.000 0.003 ± 0.001 0.573
Cer d18:1/24:0 0.003 ± 0.000 0.003 ± 0.000 0.980
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Cer d18:1/24:1 0.027 ± 0.004 0.021 ± 0.002 0.214
Cer d18:1/26:0 0.001 ± 0.000 0.000 ± 0.000 0.354
Cer d18:1/26:1 0.001 ± 0.000 0.000 ± 0.000 0.003
GluCer d18:0/18:0 0.008 ± 0.002 0.005 ± 0.001 0.140
GluCer d18:0/20:0 0.002 ± 0.000 0.001 ± 0.000 0.293
GluCer d18:0/22:0 0.019 ± 0.004 0.013 ± 0.002 0.186
GluCer d18:0/24:0 0.030 ± 0.007 0.017 ± 0.002 0.109
GluCer d18:0/24:1 0.050 ± 0.012 0.037 ± 0.005 0.319
GluCer d18:0/26:0 0.001 ± 0.000 0.001 ± 0.000 0.266
GluCer d18:0/26:1 0.001 ± 0.000 0.000 ± 0.000 0.498
GluCer d18:1/18:0 0.681 ± 0.115 0.398 ± 0.065 0.058
GluCer d18:1/20:0 0.133 ± 0.030 0.090 ± 0.015 0.230
GluCer d18:1/22:0 0.403 ± 0.143 0.227 ± 0.026 0.256
GluCer d18:1/24:0 0.507 ± 0.087 0.352 ± 0.034 0.128
GluCer d18:1/24:1 1.900 ± 0.279 1.107 ± 0.112 0.025
GluCer d18:1/26:0 0.004 ± 0.001 0.002 ± 0.000 0.082
GluCer d18:1/26:1 0.013 ± 0.002 0.009 ± 0.001 0.210
ePC 32:0 0.127 ± 0.004 0.131 ± 0.006 0.568
ePC 32:1 0.037 ± 0.009 0.036 ± 0.003 0.907
ePC 34:0 0.039 ± 0.007 0.038 ± 0.004 0.911
ePC 34:1 0.122 ± 0.023 0.130 ± 0.012 0.762
ePC 34:2 0.017 ± 0.003 0.017 ± 0.002 0.934
ePC 36:0 0.010 ± 0.002 0.009 ± 0.001 0.662
ePC 36:1 0.054 ± 0.008 0.052 ± 0.005 0.856
ePC 36:2 0.036 ± 0.004 0.033 ± 0.002 0.620
ePC 36:3 0.024 ± 0.001 0.019 ± 0.004 0.153
ePC 38:2 0.054 ± 0.005 0.056 ± 0.006 0.783
ePC 38:3 0.011 ± 0.001 0.011 ± 0.001 0.862
ePC 38:4 0.038 ± 0.004 0.039 ± 0.002 0.848
ePC 38:5 0.042 ± 0.001 0.042 ± 0.002 0.944
ePC 40:4 0.047 ± 0.002 0.048 ± 0.003 0.735
ePC 40:5 0.017 ± 0.001 0.016 ± 0.001 0.252
ePC 40:6 0.042 ± 0.003 0.041 ± 0.002 0.722
ePC 42:5 0.008 ± 0.001 0.007 ± 0.001 0.479
ePC 42:6 0.008 ± 0.001 0.007 ± 0.001 0.242
ePC 44:3 0.032 ± 0.004 0.028 ± 0.004 0.537
ePC 44:4 0.032 ± 0.005 0.025 ± 0.003 0.323
ePC 44:5 0.171 ± 0.030 0.132 ± 0.016 0.268
ePC 44:6 0.006 ± 0.001 0.005 ± 0.001 0.316
PC 30:0 0.910 ± 0.037 0.951 ± 0.034 0.437
PC 32:0 5.233 ± 0.874 5.205 ± 0.441 0.978
PC 32:1 0.582 ± 0.109 0.615 ± 0.059 0.798
PC 34:0 1.119 ± 0.261 1.123 ± 0.130 0.989
PC 34:1 2.783 ± 0.873 2.678 ± 0.418 0.916
PC 34:2 0.212 ± 0.060 0.229 ± 0.034 0.813
PC 36:0 0.195 ± 0.042 0.189 ± 0.021 0.894
PC 36:1 2.036 ± 0.404 1.958 ± 0.193 0.864
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PC 36:2 1.177 ± 0.162 1.231 ± 0.080 0.769
PC 36:3 0.596 ± 0.071 0.775 ± 0.101 0.176
PC 36:4 2.697 ± 0.339 2.841 ± 0.197 0.722
PC 38:1 0.158 ± 0.012 0.139 ± 0.010 0.271
PC 38:2 0.187 ± 0.014 0.175 ± 0.010 0.528
PC 38:3 0.264 ± 0.043 0.326 ± 0.033 0.272
PC 38:4 1.608 ± 0.319 1.608 ± 0.110 0.998
PC 38:5 0.886 ± 0.124 0.962 ± 0.066 0.599
PC 38:6 1.430 ± 0.177 1.404 ± 0.221 0.930
PC 40:4 0.152 ± 0.022 0.147 ± 0.006 0.839
PC 40:5 0.340 ± 0.024 0.340 ± 0.011 0.995
PC 40:6 1.799 ± 0.088 1.830 ± 0.069 0.786
PC 40:7 1.249 ± 0.047 1.312 ± 0.070 0.474
PC 42:5 0.033 ± 0.002 0.030 ± 0.002 0.284
PC 42:6 0.048 ± 0.004 0.045 ± 0.004 0.588
PC 42:7 0.157 ± 0.017 0.145 ± 0.016 0.645
PE 32:0 0.190 ± 0.013 0.217 ± 0.020 0.273
PE 32:1 0.104 ± 0.008 0.108 ± 0.009 0.733
PE 34:0 0.520 ± 0.018 0.555 ± 0.029 0.340
PE 34:1 2.063 ± 0.050 2.189 ± 0.081 0.216
PE 34:2 0.144 ± 0.008 0.160 ± 0.007 0.168
PE 36:0 0.111 ± 0.016 0.121 ± 0.007 0.567
PE 36:1 0.995 ± 0.114 1.111 ± 0.078 0.418
PE 36:2 0.700 ± 0.102 0.750 ± 0.067 0.694
PE 36:3 0.081 ± 0.015 0.112 ± 0.015 0.171
PE 36:4 0.172 ± 0.039 0.199 ± 0.022 0.563
PE 38:0 0.089 ± 0.008 0.083 ± 0.006 0.583
PE 38:1 0.039 ± 0.004 0.039 ± 0.006 0.981
PE 38:2 0.046 ± 0.007 0.053 ± 0.006 0.437
PE 38:3 0.091 ± 0.022 0.131 ± 0.020 0.203
PE 38:4 0.500 ± 0.141 0.516 ± 0.061 0.917
PE 38:5 0.102 ± 0.023 0.105 ± 0.016 0.910
PE 38:6 0.270 ± 0.057 0.316 ± 0.051 0.559
PE 40:3 0.008 ± 0.002 0.008 ± 0.001 0.951
PE 40:4 0.065 ± 0.018 0.061 ± 0.010 0.853
PE 40:5 0.077 ± 0.018 0.083 ± 0.012 0.772
PE 40:6 0.533 ± 0.124 0.570 ± 0.082 0.808
PE 42:5 0.001 ± 0.000 0.001 ± 0.000 0.504
PE 42:6 0.003 ± 0.000 0.002 ± 0.000 0.578
pPC 40:6 0.042 ± 0.004 0.042 ± 0.003 0.987
SM d18:0/16:0 0.010 ± 0.001 0.010 ± 0.000 0.594
SM d18:0/18:0 0.112 ± 0.011 0.113 ± 0.008 0.945
SM d18:1/16:0 0.290 ± 0.021 0.287 ± 0.018 0.899
SM d18:1/18:0 1.293 ± 0.073 1.312 ± 0.041 0.827
SM d18:1/18:1 0.286 ± 0.010 0.298 ± 0.014 0.519
SM d18:1/20:0 0.269 ± 0.014 0.260 ± 0.008 0.583
SM d18:1/22:0 0.178 ± 0.014 0.165 ± 0.010 0.464
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SM d18:1/24:0 0.116 ± 0.005 0.107 ± 0.004 0.173
SM d18:1/24:1 0.436 ± 0.019 0.392 ± 0.021 0.154
SM d18:1/26:0 0.002 ± 0.000 0.002 ± 0.000 0.302
SM d18:1/26:1 0.006 ± 0.001 0.005 ± 0.000 0.255
DG 28:0/14:0 0.002 ± 0.001 0.000 ± 0.000 0.020
DG 30:0/14:0 0.000 ± 0.000 0.000 ± 0.000 0.317
DG 32:0/16:0 0.007 ± 0.001 0.005 ± 0.001 0.112
DG 32:1/16:0 0.001 ± 0.000 0.001 ± 0.000 0.082
DG 32:2/16:1 0.001 ± 0.001 0.000 ± 0.000 0.229
DG 34:0/16:0 0.006 ± 0.001 0.004 ± 0.001 0.093
DG 34:1/16:0 0.009 ± 0.001 0.012 ± 0.002 0.361
DG 34:2/16:0 0.001 ± 0.000 0.002 ± 0.000 0.060
DG 34:2/16:1 0.001 ± 0.000 0.002 ± 0.000 0.057
DG 36:0/18:0 0.004 ± 0.001 0.002 ± 0.000 0.013
DG 36:1/18:0 0.007 ± 0.001 0.018 ± 0.003 0.009
DG 36:2/18:0 0.000 ± 0.000 0.001 ± 0.000 0.061
DG 36:2/18:1 0.005 ± 0.001 0.007 ± 0.001 0.088
DG 36:3/18:1 0.001 ± 0.000 0.001 ± 0.000 0.435
DG 38:1/18:0 0.001 ± 0.000 0.001 ± 0.000 0.023
DG 38:2/18:0 0.000 ± 0.000 0.000 ± 0.000 0.477
DG 38:2/18:1 0.001 ± 0.000 0.001 ± 0.000 0.008
DG 38:3/18:0 0.002 ± 0.000 0.002 ± 0.000 0.690
DG 38:3/18:1 0.000 ± 0.000 0.000 ± 0.000 0.151
DG 38:4/18:0 0.015 ± 0.002 0.008 ± 0.002 0.008
DG 38:4/18:1 0.001 ± 0.000 0.000 ± 0.000 0.692
DG 40:4/18:0 0.001 ± 0.000 0.001 ± 0.000 0.125
DG 40:5/18:0 0.000 ± 0.000 0.000 ± 0.000 0.654
DG 40:5/18:1 0.000 ± 0.000 0.000 ± 0.000 0.497
DG 40:6/18:0 0.001 ± 0.000 0.001 ± 0.000 0.220
DG 40:6/18:1 0.000 ± 0.000 0.000 ± 0.000 0.121
CE 16:0 0.015 ± 0.003 0.011 ± 0.001 0.311
CE 16:1 0.007 ± 0.001 0.006 ± 0.002 0.503
CE 18:0 0.017 ± 0.002 0.017 ± 0.004 0.914
CE 18:1 0.018 ± 0.004 0.018 ± 0.006 0.966
CE 18:2 0.177 ± 0.031 0.147 ± 0.018 0.422
CE 20:0 0.032 ± 0.007 0.030 ± 0.013 0.923
CE 20:2 0.010 ± 0.001 0.005 ± 0.001 0.014
CE 20:3 0.038 ± 0.009 0.034 ± 0.006 0.733
CE 20:4 0.290 ± 0.040 0.284 ± 0.044 0.918
CE 22:4 0.046 ± 0.014 0.032 ± 0.014 0.516
CE 22:5 0.093 ± 0.023 0.063 ± 0.023 0.381
CE 22:6 0.708 ± 0.183 0.616 ± 0.303 0.801
TG 48:0/16:0 0.010 ± 0.001 0.010 ± 0.001 0.916
TG 48:1/16:0 0.001 ± 0.000 0.001 ± 0.000 0.231
TG 50:0/16:0 0.005 ± 0.000 0.004 ± 0.001 0.147
TG 50:1/16:1 0.001 ± 0.000 0.000 ± 0.000 0.368
TG 50:2/16:1 0.001 ± 0.000 0.000 ± 0.000 0.055
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TG 52:0/18:0 0.004 ± 0.000 0.003 ± 0.000 0.149
TG 52:1/18:0 0.002 ± 0.000 0.002 ± 0.000 0.292
TG 52:2/18:0 0.000 ± 0.000 0.000 ± 0.000 0.040
TG 52:3/18:1 0.001 ± 0.000 0.001 ± 0.000 0.047
TG 52:4/18:1 0.000 ± 0.000 0.000 ± 0.000 0.110
TG 52:5/18:1 0.000 ± 0.000 0.000 ± 0.000 0.125
TG 52:5/20:4 0.000 ± 0.000 0.000 ± 0.000 0.002
TG 54:0/18:0 0.001 ± 0.000 0.000 ± 0.000 0.030
TG 54:1/18:0 0.001 ± 0.000 0.001 ± 0.000 0.849
TG 54:2/18:0 0.000 ± 0.000 0.000 ± 0.000 0.314
TG 54:3/18:0 0.000 ± 0.000 0.000 ± 0.000 0.878
TG 54:4/18:1 0.001 ± 0.000 0.001 ± 0.000 0.172
TG 54:4/20:4 0.001 ± 0.000 0.001 ± 0.000 0.044
TG 54:5/18:1 0.000 ± 0.000 0.000 ± 0.000 0.012
TG 54:5/20:4 0.001 ± 0.000 0.000 ± 0.000 0.006
TG 54:6/18:1 0.000 ± 0.000 0.000 ± 0.000 0.263
TG 54:6/20:4 0.000 ± 0.000 0.000 ± 0.000 0.013
TG 54:7/18:1 0.000 ± 0.000 0.000 ± 0.000 0.165
TG 56:3/18:1 0.000 ± 0.000 0.000 ± 0.000 0.182
TG 56:4/18:1 0.000 ± 0.000 0.000 ± 0.000 0.544
TG 56:4/20:4 0.000 ± 0.000 0.000 ± 0.000 0.059
TG 56:5/18:1 0.000 ± 0.000 0.000 ± 0.000 0.123
TG 56:5/20:4 0.000 ± 0.000 0.000 ± 0.000 0.075
TG 56:6/20:4 0.000 ± 0.000 0.000 ± 0.000 0.043
TG 56:7/20:4 0.000 ± 0.000 0.000 ± 0.000 0.217
TG 56:8/20:4 0.000 ± 0.000 0.000 ± 0.000 0.008
TG 56:9/20:4 0.000 ± 0.000 0.000 ± 0.000 0.318
TG 58:5/20:4 0.000 ± 0.000 0.000 ± 0.000 0.001
TG 58:6/20:4 0.000 ± 0.000 0.000 ± 0.000 0.021
TG 58:7/20:4 0.000 ± 0.000 0.000 ± 0.000 0.727
TG 58:8/22:6 0.000 ± 0.000 0.000 ± 0.000 0.053
TG 58:9/22:6 0.000 ± 0.000 0.000 ± 0.000 0.978
TG 60:7/22:6 0.000 ± 0.000 0.000 ± 0.000 0.023
TG 60:8/22:6 0.000 ± 0.000 0.000 ± 0.000 0.153
TG 60:9/22:6 0.000 ± 0.000 0.000 ± 0.000 0.163
TG 50:3/16:1 0.000 ± 0.000 0.000 ± 0.000 0.212
FC 30.986 ± 3.822 32.822 ± 2.518 0.697
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and hAPP/Pld1 KO forebrain 
hAPP/Pld1 WT hAPP/Pld1  KO Color code for t-test
C Ave SEM Ave SEM t-test p≥ 0.05
LBPA 0.038 ± 0.027 0.012 ± 0.003 0.372 p≥ 0.01
Plasmalogen PE (PEp) 12.745 ± 0.529 12.353 ± 0.785 0.687 p≥ 0.001
PG 0.074 ± 0.005 0.094 ± 0.011 0.135
Sulfatide 0.773 ± 0.091 0.809 ± 0.079 0.770
GM3 0.065 ± 0.013 0.070 ± 0.013 0.778
PA 1.381 ± 0.231 0.628 ± 0.137 0.019
PI 2.470 ± 0.268 2.240 ± 0.161 0.478
PS 8.059 ± 0.873 9.330 ± 1.012 0.364
Ceramide 0.283 ± 0.009 0.328 ± 0.041 0.308
Monhexosylceramide 2.260 ± 0.220 2.742 ± 0.434 0.344
Ether PC (ePC) 0.923 ± 0.019 0.883 ± 0.026 0.243
PC 26.261 ± 2.015 20.835 ± 2.695 0.138
PE 7.536 ± 0.453 6.070 ± 0.573 0.073
Sphingomyelin 2.950 ± 0.100 2.938 ± 0.132 0.944
Diacylglycerol 0.070 ± 0.012 0.059 ± 0.004 0.402
Cholesterol ester 1.263 ± 0.417 1.596 ± 0.267 0.516
Triacylglycerol 0.028 ± 0.003 0.032 ± 0.002 0.243
Free cholesterol 32.822 ± 2.518 38.981 ± 3.616 0.192
hAPP/Pld1 WT hAPP/Pld1  KO
C Ave SEM Ave SEM t-test
LBPA 32:0 0.000 ± 0.000 0.000 ± 0.000 0.560
LBPA 32:1 0.000 ± 0.000 0.000 ± 0.000 0.357
LBPA 34:0 0.001 ± 0.000 0.000 ± 0.000 0.353
LBPA 34:1 0.002 ± 0.001 0.001 ± 0.000 0.370
LBPA 34:2 0.001 ± 0.001 0.000 ± 0.000 0.337
LBPA 36:0 0.001 ± 0.001 0.000 ± 0.000 0.334
LBPA 36:1 0.001 ± 0.000 0.001 ± 0.000 0.254
LBPA 36:2 0.029 ± 0.021 0.009 ± 0.002 0.374
LBPA 36:3 0.000 ± 0.000 0.000 ± 0.000 0.357
LBPA 38:3 0.001 ± 0.001 0.000 ± 0.000 0.348
LBPA 38:4 0.002 ± 0.001 0.000 ± 0.000 0.358
LBPA 38:5 0.000 ± 0.000 0.000 ± 0.000 0.332
PE 32:0p 0.076 ± 0.014 0.077 ± 0.016 0.941
PE 32:1p 0.037 ± 0.003 0.043 ± 0.009 0.550
PE 34:0p 0.207 ± 0.018 0.202 ± 0.028 0.891
PE 34:1p 1.020 ± 0.085 1.197 ± 0.105 0.218
PE 34:2p 0.118 ± 0.012 0.117 ± 0.006 0.963
PE 36:0p 0.117 ± 0.011 0.115 ± 0.009 0.859
PE 36:1p 1.314 ± 0.099 1.368 ± 0.051 0.640
Dataset I: (C) Molecular and lipid composition of murine hAPP/Pld1  WT 
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PE 36:2p 1.456 ± 0.096 1.480 ± 0.035 0.818
PE 36:3p 0.196 ± 0.015 0.190 ± 0.018 0.812
PE 36:4p 0.513 ± 0.031 0.499 ± 0.041 0.794
PE 38:2p 0.339 ± 0.025 0.284 ± 0.032 0.206
PE 38:3p 0.226 ± 0.024 0.207 ± 0.013 0.507
PE 38:4p 1.206 ± 0.054 1.202 ± 0.103 0.976
PE 38:5p 0.719 ± 0.037 0.724 ± 0.074 0.952
PE 38:6p 1.571 ± 0.059 1.307 ± 0.121 0.077
PE 40:3p 0.057 ± 0.007 0.056 ± 0.005 0.839
PE 40:4p 0.440 ± 0.011 0.448 ± 0.038 0.841
PE 40:5p 0.554 ± 0.034 0.577 ± 0.059 0.745
PE 40:6p 2.467 ± 0.172 2.134 ± 0.283 0.338
PE 42:5p 0.049 ± 0.008 0.048 ± 0.010 0.967
PE 42:6p 0.064 ± 0.005 0.077 ± 0.017 0.504
PG 32:0 0.016 ± 0.002 0.020 ± 0.003 0.311
PG 32:1 0.001 ± 0.000 0.002 ± 0.000 0.168
PG 34:0 0.003 ± 0.000 0.004 ± 0.000 0.069
PG 34:1 0.025 ± 0.002 0.032 ± 0.003 0.094
PG 34:2 0.000 ± 0.000 0.000 ± 0.000 0.439
PG 36:0 0.000 ± 0.000 0.001 ± 0.000 0.111
PG 36:1 0.003 ± 0.000 0.004 ± 0.000 0.098
PG 36:2 0.011 ± 0.001 0.016 ± 0.001 0.009
PG 36:3 0.001 ± 0.000 0.001 ± 0.000 0.466
PG 38:3 0.000 ± 0.000 0.000 ± 0.000 0.473
PG 38:4 0.012 ± 0.001 0.014 ± 0.002 0.488
PG 38:5 0.000 ± 0.000 0.000 ± 0.000 0.079
Sulf d18:1/16:0 0.003 ± 0.000 0.003 ± 0.000 0.947
Sulf d18:1/18:0 0.044 ± 0.004 0.045 ± 0.003 0.884
Sulf d18:1/18:0h 0.012 ± 0.002 0.016 ± 0.003 0.252
Sulf d18:1/18:1 0.002 ± 0.000 0.002 ± 0.000 0.174
Sulf d18:1/20:0 0.011 ± 0.001 0.010 ± 0.001 0.495
Sulf d18:1/20:0h 0.013 ± 0.002 0.015 ± 0.002 0.430
Sulf d18:1/22:0 0.047 ± 0.004 0.043 ± 0.003 0.462
Sulf d18:1/22:0h 0.052 ± 0.005 0.060 ± 0.007 0.369
Sulf d18:1/22:1h 0.025 ± 0.002 0.024 ± 0.002 0.755
Sulf d18:1/24:0 0.156 ± 0.017 0.152 ± 0.015 0.862
Sulf d18:1/24:0h 0.046 ± 0.004 0.054 ± 0.007 0.368
Sulf d18:1/24:1 0.324 ± 0.059 0.339 ± 0.036 0.840
Sulf d18:1/24:1h 0.037 ± 0.004 0.045 ± 0.007 0.317
GM3 18:1/16:0 0.003 ± 0.001 0.004 ± 0.001 0.606
GM3 18:1/18:0 0.043 ± 0.009 0.046 ± 0.009 0.816
GM3 18:1/20:0 0.007 ± 0.001 0.008 ± 0.002 0.653
GM3 18:1/22:0 0.005 ± 0.001 0.005 ± 0.001 0.973
GM3 18:1/24:0 0.002 ± 0.000 0.002 ± 0.001 0.948
GM3 18:1/24:1 0.004 ± 0.001 0.005 ± 0.001 0.535
PA 32:0 0.051 ± 0.013 0.036 ± 0.005 0.312
PA 32:1 0.025 ± 0.006 0.008 ± 0.002 0.020
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PA 34:0 0.046 ± 0.007 0.017 ± 0.005 0.008
PA 34:1 0.327 ± 0.054 0.094 ± 0.022 0.002
PA 34:2 0.018 ± 0.003 0.006 ± 0.001 0.004
PA 36:0 0.033 ± 0.006 0.009 ± 0.002 0.002
PA 36:1 0.306 ± 0.054 0.055 ± 0.011 0.001
PA 36:2 0.088 ± 0.013 0.017 ± 0.003 0.000
PA 38:1 0.033 ± 0.005 0.012 ± 0.003 0.005
PA 38:2 0.040 ± 0.007 0.011 ± 0.002 0.002
PA 38:3 0.057 ± 0.010 0.033 ± 0.007 0.071
PA 38:4 0.251 ± 0.045 0.222 ± 0.051 0.674
PA 40:5 0.027 ± 0.006 0.016 ± 0.004 0.184
PA 40:6 0.080 ± 0.013 0.092 ± 0.027 0.693
PI 34:0 0.031 ± 0.003 0.035 ± 0.004 0.479
PI 34:1 0.058 ± 0.008 0.055 ± 0.009 0.770
PI 36:1 0.058 ± 0.009 0.038 ± 0.006 0.093
PI 36:2 0.019 ± 0.002 0.017 ± 0.002 0.491
PI 36:3 0.053 ± 0.008 0.047 ± 0.005 0.560
PI 36:4 0.398 ± 0.054 0.374 ± 0.045 0.735
PI 38:3 0.171 ± 0.020 0.149 ± 0.010 0.356
PI 38:4 1.315 ± 0.145 1.171 ± 0.082 0.408
PI 38:5 0.270 ± 0.026 0.264 ± 0.021 0.864
PI 38:6 0.049 ± 0.004 0.040 ± 0.005 0.184
PI 40:6 0.048 ± 0.005 0.052 ± 0.008 0.692
PS 34:0 0.029 ± 0.003 0.039 ± 0.007 0.233
PS 34:1 0.146 ± 0.009 0.208 ± 0.036 0.121
PS 36:0 0.164 ± 0.023 0.224 ± 0.030 0.139
PS 36:1 1.511 ± 0.213 2.004 ± 0.278 0.190
PS 36:2 0.445 ± 0.045 0.588 ± 0.076 0.135
PS 38:1 0.137 ± 0.024 0.216 ± 0.036 0.100
PS 38:2 0.079 ± 0.011 0.126 ± 0.019 0.061
PS 38:3 0.162 ± 0.023 0.204 ± 0.025 0.244
PS 38:4 0.368 ± 0.054 0.525 ± 0.046 0.053
PS 40:3 0.048 ± 0.006 0.065 ± 0.010 0.178
PS 40:4 0.336 ± 0.043 0.468 ± 0.048 0.069
PS 40:5 0.598 ± 0.073 0.621 ± 0.068 0.822
PS 40:6 4.017 ± 0.492 4.015 ± 0.480 0.998
PS 42:4 0.009 ± 0.002 0.014 ± 0.001 0.056
PS 42:5 0.010 ± 0.001 0.014 ± 0.002 0.095
Cer d18:0/16:0 0.000 ± 0.000 0.000 ± 0.000 0.971
Cer d18:0/18:0 0.022 ± 0.001 0.022 ± 0.002 0.941
Cer d18:0/20:0 0.001 ± 0.000 0.001 ± 0.000 0.294
Cer d18:0/22:0 0.001 ± 0.000 0.001 ± 0.000 0.674
Cer d18:0/24:0 0.000 ± 0.000 0.001 ± 0.000 0.250
Cer d18:0/24:1 0.001 ± 0.000 0.001 ± 0.000 0.645
Cer d18:1/18:0 0.223 ± 0.010 0.263 ± 0.035 0.305
Cer d18:1/18:1 0.000 ± 0.000 0.000 ± 0.000 0.620
Cer d18:1/20:0 0.007 ± 0.001 0.008 ± 0.002 0.530
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Cer d18:1/22:0 0.003 ± 0.001 0.004 ± 0.001 0.249
Cer d18:1/24:0 0.003 ± 0.000 0.003 ± 0.000 0.736
Cer d18:1/24:1 0.021 ± 0.002 0.024 ± 0.004 0.434
Cer d18:1/26:0 0.000 ± 0.000 0.001 ± 0.000 0.192
Cer d18:1/26:1 0.000 ± 0.000 0.001 ± 0.000 0.131
GluCer d18:0/18:0 0.005 ± 0.001 0.007 ± 0.001 0.368
GluCer d18:0/20:0 0.001 ± 0.000 0.001 ± 0.000 0.832
GluCer d18:0/22:0 0.013 ± 0.002 0.018 ± 0.003 0.168
GluCer d18:0/24:0 0.017 ± 0.002 0.025 ± 0.004 0.088
GluCer d18:0/24:1 0.037 ± 0.005 0.042 ± 0.007 0.515
GluCer d18:0/26:0 0.001 ± 0.000 0.001 ± 0.000 0.740
GluCer d18:0/26:1 0.000 ± 0.000 0.000 ± 0.000 0.494
GluCer d18:1/18:0 0.398 ± 0.065 0.540 ± 0.097 0.252
GluCer d18:1/20:0 0.090 ± 0.015 0.118 ± 0.020 0.289
GluCer d18:1/22:0 0.227 ± 0.026 0.309 ± 0.087 0.388
GluCer d18:1/24:0 0.352 ± 0.034 0.405 ± 0.056 0.437
GluCer d18:1/24:1 1.107 ± 0.112 1.261 ± 0.180 0.482
GluCer d18:1/26:0 0.002 ± 0.000 0.004 ± 0.000 0.026
GluCer d18:1/26:1 0.009 ± 0.001 0.010 ± 0.002 0.514
ePC 32:0 0.131 ± 0.006 0.109 ± 0.007 0.042
ePC 32:1 0.036 ± 0.003 0.028 ± 0.005 0.217
ePC 34:0 0.038 ± 0.004 0.026 ± 0.004 0.076
ePC 34:1 0.130 ± 0.012 0.104 ± 0.016 0.230
ePC 34:2 0.017 ± 0.002 0.012 ± 0.002 0.124
ePC 36:0 0.009 ± 0.001 0.007 ± 0.001 0.056
ePC 36:1 0.052 ± 0.005 0.036 ± 0.005 0.069
ePC 36:2 0.033 ± 0.002 0.023 ± 0.003 0.021
ePC 36:3 0.019 ± 0.004 0.017 ± 0.002 0.633
ePC 38:2 0.056 ± 0.006 0.040 ± 0.005 0.069
ePC 38:3 0.011 ± 0.001 0.008 ± 0.001 0.011
ePC 38:4 0.039 ± 0.002 0.036 ± 0.003 0.433
ePC 38:5 0.042 ± 0.002 0.050 ± 0.003 0.070
ePC 40:4 0.048 ± 0.003 0.049 ± 0.003 0.816
ePC 40:5 0.016 ± 0.001 0.018 ± 0.001 0.088
ePC 40:6 0.041 ± 0.002 0.042 ± 0.003 0.826
ePC 42:5 0.007 ± 0.001 0.009 ± 0.001 0.244
ePC 42:6 0.007 ± 0.001 0.008 ± 0.001 0.172
ePC 44:3 0.028 ± 0.004 0.039 ± 0.007 0.196
ePC 44:4 0.025 ± 0.003 0.035 ± 0.005 0.150
ePC 44:5 0.132 ± 0.016 0.180 ± 0.028 0.167
ePC 44:6 0.005 ± 0.001 0.006 ± 0.001 0.260
PC 30:0 0.951 ± 0.034 0.953 ± 0.074 0.982
PC 32:0 5.205 ± 0.441 4.130 ± 0.517 0.145
PC 32:1 0.615 ± 0.059 0.472 ± 0.082 0.187
PC 34:0 1.123 ± 0.130 0.806 ± 0.153 0.145
PC 34:1 2.678 ± 0.418 1.831 ± 0.357 0.155
PC 34:2 0.229 ± 0.034 0.157 ± 0.031 0.148
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PC 36:0 0.189 ± 0.021 0.144 ± 0.025 0.202
PC 36:1 1.958 ± 0.193 1.519 ± 0.263 0.209
PC 36:2 1.231 ± 0.080 0.985 ± 0.145 0.169
PC 36:3 0.775 ± 0.101 0.510 ± 0.077 0.064
PC 36:4 2.841 ± 0.197 2.278 ± 0.336 0.178
PC 38:1 0.139 ± 0.010 0.138 ± 0.015 0.925
PC 38:2 0.175 ± 0.010 0.138 ± 0.016 0.083
PC 38:3 0.326 ± 0.033 0.223 ± 0.033 0.052
PC 38:4 1.608 ± 0.110 1.285 ± 0.194 0.179
PC 38:5 0.962 ± 0.066 0.746 ± 0.105 0.114
PC 38:6 1.404 ± 0.221 1.039 ± 0.165 0.214
PC 40:4 0.147 ± 0.006 0.135 ± 0.018 0.526
PC 40:5 0.340 ± 0.011 0.303 ± 0.024 0.200
PC 40:6 1.830 ± 0.069 1.562 ± 0.124 0.089
PC 40:7 1.312 ± 0.070 1.240 ± 0.066 0.471
PC 42:5 0.030 ± 0.002 0.035 ± 0.002 0.058
PC 42:6 0.045 ± 0.004 0.049 ± 0.003 0.448
PC 42:7 0.145 ± 0.016 0.157 ± 0.016 0.635
PE 32:0 0.217 ± 0.020 0.223 ± 0.020 0.847
PE 32:1 0.108 ± 0.009 0.104 ± 0.007 0.720
PE 34:0 0.555 ± 0.029 0.530 ± 0.022 0.529
PE 34:1 2.189 ± 0.081 1.956 ± 0.126 0.152
PE 34:2 0.160 ± 0.007 0.133 ± 0.015 0.127
PE 36:0 0.121 ± 0.007 0.097 ± 0.013 0.121
PE 36:1 1.111 ± 0.078 0.838 ± 0.095 0.051
PE 36:2 0.750 ± 0.067 0.562 ± 0.065 0.072
PE 36:3 0.112 ± 0.015 0.072 ± 0.011 0.061
PE 36:4 0.199 ± 0.022 0.162 ± 0.026 0.306
PE 38:0 0.083 ± 0.006 0.081 ± 0.007 0.785
PE 38:1 0.039 ± 0.006 0.039 ± 0.004 0.946
PE 38:2 0.053 ± 0.006 0.043 ± 0.005 0.264
PE 38:3 0.131 ± 0.020 0.075 ± 0.014 0.042
PE 38:4 0.516 ± 0.061 0.376 ± 0.064 0.143
PE 38:5 0.105 ± 0.016 0.069 ± 0.012 0.097
PE 38:6 0.316 ± 0.051 0.197 ± 0.039 0.093
PE 40:3 0.008 ± 0.001 0.006 ± 0.001 0.321
PE 40:4 0.061 ± 0.010 0.047 ± 0.008 0.254
PE 40:5 0.083 ± 0.012 0.056 ± 0.011 0.113
PE 40:6 0.570 ± 0.082 0.355 ± 0.063 0.064
PE 42:5 0.001 ± 0.000 0.001 ± 0.000 0.402
PE 42:6 0.002 ± 0.000 0.002 ± 0.000 0.218
pPC 40:6 0.042 ± 0.003 0.048 ± 0.006 0.396
SM d18:0/16:0 0.010 ± 0.000 0.011 ± 0.001 0.260
SM d18:0/18:0 0.113 ± 0.008 0.126 ± 0.007 0.237
SM d18:1/16:0 0.287 ± 0.018 0.319 ± 0.025 0.317
SM d18:1/18:0 1.312 ± 0.041 1.245 ± 0.078 0.462
SM d18:1/18:1 0.298 ± 0.014 0.290 ± 0.018 0.729
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SM d18:1/20:0 0.260 ± 0.008 0.241 ± 0.010 0.171
SM d18:1/22:0 0.165 ± 0.010 0.178 ± 0.008 0.324
SM d18:1/24:0 0.107 ± 0.004 0.110 ± 0.005 0.605
SM d18:1/24:1 0.392 ± 0.021 0.410 ± 0.017 0.525
SM d18:1/26:0 0.002 ± 0.000 0.002 ± 0.000 0.549
SM d18:1/26:1 0.005 ± 0.000 0.005 ± 0.000 0.643
DG 28:0/14:0 0.000 ± 0.000 0.000 ± 0.000 0.177
DG 30:0/14:0 0.000 ± 0.000 0.000 ± 0.000 0.709
DG 32:0/16:0 0.005 ± 0.001 0.006 ± 0.000 0.195
DG 32:1/16:0 0.001 ± 0.000 0.001 ± 0.000 0.072
DG 32:2/16:1 0.000 ± 0.000 0.000 ± 0.000 0.730
DG 34:0/16:0 0.004 ± 0.001 0.005 ± 0.001 0.347
DG 34:1/16:0 0.012 ± 0.002 0.010 ± 0.001 0.585
DG 34:2/16:0 0.002 ± 0.000 0.002 ± 0.000 0.503
DG 34:2/16:1 0.002 ± 0.000 0.001 ± 0.000 0.243
DG 36:0/18:0 0.002 ± 0.000 0.002 ± 0.000 0.975
DG 36:1/18:0 0.018 ± 0.003 0.004 ± 0.000 0.002
DG 36:2/18:0 0.001 ± 0.000 0.000 ± 0.000 0.008
DG 36:2/18:1 0.007 ± 0.001 0.004 ± 0.000 0.029
DG 36:3/18:1 0.001 ± 0.000 0.001 ± 0.000 0.595
DG 38:1/18:0 0.001 ± 0.000 0.000 ± 0.000 0.001
DG 38:2/18:0 0.000 ± 0.000 0.000 ± 0.000 0.070
DG 38:2/18:1 0.001 ± 0.000 0.000 ± 0.000 0.001
DG 38:3/18:0 0.002 ± 0.000 0.002 ± 0.000 0.810
DG 38:3/18:1 0.000 ± 0.000 0.000 ± 0.000 0.941
DG 38:4/18:0 0.008 ± 0.002 0.016 ± 0.001 0.004
DG 38:4/18:1 0.000 ± 0.000 0.000 ± 0.000 0.630
DG 40:4/18:0 0.001 ± 0.000 0.001 ± 0.000 0.039
DG 40:5/18:0 0.000 ± 0.000 0.000 ± 0.000 0.875
DG 40:5/18:1 0.000 ± 0.000 0.000 ± 0.000 0.859
DG 40:6/18:0 0.001 ± 0.000 0.001 ± 0.000 0.019
DG 40:6/18:1 0.000 ± 0.000 0.000 ± 0.000 0.285
CE 16:0 0.011 ± 0.001 0.013 ± 0.002 0.406
CE 16:1 0.006 ± 0.002 0.006 ± 0.001 0.681
CE 18:0 0.017 ± 0.004 0.018 ± 0.003 0.701
CE 18:1 0.018 ± 0.006 0.019 ± 0.004 0.820
CE 18:2 0.147 ± 0.018 0.170 ± 0.017 0.390
CE 20:0 0.030 ± 0.013 0.042 ± 0.011 0.537
CE 20:2 0.005 ± 0.001 0.008 ± 0.001 0.060
CE 20:3 0.034 ± 0.006 0.032 ± 0.004 0.785
CE 20:4 0.284 ± 0.044 0.333 ± 0.029 0.372
CE 22:4 0.032 ± 0.014 0.043 ± 0.008 0.511
CE 22:5 0.063 ± 0.023 0.083 ± 0.015 0.481
CE 22:6 0.616 ± 0.303 0.827 ± 0.188 0.567
TG 48:0/16:0 0.010 ± 0.001 0.011 ± 0.001 0.528
TG 48:1/16:0 0.001 ± 0.000 0.001 ± 0.000 0.452
TG 50:0/16:0 0.004 ± 0.001 0.005 ± 0.000 0.184
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TG 50:1/16:1 0.000 ± 0.000 0.001 ± 0.000 0.329
TG 50:2/16:1 0.000 ± 0.000 0.001 ± 0.000 0.159
TG 52:0/18:0 0.003 ± 0.000 0.004 ± 0.000 0.586
TG 52:1/18:0 0.002 ± 0.000 0.002 ± 0.000 0.234
TG 52:2/18:0 0.000 ± 0.000 0.000 ± 0.000 0.344
TG 52:3/18:1 0.001 ± 0.000 0.001 ± 0.000 0.113
TG 52:4/18:1 0.000 ± 0.000 0.000 ± 0.000 0.168
TG 52:5/18:1 0.000 ± 0.000 0.000 ± 0.000 0.446
TG 52:5/20:4 0.000 ± 0.000 0.000 ± 0.000 0.013
TG 54:0/18:0 0.000 ± 0.000 0.000 ± 0.000 0.416
TG 54:1/18:0 0.001 ± 0.000 0.001 ± 0.000 0.275
TG 54:2/18:0 0.000 ± 0.000 0.000 ± 0.000 0.949
TG 54:3/18:0 0.000 ± 0.000 0.000 ± 0.000 0.880
TG 54:4/18:1 0.001 ± 0.000 0.001 ± 0.000 0.298
TG 54:4/20:4 0.001 ± 0.000 0.001 ± 0.000 0.038
TG 54:5/18:1 0.000 ± 0.000 0.000 ± 0.000 0.080
TG 54:5/20:4 0.000 ± 0.000 0.000 ± 0.000 0.004
TG 54:6/18:1 0.000 ± 0.000 0.000 ± 0.000 0.176
TG 54:6/20:4 0.000 ± 0.000 0.000 ± 0.000 0.083
TG 54:7/18:1 0.000 ± 0.000 0.000 ± 0.000 0.150
TG 56:3/18:1 0.000 ± 0.000 0.000 ± 0.000 0.291
TG 56:4/18:1 0.000 ± 0.000 0.000 ± 0.000 0.493
TG 56:4/20:4 0.000 ± 0.000 0.000 ± 0.000 0.053
TG 56:5/18:1 0.000 ± 0.000 0.000 ± 0.000 0.216
TG 56:5/20:4 0.000 ± 0.000 0.000 ± 0.000 0.160
TG 56:6/20:4 0.000 ± 0.000 0.000 ± 0.000 0.115
TG 56:7/20:4 0.000 ± 0.000 0.000 ± 0.000 0.274
TG 56:8/20:4 0.000 ± 0.000 0.000 ± 0.000 0.082
TG 56:9/20:4 0.000 ± 0.000 0.000 ± 0.000 0.342
TG 58:5/20:4 0.000 ± 0.000 0.000 ± 0.000 0.090
TG 58:6/20:4 0.000 ± 0.000 0.000 ± 0.000 0.197
TG 58:7/20:4 0.000 ± 0.000 0.000 ± 0.000 0.967
TG 58:8/22:6 0.000 ± 0.000 0.000 ± 0.000 0.232
TG 58:9/22:6 0.000 ± 0.000 0.000 ± 0.000 0.705
TG 60:7/22:6 0.000 ± 0.000 0.000 ± 0.000 0.227
TG 60:8/22:6 0.000 ± 0.000 0.000 ± 0.000 0.336
TG 60:9/22:6 0.000 ± 0.000 0.000 ± 0.000 0.339
TG 50:3/16:1 0.000 ± 0.000 0.001 ± 0.000 0.269
FC 32.822 ± 2.518 38.981 ± 3.616 0.192
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Pld1 WT hAPP Color code for t-test
A Ave SEM Ave SEM t-test p≥ 0.05
LBPA 0.004 ± 0.002 0.003 ± 0.000 0.680 p≥ 0.01
Plasmalogen PE (PEp) 18.833 ± 2.707 19.531 ± 1.299 0.809 p≥ 0.001
PG 0.073 ± 0.014 0.136 ± 0.044 0.289
Sulfatide 1.221 ± 0.498 0.780 ± 0.173 0.386
GM3 0.136 ± 0.045 0.088 ± 0.023 0.350
PA 0.129 ± 0.036 0.201 ± 0.050 0.331
PI 2.128 ± 0.472 3.701 ± 1.753 0.490
PS 4.718 ± 0.632 7.250 ± 1.849 0.312
Ceramide 0.523 ± 0.061 0.383 ± 0.076 0.231
Monhexosylceramide 1.203 ± 0.543 0.458 ± 0.167 0.192
PE 13.514 ± 2.213 14.227 ± 4.182 0.898
Ether PC (ePC) 0.731 ± 0.092 0.766 ± 0.029 0.694
PC 26.512 ± 4.617 29.810 ± 1.120 0.456
Sphingomyelin 7.694 ± 1.284 6.285 ± 1.126 0.448
Diacylglycerol 0.114 ± 0.029 0.105 ± 0.012 0.766
Cholesterol ester 0.406 ± 0.103 0.314 ± 0.120 0.604
Triacylglycerol 0.110 ± 0.031 0.109 ± 0.015 0.980
Free cholesterol 21.952 ± 5.416 15.852 ± 1.809 0.278
Pld1 WT hAPP
B Ave SEM Ave SEM t-test
LBPA 32:0 0.000 ± 0.000 0.000 ± 0.000 0.501
LBPA 32:1 0.000 ± 0.000 0.000 ± 0.000 0.295
LBPA 34:0 0.000 ± 0.000 0.000 ± 0.000 0.366
LBPA 34:1 0.000 ± 0.000 0.000 ± 0.000 0.705
LBPA 34:2 0.000 ± 0.000 0.000 ± 0.000 0.891
LBPA 36:0 0.000 ± 0.000 0.000 ± 0.000 0.842
LBPA 36:1 0.001 ± 0.000 0.000 ± 0.000 0.314
LBPA 36:2 0.002 ± 0.001 0.001 ± 0.000 0.789
LBPA 36:3 0.000 ± 0.000 0.000 ± 0.000 0.624
LBPA 38:3 0.000 ± 0.000 0.000 ± 0.000 0.675
LBPA 38:4 0.000 ± 0.000 0.000 ± 0.000 0.335
LBPA 38:5 0.000 ± 0.000 0.000 ± 0.000 0.674
PE 32:0p 0.092 ± 0.025 0.122 ± 0.021 0.396
PE 32:1p 0.085 ± 0.017 0.077 ± 0.017 0.757
PE 34:0p 0.325 ± 0.089 0.327 ± 0.089 0.991
PE 34:1p 1.523 ± 0.186 1.394 ± 0.266 0.729
PE 34:2p 0.136 ± 0.018 0.134 ± 0.031 0.952
PE 36:0p 0.164 ± 0.011 0.139 ± 0.025 0.462
PE 36:1p 1.673 ± 0.158 1.260 ± 0.151 0.122
PE 36:2p 1.875 ± 0.191 1.513 ± 0.204 0.267
PE 36:3p 0.186 ± 0.022 0.251 ± 0.036 0.217
PE 36:4p 0.578 ± 0.129 0.741 ± 0.051 0.244
PE 38:2p 0.579 ± 0.072 0.303 ± 0.046 0.019
PE 38:3p 0.313 ± 0.061 0.344 ± 0.015 0.591
PE 38:4p 1.482 ± 0.292 1.819 ± 0.218 0.387
PE 38:5p 0.823 ± 0.161 1.050 ± 0.232 0.492
PE 38:6p 1.883 ± 0.537 2.408 ± 0.286 0.394
PE 40:3p 0.160 ± 0.007 0.188 ± 0.038 0.574
PE 40:4p 0.945 ± 0.347 0.944 ± 0.092 0.998
PE 40:5p 1.080 ± 0.103 1.112 ± 0.115 0.850
Dataset 2: (A) Molecular and lipid composition of murine Pld1  WT and Pld1  KO lipid rafts 113
PE 40:6p 4.328 ± 1.567 4.758 ± 0.572 0.783
PE 42:5p 0.345 ± 0.099 0.396 ± 0.040 0.614
PE 42:6p 0.260 ± 0.072 0.255 ± 0.032 0.949
PG 32:0 0.026 ± 0.006 0.037 ± 0.014 0.565
PG 32:1 0.001 ± 0.000 0.002 ± 0.001 0.371
PG 34:0 0.004 ± 0.001 0.006 ± 0.002 0.416
PG 34:1 0.021 ± 0.004 0.047 ± 0.017 0.250
PG 34:2 0.000 ± 0.000 0.001 ± 0.000 0.177
PG 36:0 0.001 ± 0.000 0.001 ± 0.000 0.345
PG 36:1 0.010 ± 0.003 0.013 ± 0.002 0.397
PG 36:2 0.003 ± 0.000 0.016 ± 0.006 0.144
PG 36:3 0.000 ± 0.000 0.001 ± 0.000 0.165
PG 38:3 0.000 ± 0.000 0.000 ± 0.000 0.751
PG 38:4 0.005 ± 0.001 0.011 ± 0.003 0.160
PG 38:5 0.000 ± 0.000 0.000 ± 0.000 0.386
Sulf d18:1/16:0 0.003 ± 0.001 0.003 ± 0.001 0.645
Sulf d18:1/18:0 0.071 ± 0.018 0.041 ± 0.009 0.171
Sulf d18:1/18:0h 0.020 ± 0.010 0.009 ± 0.003 0.230
Sulf d18:1/18:1 0.003 ± 0.001 0.003 ± 0.000 0.857
Sulf d18:1/20:0 0.012 ± 0.004 0.008 ± 0.001 0.397
Sulf d18:1/20:0h 0.020 ± 0.011 0.009 ± 0.003 0.342
Sulf d18:1/22:0 0.052 ± 0.018 0.033 ± 0.006 0.305
Sulf d18:1/22:0h 0.072 ± 0.036 0.042 ± 0.012 0.419
Sulf d18:1/22:1h 0.031 ± 0.013 0.021 ± 0.005 0.442
Sulf d18:1/24:0 0.238 ± 0.087 0.155 ± 0.034 0.359
Sulf d18:1/24:0h 0.048 ± 0.024 0.032 ± 0.011 0.527
Sulf d18:1/24:1 0.587 ± 0.242 0.389 ± 0.093 0.429
Sulf d18:1/24:1h 0.064 ± 0.037 0.036 ± 0.010 0.443
GM3 18:0/18:0 0.018 ± 0.008 0.010 ± 0.003 0.331
GM3 18:0/20:0 0.004 ± 0.001 0.003 ± 0.001 0.740
GM3 18:1/16:0 0.003 ± 0.001 0.005 ± 0.003 0.743
GM3 18:1/18:0 0.076 ± 0.025 0.045 ± 0.010 0.268
GM3 18:1/18:1 0.005 ± 0.002 0.006 ± 0.003 0.833
GM3 18:1/20:0 0.009 ± 0.002 0.007 ± 0.001 0.277
GM3 18:1/22:0 0.010 ± 0.004 0.005 ± 0.000 0.184
GM3 18:1/24:0 0.005 ± 0.002 0.003 ± 0.001 0.543
GM3 18:1/24:1 0.007 ± 0.003 0.005 ± 0.002 0.443
PA 32:0 0.010 ± 0.001 0.012 ± 0.001 0.286
PA 32:1 0.001 ± 0.000 0.002 ± 0.000 0.306
PA 34:0 0.003 ± 0.001 0.005 ± 0.002 0.343
PA 34:1 0.031 ± 0.014 0.053 ± 0.017 0.389
PA 34:2 0.004 ± 0.001 0.008 ± 0.001 0.015
PA 36:0 0.003 ± 0.001 0.005 ± 0.002 0.454
PA 36:1 0.032 ± 0.011 0.045 ± 0.014 0.523
PA 36:2 0.010 ± 0.002 0.015 ± 0.004 0.354
PA 38:1 0.003 ± 0.001 0.003 ± 0.001 0.742
PA 38:4 0.011 ± 0.005 0.023 ± 0.008 0.270
PA 40:5 0.003 ± 0.001 0.005 ± 0.001 0.250
PA 40:6 0.020 ± 0.005 0.026 ± 0.006 0.478
PI 34:0 0.050 ± 0.005 0.034 ± 0.006 0.114
PI 34:1 0.047 ± 0.001 0.058 ± 0.016 0.597
PI 36:1 0.055 ± 0.013 0.038 ± 0.008 0.293
PI 36:2 0.017 ± 0.005 0.017 ± 0.008 0.983
PI 36:3 0.027 ± 0.007 0.041 ± 0.017 0.512
PI 36:4 0.200 ± 0.058 0.337 ± 0.141 0.464
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PI 38:3 0.166 ± 0.036 0.255 ± 0.117 0.557
PI 38:4 1.218 ± 0.263 2.211 ± 1.084 0.480
PI 38:5 0.212 ± 0.089 0.482 ± 0.255 0.423
PI 38:6 0.041 ± 0.010 0.082 ± 0.043 0.464
PI 40:6 0.095 ± 0.017 0.146 ± 0.072 0.584
PS 34:0 0.013 ± 0.002 0.028 ± 0.012 0.360
PS 34:1 0.097 ± 0.013 0.189 ± 0.067 0.306
PS 36:0 0.103 ± 0.032 0.094 ± 0.022 0.818
PS 36:1 0.882 ± 0.288 0.849 ± 0.165 0.921
PS 36:2 0.232 ± 0.048 0.335 ± 0.040 0.160
PS 38:1 0.073 ± 0.026 0.049 ± 0.007 0.372
PS 38:2 0.039 ± 0.014 0.031 ± 0.005 0.575
PS 38:3 0.051 ± 0.015 0.058 ± 0.009 0.722
PS 38:4 0.170 ± 0.055 0.178 ± 0.038 0.904
PS 40:3 0.033 ± 0.009 0.039 ± 0.011 0.705
PS 40:4 0.201 ± 0.045 0.289 ± 0.075 0.403
PS 40:5 0.362 ± 0.014 0.620 ± 0.178 0.277
PS 40:6 2.411 ± 0.168 4.433 ± 1.258 0.234
PS 42:4 0.036 ± 0.004 0.044 ± 0.012 0.623
PS 42:5 0.014 ± 0.002 0.015 ± 0.003 0.889
Cer d18:0/16:0 0.006 ± 0.003 0.007 ± 0.002 0.854
Cer d18:0/18:0 0.018 ± 0.006 0.012 ± 0.002 0.387
Cer d18:0/20:0 0.019 ± 0.012 0.014 ± 0.001 0.675
Cer d18:0/22:0 0.007 ± 0.004 0.005 ± 0.001 0.642
Cer d18:0/24:0 0.031 ± 0.027 0.015 ± 0.004 0.507
Cer d18:0/24:1 0.007 ± 0.003 0.005 ± 0.001 0.540
Cer d18:1/18:0 0.280 ± 0.048 0.233 ± 0.071 0.636
Cer d18:1/18:1 0.031 ± 0.018 0.016 ± 0.002 0.367
Cer d18:1/20:0 0.021 ± 0.006 0.016 ± 0.003 0.426
Cer d18:1/22:0 0.012 ± 0.002 0.007 ± 0.001 0.127
Cer d18:1/24:0 0.016 ± 0.006 0.010 ± 0.002 0.315
Cer d18:1/24:1 0.062 ± 0.007 0.032 ± 0.010 0.081
Cer d18:1/26:0 0.011 ± 0.007 0.006 ± 0.001 0.487
Cer d18:1/26:1 0.004 ± 0.000 0.004 ± 0.001 0.500
GluCer d18:0/18:0 0.003 ± 0.001 0.001 ± 0.000 0.178
GluCer d18:0/20:0 0.001 ± 0.000 0.001 ± 0.000 0.341
GluCer d18:0/22:0 0.004 ± 0.002 0.001 ± 0.001 0.176
GluCer d18:0/24:0 0.004 ± 0.001 0.002 ± 0.001 0.205
GluCer d18:0/24:1 0.017 ± 0.008 0.007 ± 0.002 0.189
GluCer d18:0/26:0 0.000 ± 0.000 0.000 ± 0.000 0.838
GluCer d18:0/26:1 0.000 ± 0.000 0.000 ± 0.000 0.629
GluCer d18:1/16:0 0.004 ± 0.002 0.003 ± 0.001 0.483
GluCer d18:1/18:0 0.102 ± 0.044 0.044 ± 0.012 0.199
GluCer d18:1/20:0 0.029 ± 0.014 0.014 ± 0.005 0.305
GluCer d18:1/22:0 0.120 ± 0.050 0.051 ± 0.017 0.196
GluCer d18:1/24:0 0.206 ± 0.084 0.074 ± 0.027 0.148
GluCer d18:1/24:1 0.707 ± 0.338 0.258 ± 0.100 0.203
GluCer d18:1/26:0 0.002 ± 0.001 0.001 ± 0.000 0.158
GluCer d18:1/26:1 0.004 ± 0.002 0.002 ± 0.001 0.165
PE 32:0 0.106 ± 0.037 0.122 ± 0.065 0.855
PE 32:1 0.040 ± 0.010 0.047 ± 0.021 0.794
PE 34:0 0.245 ± 0.087 0.318 ± 0.162 0.738
PE 34:1 1.206 ± 0.446 1.563 ± 0.772 0.733
PE 34:2 0.094 ± 0.032 0.117 ± 0.052 0.743
PE 36:0 0.109 ± 0.030 0.151 ± 0.046 0.509
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PE 36:1 1.052 ± 0.398 1.422 ± 0.611 0.662
PE 36:2 0.895 ± 0.353 1.160 ± 0.384 0.645
PE 36:3 0.134 ± 0.047 0.156 ± 0.064 0.806
PE 36:4 0.480 ± 0.155 0.527 ± 0.242 0.887
PE 38:0 0.145 ± 0.043 0.170 ± 0.063 0.773
PE 38:1 0.125 ± 0.025 0.153 ± 0.042 0.619
PE 38:2 0.114 ± 0.024 0.146 ± 0.035 0.513
PE 38:3 0.376 ± 0.036 0.353 ± 0.092 0.846
PE 38:4 2.223 ± 0.292 2.013 ± 0.576 0.783
PE 38:5 0.519 ± 0.048 0.543 ± 0.114 0.872
PE 38:6 1.301 ± 0.144 1.242 ± 0.314 0.886
PE 40:3 0.167 ± 0.003 0.163 ± 0.028 0.916
PE 40:4 0.371 ± 0.033 0.319 ± 0.075 0.602
PE 40:5 0.476 ± 0.019 0.444 ± 0.079 0.752
PE 40:6 3.311 ± 0.188 3.070 ± 0.546 0.732
PE 42:5 0.011 ± 0.001 0.013 ± 0.002 0.533
PE 42:6 0.016 ± 0.001 0.015 ± 0.003 0.882
ePC 30:0 0.012 ± 0.003 0.015 ± 0.003 0.527
ePC 32:0 0.123 ± 0.016 0.118 ± 0.010 0.781
ePC 32:1 0.051 ± 0.008 0.050 ± 0.002 0.862
ePC 34:0 0.091 ± 0.013 0.087 ± 0.005 0.757
ePC 34:1 0.160 ± 0.026 0.162 ± 0.011 0.939
ePC 34:2 0.024 ± 0.002 0.023 ± 0.001 0.342
ePC 36:0 0.048 ± 0.011 0.071 ± 0.004 0.073
ePC 36:1 0.068 ± 0.003 0.060 ± 0.003 0.123
ePC 36:2 0.031 ± 0.001 0.025 ± 0.001 0.030
ePC 36:3 0.014 ± 0.001 0.011 ± 0.001 0.036
ePC 38:2 0.036 ± 0.005 0.048 ± 0.004 0.098
ePC 38:3 0.006 ± 0.000 0.006 ± 0.000 0.265
ePC 38:4 0.015 ± 0.003 0.020 ± 0.000 0.086
ePC 38:5 0.013 ± 0.002 0.018 ± 0.002 0.170
ePC 40:4 0.012 ± 0.002 0.019 ± 0.004 0.169
ePC 40:5 0.006 ± 0.001 0.008 ± 0.001 0.167
ePC 40:6 0.016 ± 0.002 0.020 ± 0.002 0.284
ePC 42:5 0.002 ± 0.000 0.003 ± 0.001 0.175
ePC 42:6 0.002 ± 0.000 0.003 ± 0.001 0.286
PC 30:0 0.268 ± 0.047 0.297 ± 0.017 0.549
PC 32:0 7.009 ± 1.022 7.156 ± 0.492 0.893
PC 32:1 0.598 ± 0.104 0.717 ± 0.062 0.345
PC 34:0 1.882 ± 0.319 1.947 ± 0.117 0.839
PC 34:1 6.925 ± 1.418 7.460 ± 0.677 0.724
PC 34:2 0.427 ± 0.100 0.514 ± 0.062 0.468
PC 36:0 0.258 ± 0.027 0.236 ± 0.014 0.486
PC 36:1 2.460 ± 0.245 2.281 ± 0.155 0.542
PC 36:2 0.728 ± 0.150 0.895 ± 0.036 0.264
PC 36:3 0.270 ± 0.078 0.391 ± 0.016 0.135
PC 36:4 1.156 ± 0.300 1.739 ± 0.046 0.072
PC 38:0 0.208 ± 0.020 0.157 ± 0.018 0.119
PC 38:1 0.208 ± 0.020 0.157 ± 0.018 0.119
PC 38:2 0.100 ± 0.007 0.091 ± 0.006 0.373
PC 38:3 0.173 ± 0.032 0.232 ± 0.004 0.084
PC 38:4 1.098 ± 0.219 1.517 ± 0.041 0.077
PC 38:5 0.428 ± 0.147 0.688 ± 0.073 0.143
PC 38:6 0.965 ± 0.238 1.360 ± 0.094 0.144
PC 40:4 0.091 ± 0.013 0.124 ± 0.006 0.044
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PC 40:5 0.147 ± 0.034 0.201 ± 0.025 0.247
PC 40:6 0.777 ± 0.160 1.024 ± 0.123 0.269
PC 40:7 0.268 ± 0.101 0.517 ± 0.104 0.156
PC 42:5 0.010 ± 0.001 0.016 ± 0.003 0.195
PC 42:6 0.011 ± 0.002 0.019 ± 0.004 0.132
PC 42:7 0.023 ± 0.006 0.051 ± 0.012 0.126
pPC 40:6 0.022 ± 0.003 0.023 ± 0.002 0.752
SM d18:0/26:0 0.053 ± 0.010 0.035 ± 0.009 0.234
SM d18:0/26:1 0.003 ± 0.001 0.002 ± 0.001 0.172
SM d18:0/26:2 0.009 ± 0.002 0.005 ± 0.002 0.193
SM d18:1/26:0 0.002 ± 0.001 0.001 ± 0.000 0.228
SM d18:1/26:1 0.008 ± 0.002 0.004 ± 0.002 0.216
SM d18:0/16:0 0.026 ± 0.009 0.020 ± 0.006 0.609
SM d18:0/18:0 0.290 ± 0.058 0.266 ± 0.064 0.803
SM d18:0/18:1 0.018 ± 0.006 0.017 ± 0.007 0.902
SM d18:0/20:0 0.054 ± 0.012 0.047 ± 0.016 0.776
SM d18:0/20:1 0.004 ± 0.001 0.003 ± 0.001 0.422
SM d18:0/22:0 0.040 ± 0.011 0.024 ± 0.007 0.227
SM d18:0/22:1 0.010 ± 0.003 0.006 ± 0.002 0.184
SM d18:0/24:0 0.016 ± 0.004 0.009 ± 0.002 0.143
SM d18:0/24:1 0.263 ± 0.071 0.140 ± 0.042 0.172
SM d18:1/16:0 0.224 ± 0.066 0.171 ± 0.051 0.550
SM d18:1/18:0 4.799 ± 0.877 4.243 ± 0.588 0.606
SM d18:1/18:1 0.355 ± 0.051 0.314 ± 0.037 0.531
SM d18:1/20:0 0.628 ± 0.155 0.456 ± 0.171 0.505
SM d18:1/22:0 0.228 ± 0.071 0.157 ± 0.060 0.482
SM d18:1/24:0 0.257 ± 0.066 0.140 ± 0.041 0.175
SM d18:1/24:1 0.406 ± 0.102 0.226 ± 0.069 0.184
DG 28:0/14:0 0.012 ± 0.001 0.013 ± 0.003 0.759
DG 34:0/16:0 0.021 ± 0.004 0.020 ± 0.002 0.899
DG 34:2/16:0 0.003 ± 0.001 0.002 ± 0.000 0.304
DG 36:0/18:0 0.038 ± 0.018 0.029 ± 0.007 0.617
DG 38:2/18:1 0.003 ± 0.002 0.003 ± 0.001 0.929
DG 38:3/18:0 0.012 ± 0.001 0.012 ± 0.003 0.972
DG 38:4/18:0 0.020 ± 0.004 0.022 ± 0.003 0.599
DG 40:6/18:1 0.006 ± 0.002 0.004 ± 0.001 0.435
CE 18:1 0.024 ± 0.003 0.018 ± 0.008 0.547
CE 18:2 0.071 ± 0.032 0.085 ± 0.040 0.799
CE 20:4 0.125 ± 0.067 0.109 ± 0.046 0.840
CE 22:6 0.187 ± 0.024 0.103 ± 0.034 0.118
TG 48:0/16:0 0.033 ± 0.012 0.038 ± 0.004 0.680
TG 48:1/16:0 0.004 ± 0.001 0.003 ± 0.000 0.399
TG 50:0/16:0 0.026 ± 0.009 0.029 ± 0.004 0.799
TG 50:1/16:1 0.002 ± 0.001 0.001 ± 0.000 0.276
TG 50:2/16:1 0.002 ± 0.001 0.002 ± 0.000 0.420
TG 52:0/18:0 0.013 ± 0.003 0.014 ± 0.002 0.920
TG 52:1/18:0 0.006 ± 0.002 0.004 ± 0.000 0.313
TG 52:2/18:0 0.001 ± 0.000 0.001 ± 0.000 0.655
TG 52:3/18:1 0.004 ± 0.001 0.002 ± 0.000 0.100
TG 52:4/18:1 0.000 ± 0.000 0.000 ± 0.000 0.472
TG 54:0/18:0 0.005 ± 0.001 0.005 ± 0.001 0.853
TG 54:1/18:0 0.002 ± 0.000 0.001 ± 0.000 0.286
TG 54:2/18:0 0.002 ± 0.000 0.001 ± 0.000 0.375
TG 54:3/18:0 0.001 ± 0.000 0.001 ± 0.000 0.460
TG 54:4/18:1 0.004 ± 0.001 0.003 ± 0.001 0.297
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TG 54:4/20:4 0.001 ± 0.001 0.001 ± 0.000 0.732
TG 54:5/18:1 0.001 ± 0.000 0.001 ± 0.000 0.418
TG 54:5/20:4 0.000 ± 0.000 0.001 ± 0.000 0.331
TG 54:7/18:1 0.000 ± 0.000 0.000 ± 0.000 0.831
TG 56:3/18:1 0.001 ± 0.000 0.001 ± 0.000 0.788
TG 56:4/18:1 0.000 ± 0.000 0.000 ± 0.000 0.735
TG 56:4/20:4 0.000 ± 0.000 0.000 ± 0.000 0.728
TG 56:5/20:4 0.000 ± 0.000 0.000 ± 0.000 0.304
TG 56:6/20:4 0.000 ± 0.000 0.000 ± 0.000 0.973
TG 58:8/22:6 0.000 ± 0.000 0.000 ± 0.000 0.165
TG 58:9/22:6 0.000 ± 0.000 0.000 ± 0.000 0.879
TG 60:7/22:6 0.000 ± 0.000 0.000 ± 0.000 0.596
FC 21.952 ± 5.416 15.852 ± 1.809 0.278
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hAPP/Pld1 WT hAPP/Pld1  KO Color code for t-test
A Ave SEM Ave SEM t-test p≥ 0.05
LBPA 0.003 ± 0.000 0.002 ± 0.000 0.394 p≥ 0.01
Plasmalogen PE (PEp) 19.531 ± 1.299 15.108 ± 0.907 0.049 p≥ 0.001
PG 0.136 ± 0.044 0.310 ± 0.043 0.040
Sulfatide 0.780 ± 0.173 1.164 ± 0.173 0.187
GM3 0.088 ± 0.023 0.087 ± 0.011 0.967
PA 0.201 ± 0.050 0.086 ± 0.018 0.121
PI 3.701 ± 1.753 3.098 ± 0.585 0.789
PS 7.250 ± 1.849 6.857 ± 2.430 0.900
Ceramide 0.383 ± 0.076 0.827 ± 0.083 0.011
Monhexosylceramide 0.458 ± 0.167 1.343 ± 0.573 0.149
PE 14.227 ± 4.182 5.664 ± 0.136 0.144
Ether PC (ePC) 0.766 ± 0.029 0.798 ± 0.038 0.527
PC 29.810 ± 1.120 28.511 ± 0.906 0.434
Sphingomyelin 6.285 ± 1.126 10.408 ± 0.873 0.042
Diacylglycerol 0.105 ± 0.012 0.089 ± 0.006 0.331
Cholesterol ester 0.314 ± 0.120 0.335 ± 0.087 0.902
Triacylglycerol 0.109 ± 0.015 0.056 ± 0.005 0.031
Free cholesterol 15.852 ± 1.809 25.257 ± 1.619 0.014
hAPP/Pld1 WT hAPP/Pld1  KO
B Ave SEM Ave SEM t-test
LBPA 32:0 0.000 ± 0.000 0.000 ± 0.000 0.170
LBPA 32:1 0.000 ± 0.000 0.000 ± 0.000 0.743
LBPA 34:0 0.000 ± 0.000 0.000 ± 0.000 0.687
LBPA 34:1 0.000 ± 0.000 0.000 ± 0.000 0.946
LBPA 34:2 0.000 ± 0.000 0.000 ± 0.000 0.970
LBPA 36:0 0.000 ± 0.000 0.000 ± 0.000 0.994
LBPA 36:1 0.000 ± 0.000 0.000 ± 0.000 0.975
LBPA 36:2 0.001 ± 0.000 0.001 ± 0.000 0.205
LBPA 36:3 0.000 ± 0.000 0.000 ± 0.000 0.510
LBPA 38:3 0.000 ± 0.000 0.000 ± 0.000 0.979
LBPA 38:4 0.000 ± 0.000 0.000 ± 0.000 0.624
LBPA 38:5 0.000 ± 0.000 0.000 ± 0.000 0.980
PE 32:0p 0.122 ± 0.021 0.154 ± 0.016 0.299
PE 32:1p 0.077 ± 0.017 0.087 ± 0.008 0.653
PE 34:0p 0.327 ± 0.089 0.417 ± 0.018 0.433
PE 34:1p 1.394 ± 0.266 1.713 ± 0.082 0.368
PE 34:2p 0.134 ± 0.031 0.156 ± 0.015 0.584
PE 36:0p 0.139 ± 0.025 0.118 ± 0.017 0.558
PE 36:1p 1.260 ± 0.151 1.353 ± 0.152 0.687
PE 36:2p 1.513 ± 0.204 1.529 ± 0.150 0.954
PE 36:3p 0.251 ± 0.036 0.211 ± 0.016 0.410
PE 36:4p 0.741 ± 0.051 0.466 ± 0.078 0.027
PE 38:2p 0.303 ± 0.046 0.315 ± 0.066 0.885
PE 38:3p 0.344 ± 0.015 0.260 ± 0.022 0.022
PE 38:4p 1.819 ± 0.218 1.217 ± 0.063 0.071
PE 38:5p 1.050 ± 0.232 0.548 ± 0.061 0.133
PE 38:6p 2.408 ± 0.286 1.550 ± 0.304 0.099
PE 40:3p 0.188 ± 0.038 0.167 ± 0.025 0.701
PE 40:4p 0.944 ± 0.092 0.657 ± 0.063 0.064
PE 40:5p 1.112 ± 0.115 0.773 ± 0.088 0.080
Dataset 2: (B) Molecular and lipid composition of murine Pld1  WT and hAPP model lipid rafts 120
PE 40:6p 4.758 ± 0.572 3.049 ± 0.447 0.078
PE 42:5p 0.396 ± 0.040 0.231 ± 0.034 0.031
PE 42:6p 0.255 ± 0.032 0.135 ± 0.021 0.036
PG 32:0 0.037 ± 0.014 0.101 ± 0.021 0.043
PG 32:1 0.002 ± 0.001 0.004 ± 0.001 0.024
PG 34:0 0.006 ± 0.002 0.015 ± 0.003 0.052
PG 34:1 0.047 ± 0.017 0.104 ± 0.012 0.050
PG 34:2 0.001 ± 0.000 0.001 ± 0.000 0.021
PG 36:0 0.001 ± 0.000 0.002 ± 0.000 0.045
PG 36:1 0.013 ± 0.002 0.019 ± 0.003 0.122
PG 36:2 0.016 ± 0.006 0.034 ± 0.003 0.083
PG 36:3 0.001 ± 0.000 0.002 ± 0.000 0.076
PG 38:3 0.000 ± 0.000 0.001 ± 0.000 0.222
PG 38:4 0.011 ± 0.003 0.027 ± 0.002 0.019
PG 38:5 0.000 ± 0.000 0.001 ± 0.000 0.133
Sulf d18:1/16:0 0.003 ± 0.001 0.004 ± 0.000 0.228
Sulf d18:1/18:0 0.041 ± 0.009 0.061 ± 0.003 0.145
Sulf d18:1/18:0h 0.009 ± 0.003 0.023 ± 0.002 0.011
Sulf d18:1/18:1 0.003 ± 0.000 0.003 ± 0.000 0.957
Sulf d18:1/20:0 0.008 ± 0.001 0.009 ± 0.001 0.547
Sulf d18:1/20:0h 0.009 ± 0.003 0.020 ± 0.004 0.076
Sulf d18:1/22:0 0.033 ± 0.006 0.041 ± 0.003 0.354
Sulf d18:1/22:0h 0.042 ± 0.012 0.087 ± 0.015 0.066
Sulf d18:1/22:1h 0.021 ± 0.005 0.031 ± 0.005 0.234
Sulf d18:1/24:0 0.155 ± 0.034 0.235 ± 0.034 0.161
Sulf d18:1/24:0h 0.032 ± 0.011 0.067 ± 0.012 0.091
Sulf d18:1/24:1 0.389 ± 0.093 0.513 ± 0.089 0.391
Sulf d18:1/24:1h 0.036 ± 0.010 0.070 ± 0.014 0.100
GM3 18:0/18:0 0.010 ± 0.003 0.010 ± 0.001 0.921
GM3 18:0/20:0 0.003 ± 0.001 0.002 ± 0.000 0.295
GM3 18:1/16:0 0.005 ± 0.003 0.002 ± 0.000 0.476
GM3 18:1/18:0 0.045 ± 0.010 0.048 ± 0.005 0.829
GM3 18:1/18:1 0.006 ± 0.003 0.003 ± 0.000 0.496
GM3 18:1/20:0 0.007 ± 0.001 0.008 ± 0.001 0.400
GM3 18:1/22:0 0.005 ± 0.000 0.006 ± 0.002 0.364
GM3 18:1/24:0 0.003 ± 0.001 0.003 ± 0.001 0.934
GM3 18:1/24:1 0.005 ± 0.002 0.004 ± 0.001 0.889
PA 32:0 0.012 ± 0.001 0.009 ± 0.001 0.183
PA 32:1 0.002 ± 0.000 0.001 ± 0.000 0.290
PA 34:0 0.005 ± 0.002 0.002 ± 0.000 0.197
PA 34:1 0.053 ± 0.017 0.013 ± 0.003 0.105
PA 34:2 0.008 ± 0.001 0.003 ± 0.000 0.005
PA 36:0 0.005 ± 0.002 0.001 ± 0.000 0.107
PA 36:1 0.045 ± 0.014 0.015 ± 0.003 0.128
PA 36:2 0.015 ± 0.004 0.005 ± 0.001 0.089
PA 38:1 0.003 ± 0.001 0.001 ± 0.000 0.111
PA 38:4 0.023 ± 0.008 0.011 ± 0.002 0.237
PA 40:5 0.005 ± 0.001 0.003 ± 0.001 0.503
PA 40:6 0.026 ± 0.006 0.023 ± 0.006 0.714
PI 34:0 0.034 ± 0.006 0.047 ± 0.013 0.367
PI 34:1 0.058 ± 0.016 0.057 ± 0.014 0.986
PI 36:1 0.038 ± 0.008 0.027 ± 0.003 0.348
PI 36:2 0.017 ± 0.008 0.011 ± 0.002 0.515
PI 36:3 0.041 ± 0.017 0.039 ± 0.006 0.904
PI 36:4 0.337 ± 0.141 0.314 ± 0.061 0.899
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PI 38:3 0.255 ± 0.117 0.223 ± 0.039 0.834
PI 38:4 2.211 ± 1.084 1.808 ± 0.339 0.772
PI 38:5 0.482 ± 0.255 0.369 ± 0.088 0.729
PI 38:6 0.082 ± 0.043 0.065 ± 0.009 0.753
PI 40:6 0.146 ± 0.072 0.137 ± 0.019 0.928
PS 34:0 0.028 ± 0.012 0.027 ± 0.013 0.986
PS 34:1 0.189 ± 0.067 0.160 ± 0.070 0.783
PS 36:0 0.094 ± 0.022 0.082 ± 0.026 0.752
PS 36:1 0.849 ± 0.165 0.752 ± 0.239 0.741
PS 36:2 0.335 ± 0.040 0.253 ± 0.063 0.305
PS 38:1 0.049 ± 0.007 0.055 ± 0.017 0.728
PS 38:2 0.031 ± 0.005 0.032 ± 0.007 0.910
PS 38:3 0.058 ± 0.009 0.057 ± 0.015 0.967
PS 38:4 0.178 ± 0.038 0.199 ± 0.048 0.734
PS 40:3 0.039 ± 0.011 0.045 ± 0.014 0.745
PS 40:4 0.289 ± 0.075 0.313 ± 0.093 0.846
PS 40:5 0.620 ± 0.178 0.671 ± 0.252 0.870
PS 40:6 4.433 ± 1.258 4.163 ± 1.556 0.897
PS 42:4 0.044 ± 0.012 0.032 ± 0.017 0.580
PS 42:5 0.015 ± 0.003 0.015 ± 0.004 0.957
Cer d18:0/16:0 0.007 ± 0.002 0.004 ± 0.002 0.257
Cer d18:0/18:0 0.012 ± 0.002 0.018 ± 0.001 0.107
Cer d18:0/20:0 0.014 ± 0.001 0.007 ± 0.001 0.012
Cer d18:0/22:0 0.005 ± 0.001 0.005 ± 0.001 0.701
Cer d18:0/24:0 0.015 ± 0.004 0.010 ± 0.003 0.420
Cer d18:0/24:1 0.005 ± 0.001 0.006 ± 0.001 0.474
Cer d18:1/18:0 0.233 ± 0.071 0.611 ± 0.064 0.013
Cer d18:1/18:1 0.016 ± 0.002 0.019 ± 0.002 0.365
Cer d18:1/20:0 0.016 ± 0.003 0.025 ± 0.003 0.083
Cer d18:1/22:0 0.007 ± 0.001 0.015 ± 0.003 0.024
Cer d18:1/24:0 0.010 ± 0.002 0.011 ± 0.000 0.471
Cer d18:1/24:1 0.032 ± 0.010 0.085 ± 0.018 0.042
Cer d18:1/26:0 0.006 ± 0.001 0.005 ± 0.002 0.497
Cer d18:1/26:1 0.004 ± 0.001 0.007 ± 0.001 0.245
GluCer d18:0/18:0 0.001 ± 0.000 0.003 ± 0.001 0.121
GluCer d18:0/20:0 0.001 ± 0.000 0.001 ± 0.000 0.185
GluCer d18:0/22:0 0.001 ± 0.001 0.003 ± 0.001 0.120
GluCer d18:0/24:0 0.002 ± 0.001 0.006 ± 0.002 0.138
GluCer d18:0/24:1 0.007 ± 0.002 0.019 ± 0.009 0.180
GluCer d18:0/26:0 0.000 ± 0.000 0.000 ± 0.000 0.610
GluCer d18:0/26:1 0.000 ± 0.000 0.000 ± 0.000 0.281
GluCer d18:1/16:0 0.003 ± 0.001 0.005 ± 0.002 0.162
GluCer d18:1/18:0 0.044 ± 0.012 0.108 ± 0.034 0.095
GluCer d18:1/20:0 0.014 ± 0.005 0.032 ± 0.011 0.170
GluCer d18:1/22:0 0.051 ± 0.017 0.129 ± 0.047 0.136
GluCer d18:1/24:0 0.074 ± 0.027 0.227 ± 0.100 0.149
GluCer d18:1/24:1 0.258 ± 0.100 0.804 ± 0.370 0.160
GluCer d18:1/26:0 0.001 ± 0.000 0.001 ± 0.000 0.229
GluCer d18:1/26:1 0.002 ± 0.001 0.004 ± 0.002 0.188
PE 32:0 0.122 ± 0.065 0.026 ± 0.003 0.267
PE 32:1 0.047 ± 0.021 0.013 ± 0.000 0.221
PE 34:0 0.318 ± 0.162 0.070 ± 0.007 0.253
PE 34:1 1.563 ± 0.772 0.371 ± 0.026 0.249
PE 34:2 0.117 ± 0.052 0.032 ± 0.003 0.231
PE 36:0 0.151 ± 0.046 0.043 ± 0.005 0.101
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PE 36:1 1.422 ± 0.611 0.345 ± 0.071 0.198
PE 36:2 1.160 ± 0.384 0.355 ± 0.024 0.137
PE 36:3 0.156 ± 0.064 0.052 ± 0.006 0.226
PE 36:4 0.527 ± 0.242 0.191 ± 0.015 0.294
PE 38:0 0.170 ± 0.063 0.055 ± 0.004 0.183
PE 38:1 0.153 ± 0.042 0.054 ± 0.009 0.105
PE 38:2 0.146 ± 0.035 0.052 ± 0.011 0.075
PE 38:3 0.353 ± 0.092 0.170 ± 0.007 0.154
PE 38:4 2.013 ± 0.576 0.996 ± 0.059 0.197
PE 38:5 0.543 ± 0.114 0.263 ± 0.026 0.097
PE 38:6 1.242 ± 0.314 0.588 ± 0.067 0.142
PE 40:3 0.163 ± 0.028 0.075 ± 0.004 0.047
PE 40:4 0.319 ± 0.075 0.157 ± 0.011 0.131
PE 40:5 0.444 ± 0.079 0.228 ± 0.008 0.071
PE 40:6 3.070 ± 0.546 1.514 ± 0.075 0.062
PE 42:5 0.013 ± 0.002 0.007 ± 0.001 0.081
PE 42:6 0.015 ± 0.003 0.007 ± 0.000 0.064
ePC 30:0 0.015 ± 0.003 0.008 ± 0.000 0.121
ePC 32:0 0.118 ± 0.010 0.115 ± 0.011 0.870
ePC 32:1 0.050 ± 0.002 0.047 ± 0.002 0.460
ePC 34:0 0.087 ± 0.005 0.081 ± 0.006 0.474
ePC 34:1 0.162 ± 0.011 0.157 ± 0.010 0.753
ePC 34:2 0.023 ± 0.001 0.020 ± 0.001 0.096
ePC 36:0 0.071 ± 0.004 0.090 ± 0.005 0.036
ePC 36:1 0.060 ± 0.003 0.053 ± 0.004 0.218
ePC 36:2 0.025 ± 0.001 0.027 ± 0.002 0.487
ePC 36:3 0.011 ± 0.001 0.017 ± 0.002 0.026
ePC 38:2 0.048 ± 0.004 0.058 ± 0.003 0.126
ePC 38:3 0.006 ± 0.000 0.008 ± 0.001 0.034
ePC 38:4 0.020 ± 0.000 0.026 ± 0.001 0.003
ePC 38:5 0.018 ± 0.002 0.022 ± 0.001 0.118
ePC 40:4 0.019 ± 0.004 0.024 ± 0.001 0.317
ePC 40:5 0.008 ± 0.001 0.011 ± 0.001 0.033
ePC 40:6 0.020 ± 0.002 0.026 ± 0.002 0.103
ePC 42:5 0.003 ± 0.001 0.004 ± 0.000 0.188
ePC 42:6 0.003 ± 0.001 0.004 ± 0.000 0.178
PC 30:0 0.297 ± 0.017 0.386 ± 0.041 0.075
PC 32:0 7.156 ± 0.492 7.092 ± 0.392 0.928
PC 32:1 0.717 ± 0.062 0.533 ± 0.032 0.065
PC 34:0 1.947 ± 0.117 1.496 ± 0.030 0.024
PC 34:1 7.460 ± 0.677 4.770 ± 0.092 0.021
PC 34:2 0.514 ± 0.062 0.264 ± 0.071 0.045
PC 36:0 0.236 ± 0.014 0.260 ± 0.010 0.281
PC 36:1 2.281 ± 0.155 2.470 ± 0.190 0.471
PC 36:2 0.895 ± 0.036 0.936 ± 0.045 0.496
PC 36:3 0.391 ± 0.016 0.465 ± 0.019 0.030
PC 36:4 1.739 ± 0.046 2.311 ± 0.120 0.004
PC 38:0 0.157 ± 0.018 0.250 ± 0.038 0.059
PC 38:1 0.157 ± 0.018 0.250 ± 0.038 0.059
PC 38:2 0.091 ± 0.006 0.124 ± 0.011 0.035
PC 38:3 0.232 ± 0.004 0.289 ± 0.016 0.010
PC 38:4 1.517 ± 0.041 1.818 ± 0.121 0.044
PC 38:5 0.688 ± 0.073 0.776 ± 0.032 0.375
PC 38:6 1.360 ± 0.094 1.649 ± 0.023 0.050
PC 40:4 0.124 ± 0.006 0.150 ± 0.012 0.078
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PC 40:5 0.201 ± 0.025 0.237 ± 0.017 0.331
PC 40:6 1.024 ± 0.123 1.241 ± 0.111 0.266
PC 40:7 0.517 ± 0.104 0.595 ± 0.044 0.571
PC 42:5 0.016 ± 0.003 0.022 ± 0.000 0.138
PC 42:6 0.019 ± 0.004 0.026 ± 0.001 0.148
PC 42:7 0.051 ± 0.012 0.070 ± 0.003 0.252
pPC 40:6 0.023 ± 0.002 0.032 ± 0.002 0.044
SM d18:0/26:0 0.035 ± 0.009 0.082 ± 0.014 0.030
SM d18:0/26:1 0.002 ± 0.001 0.004 ± 0.000 0.021
SM d18:0/26:2 0.005 ± 0.002 0.013 ± 0.002 0.023
SM d18:1/26:0 0.001 ± 0.000 0.003 ± 0.000 0.014
SM d18:1/26:1 0.004 ± 0.002 0.012 ± 0.002 0.026
SM d18:0/16:0 0.020 ± 0.006 0.042 ± 0.002 0.035
SM d18:0/18:0 0.266 ± 0.064 0.449 ± 0.026 0.067
SM d18:0/18:1 0.017 ± 0.007 0.038 ± 0.003 0.055
SM d18:0/20:0 0.047 ± 0.016 0.088 ± 0.007 0.091
SM d18:0/20:1 0.003 ± 0.001 0.006 ± 0.001 0.050
SM d18:0/22:0 0.024 ± 0.007 0.057 ± 0.007 0.023
SM d18:0/22:1 0.006 ± 0.002 0.013 ± 0.003 0.065
SM d18:0/24:0 0.009 ± 0.002 0.022 ± 0.003 0.019
SM d18:0/24:1 0.140 ± 0.042 0.343 ± 0.040 0.019
SM d18:1/16:0 0.171 ± 0.051 0.370 ± 0.017 0.024
SM d18:1/18:0 4.243 ± 0.588 6.199 ± 0.563 0.067
SM d18:1/18:1 0.314 ± 0.037 0.465 ± 0.043 0.045
SM d18:1/20:0 0.456 ± 0.171 0.939 ± 0.049 0.066
SM d18:1/22:0 0.157 ± 0.060 0.385 ± 0.014 0.025
SM d18:1/24:0 0.140 ± 0.041 0.343 ± 0.040 0.019
SM d18:1/24:1 0.226 ± 0.069 0.535 ± 0.068 0.026
DG 28:0/14:0 0.013 ± 0.003 0.007 ± 0.001 0.205
DG 34:0/16:0 0.020 ± 0.002 0.020 ± 0.004 0.903
DG 34:2/16:0 0.002 ± 0.000 0.002 ± 0.000 0.745
DG 36:0/18:0 0.029 ± 0.007 0.022 ± 0.003 0.524
DG 38:2/18:1 0.003 ± 0.001 0.001 ± 0.000 0.112
DG 38:3/18:0 0.012 ± 0.003 0.007 ± 0.000 0.305
DG 38:4/18:0 0.022 ± 0.003 0.028 ± 0.005 0.293
DG 40:6/18:1 0.004 ± 0.001 0.001 ± 0.001 0.063
CE 18:1 0.018 ± 0.008 0.019 ± 0.006 0.896
CE 18:2 0.085 ± 0.040 0.044 ± 0.020 0.447
CE 20:4 0.109 ± 0.046 0.109 ± 0.023 0.999
CE 22:6 0.103 ± 0.034 0.163 ± 0.043 0.311
TG 48:0/16:0 0.038 ± 0.004 0.017 ± 0.001 0.008
TG 48:1/16:0 0.003 ± 0.000 0.004 ± 0.001 0.473
TG 50:0/16:0 0.029 ± 0.004 0.009 ± 0.001 0.010
TG 50:1/16:1 0.001 ± 0.000 0.001 ± 0.000 0.080
TG 50:2/16:1 0.002 ± 0.000 0.002 ± 0.000 0.236
TG 52:0/18:0 0.014 ± 0.002 0.004 ± 0.000 0.015
TG 52:1/18:0 0.004 ± 0.000 0.004 ± 0.000 0.304
TG 52:2/18:0 0.001 ± 0.000 0.001 ± 0.000 0.167
TG 52:3/18:1 0.002 ± 0.000 0.003 ± 0.000 0.130
TG 52:4/18:1 0.000 ± 0.000 0.000 ± 0.000 0.134
TG 54:0/18:0 0.005 ± 0.001 0.002 ± 0.000 0.066
TG 54:1/18:0 0.001 ± 0.000 0.001 ± 0.000 0.103
TG 54:2/18:0 0.001 ± 0.000 0.001 ± 0.000 0.565
TG 54:3/18:0 0.001 ± 0.000 0.001 ± 0.000 0.898
TG 54:4/18:1 0.003 ± 0.001 0.003 ± 0.000 0.708
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TG 54:4/20:4 0.001 ± 0.000 0.001 ± 0.000 0.501
TG 54:5/18:1 0.001 ± 0.000 0.001 ± 0.000 0.556
TG 54:5/20:4 0.001 ± 0.000 0.001 ± 0.000 0.575
TG 54:7/18:1 0.000 ± 0.000 0.000 ± 0.000 0.179
TG 56:3/18:1 0.001 ± 0.000 0.001 ± 0.000 0.303
TG 56:4/18:1 0.000 ± 0.000 0.000 ± 0.000 0.634
TG 56:4/20:4 0.000 ± 0.000 0.000 ± 0.000 0.344
TG 56:5/20:4 0.000 ± 0.000 0.000 ± 0.000 0.335
TG 56:6/20:4 0.000 ± 0.000 0.000 ± 0.000 0.746
TG 58:8/22:6 0.000 ± 0.000 0.000 ± 0.000 0.570
TG 58:9/22:6 0.000 ± 0.000 0.000 ± 0.000 0.923
TG 60:7/22:6 0.000 ± 0.000 0.000 ± 0.000 0.072
FC 15.852 ± 1.809 25.257 ± 1.619 0.014
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and hAPP/Pld1 KO lipid rafts
Pld1 WT Pld1  KO Color code for t-test
A Ave SEM Ave SEM t-test p≥ 0.05
LBPA 0.004 ± 0.002 0.002 ± 0.001 0.409 p≥ 0.01
Plasmalogen PE (PEp) 18.833 ± 2.707 21.733 ± 1.791 0.393 p≥ 0.001
PG 0.073 ± 0.014 0.055 ± 0.012 0.399
Sulfatide 1.221 ± 0.498 1.540 ± 0.083 0.490
GM3 0.136 ± 0.045 0.062 ± 0.017 0.145
PA 0.129 ± 0.036 0.084 ± 0.013 0.242
PI 2.128 ± 0.472 1.187 ± 0.246 0.113
PS 4.718 ± 0.632 3.731 ± 0.543 0.289
Ceramide 0.523 ± 0.061 0.354 ± 0.037 0.052
Monhexosylceramide 1.203 ± 0.543 1.409 ± 0.198 0.703
PE 13.514 ± 2.213 12.354 ± 1.018 0.622
Ether PC (ePC) 0.731 ± 0.092 0.695 ± 0.048 0.728
PC 26.512 ± 4.617 24.622 ± 1.666 0.681
Sphingomyelin 7.694 ± 1.284 6.509 ± 0.469 0.372
Diacylglycerol 0.114 ± 0.029 0.121 ± 0.028 0.878
Cholesterol ester 0.406 ± 0.103 0.215 ± 0.053 0.133
Triacylglycerol 0.110 ± 0.031 0.102 ± 0.007 0.788
Free cholesterol 21.952 ± 5.416 25.224 ± 2.229 0.560
Pld1 WT Pld1  KO
B Ave SEM Ave SEM t-test
LBPA 32:0 0.000 ± 0.000 0.000 ± 0.000 0.039
LBPA 32:1 0.000 ± 0.000 0.000 ± 0.000 0.908
LBPA 34:0 0.000 ± 0.000 0.000 ± 0.000 0.631
LBPA 34:1 0.000 ± 0.000 0.000 ± 0.000 0.443
LBPA 34:2 0.000 ± 0.000 0.000 ± 0.000 0.571
LBPA 36:0 0.000 ± 0.000 0.000 ± 0.000 0.482
LBPA 36:1 0.001 ± 0.000 0.000 ± 0.000 0.246
LBPA 36:2 0.002 ± 0.001 0.001 ± 0.001 0.552
LBPA 36:3 0.000 ± 0.000 0.000 ± 0.000 0.746
LBPA 38:3 0.000 ± 0.000 0.000 ± 0.000 0.580
LBPA 38:4 0.000 ± 0.000 0.000 ± 0.000 0.168
LBPA 38:5 0.000 ± 0.000 0.000 ± 0.000 0.505
PE 32:0p 0.092 ± 0.025 0.124 ± 0.008 0.214
PE 32:1p 0.085 ± 0.017 0.078 ± 0.013 0.767
PE 34:0p 0.325 ± 0.089 0.263 ± 0.029 0.480
PE 34:1p 1.523 ± 0.186 1.920 ± 0.125 0.124
PE 34:2p 0.136 ± 0.018 0.177 ± 0.026 0.293
PE 36:0p 0.164 ± 0.011 0.263 ± 0.026 0.029
PE 36:1p 1.673 ± 0.158 2.807 ± 0.242 0.016
PE 36:2p 1.875 ± 0.191 3.030 ± 0.458 0.096
PE 36:3p 0.186 ± 0.022 0.304 ± 0.034 0.046
PE 36:4p 0.578 ± 0.129 0.440 ± 0.038 0.292
PE 38:2p 0.579 ± 0.072 1.145 ± 0.245 0.114
PE 38:3p 0.313 ± 0.061 0.489 ± 0.072 0.137
PE 38:4p 1.482 ± 0.292 1.661 ± 0.182 0.607
PE 38:5p 0.823 ± 0.161 0.974 ± 0.081 0.402
PE 38:6p 1.883 ± 0.537 1.485 ± 0.132 0.440
PE 40:3p 0.160 ± 0.007 0.258 ± 0.037 0.077
PE 40:4p 0.945 ± 0.347 1.152 ± 0.058 0.517
Dataset 2: (C) Molecular and lipid composition of murine hAPP/Pld1  WT 126
PE 40:5p 1.080 ± 0.103 1.237 ± 0.145 0.449
PE 40:6p 4.328 ± 1.567 3.172 ± 0.251 0.429
PE 42:5p 0.345 ± 0.099 0.457 ± 0.095 0.460
PE 42:6p 0.260 ± 0.072 0.297 ± 0.061 0.708
PG 32:0 0.026 ± 0.006 0.017 ± 0.004 0.220
PG 32:1 0.001 ± 0.000 0.001 ± 0.000 0.450
PG 34:0 0.004 ± 0.001 0.003 ± 0.001 0.438
PG 34:1 0.021 ± 0.004 0.017 ± 0.005 0.558
PG 34:2 0.000 ± 0.000 0.000 ± 0.000 0.960
PG 36:0 0.001 ± 0.000 0.001 ± 0.000 0.195
PG 36:1 0.010 ± 0.003 0.007 ± 0.001 0.246
PG 36:2 0.003 ± 0.000 0.005 ± 0.002 0.368
PG 36:3 0.000 ± 0.000 0.000 ± 0.000 0.645
PG 38:3 0.000 ± 0.000 0.000 ± 0.000 0.693
PG 38:4 0.005 ± 0.001 0.004 ± 0.001 0.592
PG 38:5 0.000 ± 0.000 0.000 ± 0.000 0.188
Sulf d18:1/16:0 0.003 ± 0.001 0.004 ± 0.001 0.970
Sulf d18:1/18:0 0.071 ± 0.018 0.101 ± 0.013 0.239
Sulf d18:1/18:0h 0.020 ± 0.010 0.020 ± 0.003 0.932
Sulf d18:1/18:1 0.003 ± 0.001 0.004 ± 0.001 0.344
Sulf d18:1/20:0 0.012 ± 0.004 0.017 ± 0.001 0.164
Sulf d18:1/20:0h 0.020 ± 0.011 0.019 ± 0.002 0.955
Sulf d18:1/22:0 0.052 ± 0.018 0.081 ± 0.003 0.126
Sulf d18:1/22:0h 0.072 ± 0.036 0.081 ± 0.006 0.789
Sulf d18:1/22:1h 0.031 ± 0.013 0.035 ± 0.002 0.767
Sulf d18:1/24:0 0.238 ± 0.087 0.308 ± 0.020 0.402
Sulf d18:1/24:0h 0.048 ± 0.024 0.056 ± 0.006 0.726
Sulf d18:1/24:1 0.587 ± 0.242 0.753 ± 0.056 0.469
Sulf d18:1/24:1h 0.064 ± 0.037 0.062 ± 0.006 0.955
GM3 18:0/18:0 0.018 ± 0.008 0.006 ± 0.001 0.141
GM3 18:0/20:0 0.004 ± 0.001 0.003 ± 0.002 0.897
GM3 18:1/16:0 0.003 ± 0.001 0.002 ± 0.001 0.640
GM3 18:1/18:0 0.076 ± 0.025 0.032 ± 0.009 0.131
GM3 18:1/18:1 0.005 ± 0.002 0.004 ± 0.001 0.653
GM3 18:1/20:0 0.009 ± 0.002 0.005 ± 0.001 0.107
GM3 18:1/22:0 0.010 ± 0.004 0.003 ± 0.001 0.116
GM3 18:1/24:0 0.005 ± 0.002 0.003 ± 0.001 0.361
GM3 18:1/24:1 0.007 ± 0.003 0.003 ± 0.001 0.136
PA 32:0 0.010 ± 0.001 0.016 ± 0.003 0.195
PA 32:1 0.001 ± 0.000 0.001 ± 0.000 0.950
PA 34:0 0.003 ± 0.001 0.002 ± 0.001 0.711
PA 34:1 0.031 ± 0.014 0.013 ± 0.002 0.219
PA 34:2 0.004 ± 0.001 0.003 ± 0.001 0.355
PA 36:0 0.003 ± 0.001 0.003 ± 0.001 0.786
PA 36:1 0.032 ± 0.011 0.024 ± 0.007 0.528
PA 36:2 0.010 ± 0.002 0.004 ± 0.000 0.042
PA 38:1 0.003 ± 0.001 0.003 ± 0.001 0.843
PA 38:4 0.011 ± 0.005 0.006 ± 0.000 0.352
PA 40:5 0.003 ± 0.001 0.001 ± 0.000 0.108
PA 40:6 0.020 ± 0.005 0.007 ± 0.001 0.032
PI 34:0 0.050 ± 0.005 0.031 ± 0.004 0.029
PI 34:1 0.047 ± 0.001 0.038 ± 0.009 0.428
PI 36:1 0.055 ± 0.013 0.032 ± 0.008 0.177
PI 36:2 0.017 ± 0.005 0.011 ± 0.003 0.303
PI 36:3 0.027 ± 0.007 0.021 ± 0.005 0.544
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PI 36:4 0.200 ± 0.058 0.142 ± 0.028 0.365
PI 38:3 0.166 ± 0.036 0.086 ± 0.020 0.089
PI 38:4 1.218 ± 0.263 0.639 ± 0.134 0.086
PI 38:5 0.212 ± 0.089 0.116 ± 0.027 0.288
PI 38:6 0.041 ± 0.010 0.026 ± 0.006 0.224
PI 40:6 0.095 ± 0.017 0.045 ± 0.011 0.048
PS 34:0 0.013 ± 0.002 0.007 ± 0.001 0.023
PS 34:1 0.097 ± 0.013 0.046 ± 0.008 0.016
PS 36:0 0.103 ± 0.032 0.117 ± 0.023 0.714
PS 36:1 0.882 ± 0.288 1.048 ± 0.183 0.630
PS 36:2 0.232 ± 0.048 0.156 ± 0.024 0.177
PS 38:1 0.073 ± 0.026 0.135 ± 0.033 0.229
PS 38:2 0.039 ± 0.014 0.057 ± 0.012 0.370
PS 38:3 0.051 ± 0.015 0.081 ± 0.019 0.311
PS 38:4 0.170 ± 0.055 0.201 ± 0.034 0.628
PS 40:3 0.033 ± 0.009 0.041 ± 0.005 0.447
PS 40:4 0.201 ± 0.045 0.218 ± 0.027 0.752
PS 40:5 0.362 ± 0.014 0.219 ± 0.031 0.013
PS 40:6 2.411 ± 0.168 1.359 ± 0.207 0.014
PS 42:4 0.036 ± 0.004 0.023 ± 0.004 0.066
PS 42:5 0.014 ± 0.002 0.024 ± 0.005 0.141
Cer d18:0/16:0 0.006 ± 0.003 0.005 ± 0.002 0.774
Cer d18:0/18:0 0.018 ± 0.006 0.009 ± 0.002 0.157
Cer d18:0/20:0 0.019 ± 0.012 0.012 ± 0.004 0.541
Cer d18:0/22:0 0.007 ± 0.004 0.007 ± 0.003 0.971
Cer d18:0/24:0 0.031 ± 0.027 0.023 ± 0.008 0.763
Cer d18:0/24:1 0.007 ± 0.003 0.009 ± 0.003 0.634
Cer d18:1/18:0 0.280 ± 0.048 0.175 ± 0.016 0.062
Cer d18:1/18:1 0.031 ± 0.018 0.015 ± 0.004 0.345
Cer d18:1/20:0 0.021 ± 0.006 0.015 ± 0.004 0.389
Cer d18:1/22:0 0.012 ± 0.002 0.010 ± 0.003 0.761
Cer d18:1/24:0 0.016 ± 0.006 0.009 ± 0.003 0.340
Cer d18:1/24:1 0.062 ± 0.007 0.053 ± 0.007 0.426
Cer d18:1/26:0 0.011 ± 0.007 0.007 ± 0.003 0.570
Cer d18:1/26:1 0.004 ± 0.000 0.006 ± 0.001 0.153
GluCer d18:0/18:0 0.003 ± 0.001 0.003 ± 0.000 0.512
GluCer d18:0/20:0 0.001 ± 0.000 0.001 ± 0.000 0.720
GluCer d18:0/22:0 0.004 ± 0.002 0.004 ± 0.001 0.941
GluCer d18:0/24:0 0.004 ± 0.001 0.005 ± 0.001 0.439
GluCer d18:0/24:1 0.017 ± 0.008 0.020 ± 0.003 0.707
GluCer d18:0/26:0 0.000 ± 0.000 0.000 ± 0.000 0.177
GluCer d18:0/26:1 0.000 ± 0.000 0.000 ± 0.000 0.114
GluCer d18:1/16:0 0.004 ± 0.002 0.005 ± 0.001 0.771
GluCer d18:1/18:0 0.102 ± 0.044 0.119 ± 0.010 0.671
GluCer d18:1/20:0 0.029 ± 0.014 0.032 ± 0.004 0.869
GluCer d18:1/22:0 0.120 ± 0.050 0.137 ± 0.018 0.734
GluCer d18:1/24:0 0.206 ± 0.084 0.234 ± 0.041 0.759
GluCer d18:1/24:1 0.707 ± 0.338 0.842 ± 0.127 0.692
GluCer d18:1/26:0 0.002 ± 0.001 0.002 ± 0.000 0.658
GluCer d18:1/26:1 0.004 ± 0.002 0.005 ± 0.001 0.721
PE 32:0 0.106 ± 0.037 0.062 ± 0.008 0.233
PE 32:1 0.040 ± 0.010 0.030 ± 0.004 0.340
PE 34:0 0.245 ± 0.087 0.164 ± 0.030 0.362
PE 34:1 1.206 ± 0.446 0.845 ± 0.132 0.413
PE 34:2 0.094 ± 0.032 0.069 ± 0.012 0.450
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PE 36:0 0.109 ± 0.030 0.094 ± 0.020 0.683
PE 36:1 1.052 ± 0.398 0.824 ± 0.187 0.594
PE 36:2 0.895 ± 0.353 0.729 ± 0.120 0.635
PE 36:3 0.134 ± 0.047 0.110 ± 0.018 0.608
PE 36:4 0.480 ± 0.155 0.376 ± 0.064 0.519
PE 38:0 0.145 ± 0.043 0.121 ± 0.019 0.588
PE 38:1 0.125 ± 0.025 0.126 ± 0.022 0.965
PE 38:2 0.114 ± 0.024 0.129 ± 0.022 0.661
PE 38:3 0.376 ± 0.036 0.367 ± 0.030 0.852
PE 38:4 2.223 ± 0.292 2.043 ± 0.256 0.663
PE 38:5 0.519 ± 0.048 0.566 ± 0.051 0.546
PE 38:6 1.301 ± 0.144 1.162 ± 0.092 0.431
PE 40:3 0.167 ± 0.003 0.167 ± 0.006 0.960
PE 40:4 0.371 ± 0.033 0.354 ± 0.038 0.767
PE 40:5 0.476 ± 0.019 0.513 ± 0.020 0.251
PE 40:6 3.311 ± 0.188 3.472 ± 0.252 0.651
PE 42:5 0.011 ± 0.001 0.015 ± 0.002 0.175
PE 42:6 0.016 ± 0.001 0.017 ± 0.001 0.430
ePC 30:0 0.012 ± 0.003 0.016 ± 0.002 0.349
ePC 32:0 0.123 ± 0.016 0.119 ± 0.010 0.847
ePC 32:1 0.051 ± 0.008 0.045 ± 0.003 0.447
ePC 34:0 0.091 ± 0.013 0.086 ± 0.005 0.710
ePC 34:1 0.160 ± 0.026 0.136 ± 0.007 0.357
ePC 34:2 0.024 ± 0.002 0.025 ± 0.002 0.911
ePC 36:0 0.048 ± 0.011 0.040 ± 0.003 0.453
ePC 36:1 0.068 ± 0.003 0.077 ± 0.007 0.345
ePC 36:2 0.031 ± 0.001 0.031 ± 0.002 0.879
ePC 36:3 0.014 ± 0.001 0.015 ± 0.002 0.861
ePC 38:2 0.036 ± 0.005 0.037 ± 0.004 0.897
ePC 38:3 0.006 ± 0.000 0.007 ± 0.001 0.451
ePC 38:4 0.015 ± 0.003 0.014 ± 0.001 0.556
ePC 38:5 0.013 ± 0.002 0.010 ± 0.001 0.344
ePC 40:4 0.012 ± 0.002 0.012 ± 0.001 0.762
ePC 40:5 0.006 ± 0.001 0.006 ± 0.001 0.982
ePC 40:6 0.016 ± 0.002 0.015 ± 0.001 0.720
ePC 42:5 0.002 ± 0.000 0.002 ± 0.000 0.844
ePC 42:6 0.002 ± 0.000 0.002 ± 0.000 0.525
PC 30:0 0.268 ± 0.047 0.212 ± 0.026 0.310
PC 32:0 7.009 ± 1.022 6.713 ± 0.555 0.794
PC 32:1 0.598 ± 0.104 0.563 ± 0.051 0.748
PC 34:0 1.882 ± 0.319 1.715 ± 0.073 0.578
PC 34:1 6.925 ± 1.418 6.355 ± 0.443 0.678
PC 34:2 0.427 ± 0.100 0.387 ± 0.024 0.670
PC 36:0 0.258 ± 0.027 0.269 ± 0.011 0.689
PC 36:1 2.460 ± 0.245 2.562 ± 0.104 0.687
PC 36:2 0.728 ± 0.150 0.639 ± 0.026 0.523
PC 36:3 0.270 ± 0.078 0.206 ± 0.016 0.387
PC 36:4 1.156 ± 0.300 0.849 ± 0.095 0.315
PC 38:0 0.208 ± 0.020 0.285 ± 0.024 0.069
PC 38:1 0.208 ± 0.020 0.285 ± 0.024 0.069
PC 38:2 0.100 ± 0.007 0.117 ± 0.010 0.281
PC 38:3 0.173 ± 0.032 0.157 ± 0.017 0.660
PC 38:4 1.098 ± 0.219 0.916 ± 0.089 0.428
PC 38:5 0.428 ± 0.147 0.371 ± 0.034 0.677
PC 38:6 0.965 ± 0.238 0.826 ± 0.090 0.566
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PC 40:4 0.091 ± 0.013 0.088 ± 0.009 0.858
PC 40:5 0.147 ± 0.034 0.130 ± 0.009 0.594
PC 40:6 0.777 ± 0.160 0.653 ± 0.042 0.424
PC 40:7 0.268 ± 0.101 0.257 ± 0.024 0.904
PC 42:5 0.010 ± 0.001 0.010 ± 0.001 0.599
PC 42:6 0.011 ± 0.002 0.009 ± 0.001 0.529
PC 42:7 0.023 ± 0.006 0.023 ± 0.003 0.885
pPC 40:6 0.022 ± 0.003 0.025 ± 0.003 0.439
SM d18:0/26:0 0.053 ± 0.010 0.057 ± 0.002 0.712
SM d18:0/26:1 0.003 ± 0.001 0.003 ± 0.001 0.668
SM d18:0/26:2 0.009 ± 0.002 0.012 ± 0.002 0.273
SM d18:1/26:0 0.002 ± 0.001 0.003 ± 0.000 0.722
SM d18:1/26:1 0.008 ± 0.002 0.011 ± 0.001 0.289
SM d18:0/16:0 0.026 ± 0.009 0.020 ± 0.002 0.493
SM d18:0/18:0 0.290 ± 0.058 0.212 ± 0.017 0.198
SM d18:0/18:1 0.018 ± 0.006 0.013 ± 0.001 0.367
SM d18:0/20:0 0.054 ± 0.012 0.037 ± 0.003 0.186
SM d18:0/20:1 0.004 ± 0.001 0.003 ± 0.000 0.177
SM d18:0/22:0 0.040 ± 0.011 0.043 ± 0.005 0.795
SM d18:0/22:1 0.010 ± 0.003 0.012 ± 0.001 0.586
SM d18:0/24:0 0.016 ± 0.004 0.019 ± 0.002 0.542
SM d18:0/24:1 0.263 ± 0.071 0.308 ± 0.028 0.533
SM d18:1/16:0 0.224 ± 0.066 0.180 ± 0.009 0.475
SM d18:1/18:0 4.799 ± 0.877 3.863 ± 0.315 0.307
SM d18:1/18:1 0.355 ± 0.051 0.342 ± 0.032 0.829
SM d18:1/20:0 0.628 ± 0.155 0.349 ± 0.049 0.107
SM d18:1/22:0 0.228 ± 0.071 0.183 ± 0.028 0.535
SM d18:1/24:0 0.257 ± 0.066 0.308 ± 0.028 0.466
SM d18:1/24:1 0.406 ± 0.102 0.533 ± 0.047 0.268
DG 28:0/14:0 0.012 ± 0.001 0.018 ± 0.003 0.169
DG 34:0/16:0 0.021 ± 0.004 0.020 ± 0.004 0.921
DG 34:2/16:0 0.003 ± 0.001 0.002 ± 0.000 0.112
DG 36:0/18:0 0.038 ± 0.018 0.045 ± 0.017 0.782
DG 38:2/18:1 0.003 ± 0.002 0.003 ± 0.001 0.946
DG 38:3/18:0 0.012 ± 0.001 0.015 ± 0.003 0.352
DG 38:4/18:0 0.020 ± 0.004 0.011 ± 0.002 0.086
DG 40:6/18:1 0.006 ± 0.002 0.006 ± 0.002 0.985
CE 18:1 0.024 ± 0.003 0.023 ± 0.003 0.906
CE 18:2 0.071 ± 0.032 0.029 ± 0.003 0.186
CE 20:4 0.125 ± 0.067 0.033 ± 0.004 0.162
CE 22:6 0.187 ± 0.024 0.130 ± 0.052 0.420
TG 48:0/16:0 0.033 ± 0.012 0.027 ± 0.003 0.554
TG 48:1/16:0 0.004 ± 0.001 0.006 ± 0.002 0.471
TG 50:0/16:0 0.026 ± 0.009 0.021 ± 0.003 0.538
TG 50:1/16:1 0.002 ± 0.001 0.001 ± 0.000 0.443
TG 50:2/16:1 0.002 ± 0.001 0.003 ± 0.001 0.373
TG 52:0/18:0 0.013 ± 0.003 0.011 ± 0.001 0.425
TG 52:1/18:0 0.006 ± 0.002 0.007 ± 0.001 0.933
TG 52:2/18:0 0.001 ± 0.000 0.002 ± 0.000 0.162
TG 52:3/18:1 0.004 ± 0.001 0.006 ± 0.001 0.283
TG 52:4/18:1 0.000 ± 0.000 0.001 ± 0.000 0.091
TG 54:0/18:0 0.005 ± 0.001 0.006 ± 0.001 0.444
TG 54:1/18:0 0.002 ± 0.000 0.002 ± 0.000 0.842
TG 54:2/18:0 0.002 ± 0.000 0.002 ± 0.000 0.242
TG 54:3/18:0 0.001 ± 0.000 0.001 ± 0.000 0.438
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TG 54:4/18:1 0.004 ± 0.001 0.005 ± 0.001 0.579
TG 54:4/20:4 0.001 ± 0.001 0.000 ± 0.000 0.142
TG 54:5/18:1 0.001 ± 0.000 0.001 ± 0.000 0.670
TG 54:5/20:4 0.000 ± 0.000 0.000 ± 0.000 0.151
TG 54:7/18:1 0.000 ± 0.000 0.000 ± 0.000 0.363
TG 56:3/18:1 0.001 ± 0.000 0.002 ± 0.000 0.398
TG 56:4/18:1 0.000 ± 0.000 0.000 ± 0.000 0.537
TG 56:4/20:4 0.000 ± 0.000 0.000 ± 0.000 0.179
TG 56:5/20:4 0.000 ± 0.000 0.000 ± 0.000 0.092
TG 56:6/20:4 0.000 ± 0.000 0.000 ± 0.000 0.247
TG 58:8/22:6 0.000 ± 0.000 0.000 ± 0.000 0.503
TG 58:9/22:6 0.000 ± 0.000 0.000 ± 0.000 0.164
TG 60:7/22:6 0.000 ± 0.000 0.000 ± 0.000 0.590
FC 21.952 ± 5.416 25.224 ± 2.229 0.560
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